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Abstract 
This thesis studies the development of a method to knockdown CLEC14A in-vivo. CLEC14A has 
been shown to have strong pro-angiogenic signalling properties and its knockdown in-vitro has 
been shown to decrease wound healing and tube formation. Additionally, CLEC14A knockout mice 
showed a decreased rate of tumour growth in implanted Lewis Lung Carcinoma tumours. siRNA 
is a common tool used to knockdown genes but needs protection from degrading enzymes found in 
serum. To this end, a chitosan-based nanoparticle was developed to deliver siRNA. A 60% 
knockdown of CLEC14A was achieved in-vitro using untargeted chitosan nanoparticles. 
Microarray analysis of HUVEC cells treated with siRNA entrapped nanoparticles showed that 
CLEC14A was not knocked down at an mRNA level but that endothelial genes related to blood 
flow were affected in a similar manner to an increase in laminar blood flow, suggesting that 
CLEC14A has a regulatory role in endothelial gene expression.  Conjugating antibodies to the 
surface of the chitosan nanoparticles may increase cellular uptake and improve knockdown of 
CLEC14A. Antibody targeting of the nanoparticles did not improve knockdown, and in fact, 
decreased efficiency at higher concentrations. Bio-distribution studies were performed with 
untargeted nanoparticles and showed localisation to tumour vascular endothelium. Nanoparticles 
were found in the liver and kidneys as well as the tumour.  
 
An anti-angiogenic, CLEC14A based, vaccine was developed to be delivered by the chitosan 
nanoparticles. A CLEC14A-Tetanus FrC fusion protein was produced in HEK293 cells but failed 
to fold correctly and be excreted at a sufficient concentration. A CLEC14A-VLRB fusion was 
created and cloned into a bacterial plasmid. Two fragments of CLEC14A were created to fuse to 
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VLRB with the small fragment being successfully synthesised and purified ready for in-vivo 
immunisation studies.  
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Glossary 
 
Bp – Base Pairs (DNA)  
BSA – bovine serum albumin 
cDNA – complementary DNA 
ChNP – Chitosan Nanoparticles  
ChNP-siRNA – Chitosan nanoparticles with siRNA entrapped inside  
ChGlutNP – Chitosan glutamate nanoparticles 
ChGlutNP-siRNA – Chitosan glutamate nanoparticles with siRNA entrapped inside 
CRT4 – CLEC14A Antibody Cancer Research Type 4 
DAPI – (4’, 6-damidino-2-phenylindole) 
dH2O – distilled water 
DMSO – Dimethyl sulfoxide 
E. coli – Escherichia coli 
EDTA – Ethylene-diamine-tetra-acetic acid 
EGF – epidermal growth factor 
FC – Fragment crystallisable 
FCS – Foetal Calf Serum 
HIS-Tag – Polyhistidine tag 
HRP – Horse Radish Peroxidase 
IgG – immunoglobulin G 
IPTG – Isopropyl β-D-1-thiogalactopyranoside  
kDa – Kilo Dalton 
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NaCl – Sodium Chloride 
NP-Antibody-1 – Antibody conjugation adapted from (Lee et al., 2012) 
NP-Antibody-2 – Antibody conjugation adapted from (Zhu et al., 2015) 
PBS – Phosphate Buffered Saline  
PEI - Polyethylenimine 
PVDF – Polyvinylidene difluoride  
Rpm – Revolutions per minute  
SDS – Sodium dodecyl sulphate 
siRNA – Small interfering ribonucleic acid 
VEGF – Vascular endothelial growth factor 
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Chapter I. 
Introduction 
CLEC14A: 
C-type lectin family 14 member A (CLEC14A) is a trans-membrane, endothelial cell 
specific, glycoprotein (Figure 1.1); first discovered through microarray analysis (Ho et al., 
2003). The identification as a novel endothelial specific gene was further validated through 
in silico analysis (Herbert et al., 2008). Identification of CLEC14A as a potential tumour 
endothelial marker was achieved through immunohistochemical staining of tumour vs 
healthy tissue. The strong staining of vessels in the tumour compared to the near absence 
in healthy tissue confirmed the upregulation and high expression of CLEC14A in tumour 
blood vessel tissue (Mura et al., 2012). It has been shown that CLEC14A is upregulated on 
the messenger RNA level in non-small cell lung cancer when compared to healthy tissue 
(Pircher et al., 2013). Two separate, pancreatic and ovarian, spontaneous mouse tumour 
models have shown that up-regulation of CLEC14A at the tumour level is correlated with 
tumour progression (Zanivan et al., 2013). Bevacizumab has been shown to down-regulate 
CLEC14A as well as CD93, further suggesting an angiogenic role for CLEC14A (Bais, 
2011). Meta-analysis of 959 breast cancer, 170 renal cancers and 212 head and neck 
cancers lead to CLEC14A being labelled a “tumour angiogenesis signature”. The potential 
for CLEC14A as a prognostic tool was further made a possibility by the detection of 
CLEC14A in the urine of patients with low grade bladder cancer (Ambrose et al., 2015). It 
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has also been proposed as a marker for circulating endothelial cells from blood cancer 
patients (Mancuso et al., 2014).  CLEC14A can be shed from the membrane of endothelial 
cells by serine protease rhomboid-like 2 (RHBDL2), cleaving close to the transmembrane 
domain. The shedding of the extracellular domain of CLEC14A allows for the regulation 
of sprouting angiogenesis in-vivo.  
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Figure 1.1  
Figure 1.1 | C-Type-Lectin Family and CLEC14A  
(A) From left to right, CLEC14A, CD93, thrombomodulin and endosialin. The multiple domains of the C-type lectin 
domain group 14 family proteins can be seen. C-type Lectin Domain (Red), Sushi Domain (Blue), Epidermal 
Growth Factor-like Domain (Green), Mucin-like Region, Transmembrane domain and cytoplasmic domain.  
(B) the structure of CLEC14A can be more clearly seen with each domain mapped to its amino acid numbers, for 
example, the C-type lectin domain on the N terminus of the extracellular portion of the protein is made up from amino 
acids 32 to 173.  
kDa 
B 
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CLEC14A Expression and Function: 
Low shear stress has been shown to up-regulate CLEC14A (Mura et al., 2012).  A gene 
expression study during zebra fish embryo development showed that CLEC14A expression 
decreased as the heart began beating due to the increase in sheer stress from blood flow 
(Mura et al., 2012). 2 Pa of laminar shear flow applied to HUVEC in culture is enough to 
reduce CLEC14A expression by over 90%. Data showing high expression of CLEC14A in 
tumour blood vessels seems to corroborate with the disordered nature of tumour blood 
vessels and lack of shear flow from blood (Wragg et al., 2014). Apart from tumour 
vasculature, atherosclerosis is another area showing increased CLEC14A expression. 
Microarray analysis of atherosclerotic vessels show an up-regulation of CLEC14A 
proportional to stenosis (Hagg et al., 2009). A previous study also suggested that shear 
stress is lower in atherosclerotic vessels compared to healthy tissue (Gnasso et al., 1997). 
The Sp1 transcription factor binding site found on CLEC14A could be a method by which 
this shear stress is translated to a cell signal. Sp1 has been shown to be phosphorylated in 
response to shear stress resulting in the inhibition of MT1-MMP cell migration mechanics 
(Yun et al., 2002).  
 
A morpholino knockdown of CLEC14A at 24 hours post fertilization has been shown to 
have strong anti-angiogenic during development resulting in deformed vasculature in 
zebrafish embryos (Mura et al., 2012). The introduction of human mRNA to the 
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knockdown embryos reverted the vasculature morphology to normal, showing the 
conserved nature of the CLEC14A gene.  
 
The study of mouse embryos has shown expression of CLEC14A in the intersomitic vessels 
and vessels within the brain at day 10.5 as well as the vessels of the retina day 12 (Rho et 
al., 2011, Maeng et al., 2009).  
 
A study that reinforced the role of CLEC14A in angiogenesis looked at a homozygous 
knockout in mice (Noy et al., 2015). The mice were viable and showed no defects during 
development. Lewis lung carcinomas (LLC) were introduced and it was shown that tumour 
growth and angiogenesis were reduced compared to wild type mice. Subcutaneous sponge 
implants also showed FGF2-induced angiogenesis to be reduced.  
 
CLEC14A Interactions: 
The intracellular domain of CLEC14A currently has no known protein interactions but 
global phosphoproteomic analysis of HUVEC show the potential of up to five serine 
phosphorylation sites (Meijer et al., 2013, van den Biggelaar et al., 2014). Scratch assays 
have been used to assess the requirement of CLEC14A in angiogenesis. siRNA mediated 
knockdown of CLEC14A reduced the ability of HUVEC to form tubes or close wounds 
formed on cell monolayers (Mura et al., 2012, Rho et al., 2011). Spheroid assays, with 
siRNA knockdown, demonstrated a reduction in sprout formation and showed cells with a 
lack of CLEC14A expression were likely to be found on the tip of sprouts (Noy et al., 
2015). A final study in the involvement of CLEC14A in filopodia formation induced 
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ectopic expression of CLEC14A in cells that normally do not resulting in the formation of 
filopodia-like protrusions (Mura et al., 2012). All of this shows the importance of 
CLEC14A and its involvement in angiogenesis.  
 
As well as filopodia formation, CLEC14A has been implicated in cell-cell interactions. 
Over expression of CLEC14A in HEK293 cells results in the formation of clumps which 
disperse upon addition of antibodies targeted at the CTLD of CLEC14A. (Ki et al., 2013).  
Antibodies targeted at the CTLD also resulted in a down-regulation of CLEC14A on the 
surface of HUVEC due to internalization of the protein. This down-regulation of 
CLEC14A resulted in decreased cell migration and tube formation in in vitro analysis.  
 
Angiogenesis: 
Angiogenesis is a word derived from the Greek words Angeion meaning vessel and Genesis 
meaning birth. Angiogenesis is the birth or generation of new blood vessels from pre-
existing vessels. Perturbation of normal angiogenesis is the basis for many serious diseases 
including inflammatory diseases, retinal disorders and tumour formation and regenerative 
medicine (Carmeliet, 2003).   
 
Tumour growth is limited to around 1-2 mm3 without the growth of new, invasive, vessels 
to supply the growing tumour with extra oxygen and nutrients. Autopsies from deceased 
patients, that did not die from cancer, proved this through the discovery of many small, 
non-malignant, tumours (Naumov et al., 2008). Preventing this invasion of new blood 
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vessels or destroying existing vessels that supply the tumour present exciting aims for anti-
cancer therapies and cancer preventions. 
 
Many growth factors and cell signalling pathways regulate angiogenesis during 
development and in healthy tissue. A balance is maintained in quiescent endothelial cells. 
When this balance shifts in favour of pro-antigenic signals then it is said to turn on the 
“angiogenic switch” (Hanahan and Folkman, 1996).  
 
Many different forms of angiogenesis exist but the main method of new vessel formation 
is sprouting angiogenesis, first elucidated in 1977 (Ausprunk and Folkman, 1977). Later in 
1984 Folkman worked with Haudenschild to show that human endothelial cells placed on 
dishes coated in a thin layer of extracellular matrix organised into tube like structures 
(Folkman and Haudenschild, 1980). In 1991 Grant et al., used electron microscopy to 
confirm that these tubes acted like capillary networks with lumens and cell specialization 
much like blood vessels found in in-vivo models (Grant et al., 1991). Figure 1.2 describes 
sprouting angiogenesis with its main stages and functional cells. Figure 1.3 shows other 
variations of angiogenesis that can be used by a tumour to develop its own blood supply.  
 
1: Activation of quiescent endothelial cells by pro-angiogenic growth factor stimuli such 
as vascular endothelial growth factor (VEGF). 
2: Extracellular matrix (ECM) is degraded by matrix metalloproteinases (MMPs) as 
perivascular cells detach from the vessel.  
 
20 
3: The sprout forms a tip with “tip cells” generating filopodia to migrate towards the pro-
angiogenic stimulus.  
4: Proliferation of stalk cells causes the lengthening of the sprout and the formation of a 
lumen just behind the tip. 
5: Sprouts join and form new vessels via anastomosis and perivascular cells are recruited 
through the secretion of platelet derived growth factor-B (PDGFB). Perivascular cells 
promote maturation of the newly formed vessel (Bjarnegard et al., 2004).  
 
This sprouting tip is highly regulated by complex signalling pathways; however, its 
elucidation gave rise to some of the first anti-angiogenic therapies targeting VEGF 
stimulation. It was shown that, upon binding of VEGF to its receptor, tip cells develop 
filopodia and begin migratory processes. The tip cells begin to express high levels of VEGF 
receptor-2, DII-4, PDGF-b and other proteins (Hellstrom et al., 2007). Low levels of Notch 
signalling also begins. The filopodia are numerous and guide the new sprout towards the 
angiogenic stimulus, up the chemical concentration gradient. The tip cells divide only 
minimally but cells with fewer filopodia divide more rapidly to form lumens, branches and 
basement membranes. Nearing the end of vessel formation endothelial cells adopt a 
phalanx structure. This phalanx of immobile endothelial cells promotes vessel integrity, 
increases cell adhesion and dampens the response to VEGF resulting in a halt to vessel 
growth (Jakobsson et al., 2010).  
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Figure 1.2 
Figure 1.2 | Sprouting Angiogenesis 
(A)  Endothelial cells (pink) are stimulated by a pro angiogenic signal represented by the yellow arrow. (B) the 
perivascular cells, detailed in green, detach from the extracellular matrix (cross hatch mesh), resulting in 
degradation of the matrix. (C) stimulated endothelial cells form tip or stalk cells that digest and migrate through 
the basement membrane (Blue lines). (D) the growing sprout elongates through proliferation of the stalk cells. 
(E) The new vessel sprout tip comes into contact with a secondary sprout resulting in fusion of the two 
branches to form one single vessel. The (green) perivascular cells are recruited to mature the vessel. (Diagram 
Adapted from (Bergers and Benjamin 2003).   
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Figure 1.3 
Figure 1.3 | Less common variations of vessel formation 
The less common variants of vessel formation: (A) shows the splitting of an existing vessel into two separate 
vessels. This is called intussusception. (B) cancer cells (grey) co-opt or “hijack” the existing vasculature 
structure. (C) cancer cells mimic endothelial cells and exhibit endothelial like characteristics and 
functions. (D) The differentiation of cancer stem cells (yellow) into endothelial like cells to form a 
vascular structure. (E) endothelial progenitor cells (purple) are recruited from the bone marrow through 
post-natal vasculogenesis. These progenitor cells differentiate into endothelial cells that line the vessel. 
(Diagram Adapted from Bergers and Benjamin 2003).   
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Figure 1.4 
Figure 1.4 | Sprouting Angiogenesis and CLEC14A 
A blood vessel sprout forms a tip that protrudes out from an existing vessel. CLEC14A expression is 
extremely high on the tip cell, resulting in more recruitment of Multimerin 2 (MMRN2) and increased 
CLEC14A signalling. Cells further down from the tip cell shed their CLEC14A thereby resulting in the 
sprouting vessel being ‘led’ by the tip cell with new cells being generated at the base of the sprout. 
(Diagram Adapted from Bergers and Benjamin 2003).   
 
24 
 
 
CLEC14A plays an integral role in sprouting angiogenesis as its high expression on tip 
cells drive filopodia formation and cell migration to move the new vessel towards its target 
(Figure 1.4).  
 
There are other processes for the development of new blood vessels such as intussusception 
(Figure 1.2). Intussusception involves the splitting of existing blood vessels thereby 
increasing the complexity of the existing network (Burri et al., 2004). Other processes for 
tumours to increase their vascularization include hijacking existing vasculature by the 
invasion of cancer cells that adapt to perform endothelial-like functions. This method of 
cancer cell hijacking is also known as co-option. Cancer stem cells have also been known 
to differentiate into endothelial like cells and perform vascular mimicry. It has also been 
suggested that endothelial progenitor cells can be sequester from the bone marrow and 
differentiated to form new vessels. This “sequestering” is a form of post-natal 
vasculogenesis and is a controversial mechanism (Carmeliet and Jain, 2011). There is also 
some evidence for a tumour promoting nature in endothelial cells that goes past simple 
vessel formation. Endothelial cells have been shown to produce angiocrine factors in the 
liver and pancreas during low blood flow. It is hypothesised that these factors aid in tissue 
regeneration and could potentially contribute to tumour progression or recurrence after 
anti-cancer therapy (Lammert et al., 2001). It must not go unsaid that blood vessel invasion 
is also a major contributor to metastasis.  
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Anti-angiogenic therapies 
 
The Hallmarks of Cancer was a landmark paper that laid out six “hallmarks” that every 
cancer cell possesses (Hanahan and Weinberg, 2000). Invasion and metastasis was one of 
these original 6 hallmarks and a large amount of focus was put on elucidating the 
mechanisms that allow this. In 2011 The Hallmarks of Cancer: The Next Generation 
established inducing angiogenesis as a hallmark in its own right (Hanahan and Weinberg, 
2011). Inhibiting unwanted angiogenesis quickly became a focus in the fight on cancer. 
Attempting to disrupt tumour blood vessels as a viable therapy was not considered until 
well into the late 1960’s early 1970s by Folkman and his team who did much of the ground 
work in understanding angiogenesis at the beginning of the field. The team assumed that 
there must exist natural inhibitors to angiogenesis that could tip the equilibrium of pro vs 
anti-angiogenic signals towards the negative and block tumour angiogenesis (Folkman, 
1971).  
At present the most successful and commonly used methods to prevent tumour 
angiogenesis are through blocking vascular endothelial growth factor (VEGF), a pro 
angiogenic protein. Bevacizumab is an anti-VEGFA antibody that gained FDA approval 
in 2004 for use on colorectal cancer (Hurwitz et al., 2004). Small molecule tyrosine kinase 
inhibitors such as sunitinib and sorafenib, which target the intracellular kinase domain of 
several types of receptors, have also been approved (Roskoski, 2007, Wilhelm et al., 2008). 
The birth of anti-angiogenic therapies promised highly effective drugs that would 
significantly aid in the fight against cancer. Most modern anti-angiogenics are able to 
 
26 
prolong survival but only for a few months and this early optimism was most likely due to 
the results garnered from early mouse model experiments (Kerbel, 2008).  
 
Drug resistance is a major obstacle in many anti-cancer therapies, but it seems to play a 
particularly large role in anti-angiogenics. Most anti-VEGF therapies are extremely 
effective at blocking the signalling produced by VEGF and its associated receptors but the 
highly adaptive nature of the tumour microenvironment simply results in a switch to the 
production of other growth factors such as angiopoietin-2 (Ang2) or fibroblast growth 
factor-2 (FGF2) (Casanovas et al., 2005). Apart from the issue of resistance, anti-VEGF 
therapies have also been shown to increase the invasive and metastatic phenotypes in 
multiple cancer types (Ebos et al., 2009, Paez-Ribes et al., 2009).   
Other growth and signalling factors can be targeted to prevent blood vessel growth in 
tumours. Blockage of platelet-derived growth factors (PDGFs) (Hellberg et al., 2010), 
integrins (Desgrosellier and Cheresh, 2010), regulator of G-Protein signalling 5 (Rgs5) 
(Hamzah et al., 2008) and epidermal growth factor receptor (EGFR) (Cerniglia et al., 2009) 
all present potential targets of inhibition. 
Proteolytic enzymes have also been shown to have vascular normalization effects and 
trastuzumab has been shown to decrease the volume, diameter and permeability of tumour 
vessels (Izumi et al., 2002).  
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Tumour vasculature vaccines 
 
Vaccination is yet another approach taken to prevent the growth of new vessels in tumours. 
There are many advantages to using a vaccine rather than a traditional therapy including 
lower cost and lower doses. Vaccines are generally recombinant proteins and so require far 
less complicated synthesis than an antibody or aptamer and induce a polyclonal antibody 
response rather than monoclonal like an antibody would.  
 
An issue with cancer vaccines is that the nature of the patients often mean they have an 
already compromised immune system, either from some other pre-existing condition 
(resulting in a higher cancer of the development of cancer) or as a result of chemotherapy 
already administered. A 2014 study that looked at the combination of ipilimumab (a 
checkpoint inhibitor) and bevacizumab showed promising results (Hodi et al., 2014). 
 
To produce a viable anti-cancer vaccination, several factors must be considered: The 
magnitude of the immune response induced, the type of immunity generated and how long 
the immune protection lasts. The correct antigens must be introduced to the appropriate 
dendritic cell groups thereby inducing differentiation of the DC cells into their 
immunostimulatory state. Activated on DC can be achieved either in-vivo or ex-vivo. This 
thesis will focus on in-vivo activation as the development of a vaccine involves inducing 
an immune response from within a host.  
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To induce an immune response via the in-vivo method involves injection of the target 
antigen in combination with an adjuvant. Adjuvants were used long before their function 
was understood. Antigens must be injected into the host and taken up by immature DCs 
thereby stimulating them to mature and activate an immune response. The likelihood of 
uptake by DC’s is greatly improved by targeting of the antigen (Biragyn et al., 2001).      
Adjuvants are chemicals or molecules that strongly stimulate the immune system and if 
given in conjunction with a self-antigen may allow tolerance to be broken. 
Lipopolysaccharides (LPS) are a common adjuvant as they simulate the liposomes that 
often contain bacterial antigens and therefore induce a strong immunogenic response.  
 
Adjuvants important in stimulating a strong immune response however only a small 
number of adjuvants have ever been licensed for human use due to concerns with toxicity 
and safety. Fusing an immunogenic protein fragment to the self-antigen before injection 
into the host may remove the need for toxic adjuvants (Herrin et al., 2008, Hirano et al., 
2011, Kasahara and Sutoh, 2014). If an immunity against a particular antigen already 
exists, say through vaccination, then a strong immunogenic response will be mounted 
against the foreign part of the fusion protein.   
 
A novel study was recently released that showed an effective immune response could be 
mounted against primary tumour masses and metastasis without the need to identify a 
tumour specific antigen (Sagiv-Barfi et al., 2018).  
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The covalent coupling of short 6-12 amino acids strings of non-self-antigen to self-antigens 
can induce a high antibody titre against the self-antigen. Unfortunately, it has been shown 
that this response is variable among individuals and it has been shown that using a larger 
non self-antigen in the fusion protein resulted in a more stable response but also correlated 
with a lower average immune response.  This effect has been dubbed carrier suppression 
and has been noted by several other publications (Herzenberg and Tokuhisa, 1982, 
Herzenberg et al., 1982, Jegerlehner et al., 2010, McCluskie et al., 2016)  
 
Robo4 and fibronectin (extra domain A and B) represent two examples of tumour 
endothelial markers used for vaccination (Zhuang et al., 2015, Huijbers et al., 2010, Femel 
et al., 2014) 
 
Another way of improving immune response is improving the delivery of the antigen to 
the antigen presenting cells or providing a slow release of the antigen over a long period 
of time. Both methods were attempted through the use of nanoparticles.  
 
Targeting anti-angiogenic therapies 
 
The efficacy of most therapies can be increased through the targeting of said therapy to its 
desired tissue. Targeting of anti-angiogenics involves the identification of tumour 
endothelial markers. The endothelium presents as a desirable target due to its easy access 
using the blood vessels themselves.  Another large advantage is the relative stability of 
endothelial cell genome. The issue with anti-VEGF therapies is that the tumour itself is 
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extremely genetically unstable. In somatic tissues the rate of mutation is approximately 
1.62-9.0 mutations per cell division (Lynch, 2010). Genomic instability in cancer cells is 
likely to raise this number much higher. More rapid cell division (once every 3-4 days) 
sees the accumulated number of mutations drastically increase to several thousand over a 
life-time for individual cancer cells. The majority of these mutations remain present in only 
a small subset of cells.  When looked at as a whole, the total accumulated individual 
mutations of the entire tumour can quickly reach into the hundreds of millions or 
potentially billions (Ling et al., 2015, Diaz et al., 2012). This rapid mutation allows the 
tumour to adapt and express other pro-angiogenic factors other than VEGF.  
 
Targeting the endothelium of the blood vessels directly removes the risk of rapid adaptation 
away from a therapy. This is especially important when it comes to the targeting of a 
therapy. Highly targeted therapies have a high chance of the tumour mutating so that it 
down-regulates the target protein.  
 
Antibody Conjugates: 
 
It was not until 1993 that the first antibody drug conjugate was created to target tumour 
endothelium. To demonstrate complete necrosis of solid tumours the study conjugated ricin 
to antibodies raised against MHC class II proteins (Burrows and Thorpe, 1993). MHC class 
II proteins were expressed on tumour endothelium due to being induced by tumour cells 
releasing interferon-γ (IFN- γ). Antibody drug conjugates (ADCs) are typically used to 
increase the concentration, and specific distribution, of drugs in a tissue (Amani et al., 
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2019). It is thought that internalization of the protein takes the antibody and linked drug 
with it inside the cell, however, recent evidence suggests that simply releasing the drug 
into the tumour microenvironment can still result in entry into endothelial cells (Perrino et 
al., 2014). 
 
There has been positive pre-clinical data produced with the tumour endothelial marker 
Robo4. Antibodies against Robo4 were conjugated to neocarzinostatin resulting in the 
reduction of tumour growth and less negative side effects such as weight loss compared to 
anti-VEGFR2 conjugates (unpublished Data).  
 
Fibronectin is one of the most widely studied tumour endothelial markers (specifically 
extra domain B). It represents a useful marker for tumour specific endothelium as it is only 
present during remodelling of the endothelium and so is highly expressed in a multitude of 
developing tumours (Neri and Bicknell, 2005). Antibodies conjugated with radioactive 
iodine (131I) directed radiation therapy selectively at the tumour vasculature in glioma rat 
models (Spaeth et al., 2006). 
 
Introduction to Nanoparticles: 
 
The success of ADCs has prompted the study of how to most effectively target and deliver 
drugs and small molecules to specific tissues in a patient. Nanoparticles allow for the 
delivery of large numbers of drugs or molecules with many other benefits. The designing 
of “intelligent” particles that possess specific physiochemical properties such as size, 
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shape, surface chemistry, drug binding methods and drug release methods, can increase the 
efficacy and effectiveness of many anti-cancer therapies. By shielding small molecules like 
small interfering RNA (siRNA) from the highly reducing conditions inside an organism as 
well as endogenous nucleotide enzymes, nanoparticles are set to make DNA and RNA 
delivery  a more viable possibility (Zhang et al., 2011). 
The abnormal structure and growth of tumour vasculature results in a chaotic maze of 
vessels resultant from aberrant and imbalanced expression of angiogenic growth factors 
(Tredan et al., 2007). Healthy growth of vessels results in a hierarchical distribution from 
arteries to veins to capillaries. The structure of each individual vessel is also organized with 
endothelial cells aligned tightly together as monolayers with the basement membrane intact 
and pericyte intermediated close to the endothelial cells. To contrast this, tumour blood 
vessels are disorganized with a lack of regular monolayer structure to the endothelial cells 
(resulting in a lack of endothelial barrier, chaotic blood flow and leakiness). The basement 
membrane is discontinuous with large gaps left (some hundreds of nanometers in size 
(Hashizume et al., 2000)). These holes result in leakage from the tumour and vessels 
increasing the interstitial fluid pressure (IFP) and reducing blood supply resulting in 
hypoxia which stimulates angiogenesis and aids drug resistance (Rapisarda and Melillo, 
2009).  
Nano-therapies aim to circumvent or exploit these differences so as to normalize or destroy 
the tumour blood supply. Normalization aids in the effectiveness of other anti-cancer 
therapies. One approach taken is the prevention of binding of pro-angiogenic factors to 
their cell surface receptors. Antibodies, or other ligands, are raised against the desired 
receptor (such as VEGFR-2) and are conjugated to the surface of the nanoparticles. Upon 
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binding their pro-angiogenic growth factors these receptors can activate endothelial cells 
to release several proteases that degrade the basement membrane. Li et al., designed a 
nanoparticle to hold low molecular weight heparin and ursolic acid that would inhibit 
matrix metalloproteinase enzymes thereby disrupting the degrading of the basement 
membrane by pro-angiogenic growth factor signalling (Li et al., 2016b).  
 
Different types of nanoparticles used for siRNA delivery 
 
Nanoparticles and nanomaterials have gained greater interest due to their tuneable 
characteristics. Their physical, chemical, and biological interactions can be tailored to fit 
the required job. Three main factors differentiate nanoparticles: Their size, shape and 
composition. Generally, nanoparticles vary in size ranging from 10s of nanometers to 
hundreds.  
Nanoparticles are becoming more important as modern drugs require precise dosage or 
protection due to the presence of proteins or nucleic acids (Vo et al., 2012). The efficiency 
of most existing drug delivery methods are directly related to their size. Smaller 
nanoparticle carriers present with higher bioavailability, can cross the blood brain barrier, 
enter the pulmonary system, be absorbed directly by cells or move through tight junctions 
of endothelial cells (Kohane, 2007).  
Particles biodegradability level has also been an area of interest. Changing the bioactivity 
of the particle can change biodistribution and breakdown via endogenous enzymes (Zhang 
and Saltzman, 2013).   
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Before attempting to “design” the perfect nanoparticle vector for drug delivery, one must 
first understand how the body deals with these foreign nano-bodies.  
Nanoparticles can be administered through three main routes, injection, inhalation or be 
taken orally. Once inside an organism, the first hurdle is nanoparticle-protein interactions 
to form protein coronas. (Mu et al., 2014, Prado-Gotor and Grueso, 2011). Protein coronas, 
if they last long enough, are said to potentially even out govern the particle own 
biochemistry (Lundqvist et al., 2011). These coronas evolve and equilibrate over time as 
the particles pass from one fluid to another.  
After the nanoparticle-protein interactions the particles are absorbed from the blood vessels 
and distributed via the lymphatic system. If nanoparticles are recognized by lymph nodes 
as foreign bodies, then they will be engulfed by macrophages and cleared from the body. 
This makes nanoparticle delivery challenging but can be overcome through altering of size 
and surface characteristics of the particle.  
 
Gold: 
Gold nanoparticles (AuNPs) have attracted greater and greater interest as the study of 
nanomaterials progresses (Zhang et al., 2014b). AuNPs possess high X-ray absorption, are 
easy to synthesize, due to their inert nature their physiochemical properties are easy to 
control (Zhang et al., 2014a). They have strong affinity for thiols, amines and disulphides 
possess tuneable optical properties and also unique electronic characteristics (Y. Zhou, 
1999, Zhang et al., 2014b, Zhang et al., 2013).  
AuNPs can be divided into three groups:  
One dimensional nanorods, wires, tubes and belts. 
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Two dimensional nanoplate stars, pentagons, squares, hexagons and dimpled nanoplates  
Three dimensional nanotadpoles, dumbbells, nanodendrites and nanostars.  
Spherical AuNPs are the structure that has received the most interest due to the ease of 
synthesis (S. Zeng, 2011, Zhang et al., 2014b).  
AuNPs have potential use in therapeutics, detection biolabeling, drug delivery and 
diagnostics, imaging, photovoltaics and catalysis (Zhang et al., 2013, Youssef et al., 2014, 
Zhang et al., 2014b). 
The high surface area of AuNPs, along with their nontoxicity, make them ideal for loading 
drugs to including siRNAs and other anti-cancer agents (Luo et al., 2011).    
 
Liposome:  
Liposome nanoparticles are known as soft or organic nanoparticles. The simplest method 
for integration of siRNA is to simply mix liposomes with siRNA at the correct ratio to form 
lipoplexes (Podesta and Kostarelos, 2009). These complexes are easily endocytosed by the 
cell and so represent fantastic delivery vehicles. Liposomes synthesized by mixing siRNA 
with glycosylated liposomes to knockdown a hepatic gene Ubc13 (Sato et al., 2007). 
Integration of PEG is vital to the protection from reticuloendothelial breakdown and 
increase circulation time in the vasculature (Ho et al., 2013). PEG modification improves 
the nanoparticles stability and half-life in the blood circulation  however these still remain 
an issue for liposome nanoparticles, remaining at around 30 minutes (Santel et al., 2006, 
Aigner, 2007). 
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Silica:  
Hom et al., developed mesoporous silica nanoparticles containing 2.5nm pores within the 
nanoparticle providing potential binding locations for siRNA molecules. Hom et al., 
showed that binding within a pore gives siRNA molecules more protection from nuclease 
enzymes and other degrading conditions like low pH and oxidising environments, 
increasing the lifetime of the siRNA in serum.  
 
Chitosan: 
Chitosan is a polymer, specifically a mucopolysaccharide which is close in relation to 
cellulose. Crustacean shells are the major source of chitin which is deacetylated to form 
chitosan. The deacetylation of chitosan was first described by Rouget in 1859 through the 
decolouring of chitin in potassium permanganate and then boiling in sodium hydroxide 
(van der Lubben et al., 2001)  
 
The low toxicity of chitosan has been demonstrated in mice with the LD50 reaching above 
16 g/kg (Paul W., 2000). Chitosan is digested by chitinases which are secreted by the 
intestinal microorganisms after oral administration. Chitosan is an umbrella term that can 
be separated into many groups, along with its physical structure, this makes chitosan 
readily biodegradable. The biodegradable nature, biocompatibility and FDA approval, 
chitosan provides a fantastic medium for nanoparticle synthesis (Lee K. Y., 1995, 
Muzarelli R. A. A., 1996, Dodane V.).  
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Chitosan is formally given as a name once the polymer chitin has its acetylglucosamine 
units decreased to below 50% creating N-acetyl-glucosamine (chitosan) the presence of a 
primer amine at the C-2 position of N-acetyl-glucosamine results in the unique structural 
properties that can be exploited for nanoparticle synthesis and other bio-fabrication aims 
(van der Lubben et al., 2001) (Figure 2.1).  
 
Deacetylation is key to the properties of the chitosan polymer. Low deacetylation 
chitosan’s have increased absorption qualities with dose dependent toxicity at high and low 
molecular weights. Highly deacetylated chitosan’s show low toxicity at low molecular 
weights but that this may not be relating to absorption (Schipper N. G., 1996).  Chitosan 
has a pKa of around 6.5 so a pH of less than about 6 results in protonation of its amines. 
For this reason, synthesis is kept at a pH of 5.5 to ensure chitosan’s solubility in organic 
acid solutions. 
 
Chitosan is ideal for the development of drug delivery through nanostructures (anything 
from 1 nm – 100s of nm) due to stability, low toxicity and simple preparation methods 
(Tiyaboonchai W., 2003) (Figure 2.1).  
 
38 
Figure 1.5 
 
Figure 1.5 | Structure of Chitosan and Tripolyphosphate 
(A) Chitosan is a polymer of β-(1→4)-linked D-glucosamine, created by the deacetylation of a N-acetyl-D-
glucosamine polymer chain. The deacetylation percentage varies but must be above 50% to change chitin 
to chitosan.  
 
(B) Tripolyphosphate is the crosslinking agent used to form the chitosan nanoparticle. Nanoparticle 
formation is achieved through electrostatic interaction between amine groups on the chitosan polymer and 
the negatively charged groups of TPP. 
 
Chitosan 
Tripolyphosphate 
A 
B 
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Figure 1.6 
ChNP  
(-siRNA)  
Figure 1.6 | Chitosan Nanoparticle Crosslinking and siRNA Entrapment 
Figure 1.5 shows the crosslinking characteristics of TPP on chitosan and the ability of siRNA to become entrapped 
inside the chitosan-TPP mesh acting as a cross linker itself. The siRNA (orange) or the TPP (blue) are both 
negatively charged and so bind to the positive chains on the chitosan polymer (green) inducing polymerisation and 
formation of the nanoparticle.    
As can be seen in ChNP (-siRNA), the TPP acts as a crosslinker, binding the different strands of chitosan 
together.  
ChNP (+siRNA) Shows that siRNA also acts as a crosslinker, binding to the chitosan and becoming 
entrapped inside the chitosan-TPP crosslinked mesh.  
 
ChNP  
(+siRNA)  
siRNA 
TPP 
Chitosan 
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Ionic gelation has been shown to be an extremely successful method for drug entrapment 
inside chitosan nanoparticles (Raja et al., 2015). Tripolyphosphate (TPP) represents a 
common polyanion used in chitosan-nanoparticle synthesis (Figure 1.5). Ionic gelation is 
based on the method of electrostatic interaction between carboxyl groups on the chitosan 
polymer with negatively charged groups of polyanions (Figure 1.6). The size of 
nanoparticles is directly affected by chitosan:TPP weight ratio and must be kept between 
3:1 and 6:1. Increasing temperature has also been shown to decrease particle size 
(HueiChen, 2008a). Other methods of drug binding exist such as the microemulsion 
method in which free amino groups on the chitosan polymer conjugate with glutaraldehyde 
or the polyelectrolyte complex (PEC) method emulsification-crosslinking method, 
complex coacervation method, solvent evaporation method and coprecipitation method 
(Nagpal et al., 2010). 
 
Nanoparticle Characteristics: 
 
• Size: 
The size and shape of any given nanoparticle defines how the body will interact with and 
affects biodistribution, toxicity, absorption and whether targeting moiety’s can be attached 
(McMillan et al., 2011). It has been shown that 100 nm particles have a 2.5 times greater 
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cell uptake compared to 1000 nm nanoparticles and over a 6 times increase in uptake 
compared to 10 µm particles (Desai et al., 1997). 
 
An obvious key role for any nanoparticle delivery system is the eventual release of its drug 
at the desired location. Size has a direct effect on drug release. Smaller particles have a 
larger surface area to volume ratio. If the drug in question is kept inside the particle then a 
larger volume to surface area will result in a more rapid release (Buzea et al., 2007). The 
size is one of the key factors in biodistribution, determining filtering by the lymph system 
and absorption by various tissues. It has been demonstrated that nanoparticles synthesized 
at greater than 200 nm are more likely to activate the lymphatic system and be removed 
from the vascular system sooner (Prokop and Davidson, 2008) In 2005 nanoparticle uptake 
in red blood cells was studied. Red blood cells were used to study passive uptake of 
particles due to their lack of a nucleus and other complex organelles. The study found that 
particles smaller than 200 nm we capable of passive cellular uptake (Geiser et al., 2005). 
Therefore, 200 nm represented an important limit due to filtration, immune activation and 
cellular uptake.  
 
• Surface Properties: 
It can now be seen that size has a large role to play in the effectiveness of any nanoparticle 
therapy, however, the surface characteristics of a nanoparticle also play a vital role in its 
interaction with cells and drug delivery (Bantz et al., 2014). Many factors must be taken 
into account for surface properties: targeting ligands, surface charge, stability and receptor 
binding (Khanbabaie and Jahanshahi, 2012). Clearance of nanoparticles from the system 
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is of obvious concern. Hydrophobic nanoparticles are more likely to trigger an immune 
response or be cleared by the lymphatic system through binding to other components of 
the blood (Kou L., 2013). Polyethylene glycol (PEG) can be used to diminish surface 
hydrophobicity and has been shown to decrease opsonization (Araujo et al., 1999).   
 
Aggregation is also a real issue for any nanoparticle therapy. A nanoparticles particular 
chemistry and size are what define its interaction with any biological structure. 
Aggregation of smaller particles into a larger “clump” chances these characteristics and 
can have huge impacts on receptor binding and cellular uptake. Several methods have been 
developed to attempt to prevent aggregation of particles such as alteration of zeta potential 
or capping agents (Li and Kaner, 2006).  
 
Binding moieties also play a role in nanoparticle therapies. Many particles store drugs 
inside the particle to protect them from the reducing conditions inside the vascular system. 
However, should it be better to have the drug on the outside or if targeting 
moieties/antibodies are to be attached then the surface chemistry of the nanoparticle is key 
in achieving these ends.  
 
• Drug Loading and Release: 
Perfecting the size and surface properties of a nanoparticle ensure that the drug is delivered 
to precisely where you want it without being cleared by the body’s natural systems. 
However, there is no benefit to perfecting the chemistry of your particle if the drug cannot 
be released once it reaches the desired target. Many factors can go into stimulating drug 
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release e.g. pH, drug solubility, temperature, desorption of a surface bound drug, diffusion 
from inside the particle, dissolving of the particle matrix/polymer (Siepmann and 
Gopferich, 2001, Son G.H., 2017).  
 
Two main types of nanoparticle are used for carrying drugs within the nanoparticle itself; 
Nanospheres and nanocapsules. Nanospheres are a homogeneous particle made from the 
introduction of surfactants and micelle formation during synthesis. Nanocapsules are 
heterogeneous and contain the drug inside a reservoir formed from a polymer (Mora-
Huertas et al., 2010). Nanocapsules are formed through an ionic interaction between 
negatively charged and positively charged particles. Chitosan is one of the better-known 
materials used to create nanocapsule particles. An ionic interaction between negatively 
charged phospholipids and positively charged chitosan molecules forms the nanoparticle 
polymer mesh.  
 
Nanospheres release their contents through erosion of the particle matrix until a rapid burst 
of drug is released in one go. Nanocapsules hold the drugs more dispersed throughout the 
particle mesh and require it to diffuse out. If there are ionic interactions between the drug 
and particle polymer strands, then other agents are required to induce release. For chitosan 
it is known that heparin induces rapid depolymerisation and release of ionicly bound 
molecules within the nanoparticle mesh due to its strong ionic interaction out competing 
other bound molecules (Raja et al., 2015).  
 
• Targeted Drug Delivery: 
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Choosing the correct starting materials can improve the particles chances at reaching its 
desired target but to improve the specificity of any therapy, additional targeting moieties 
are required. Passive targeting is when a particle reaches its target without active methods 
via diffusion through large epithelial junctions for example (Varshosaz and Farzan, 2015). 
Active targeting involves conjugation of a specific ligand that is bound upon reaching its 
target. A perfect nanoparticle therapy can reach its target, recognize a specific ligand, bind 
to said ligand and deliver its payload to specific cells, tissues or pathogens. Targeting 
methods include peptides, antibodies and aptamers (Rihe Liu, 2009, Friedman et al., 2013). 
A wealth of literature already exists on antibody targeting of drug therapies (Padma, 2015) 
Small molecules predominate the nanoparticle targeting landscape due to their ease of 
synthesis and conjugation with the particles. Biotin (vitamin H) is a prime molecule in 
particle targeting due to its high affinity for streptavidin (Pramanik et al., 2016). Folic acids 
affinity for the folate receptor has also placed it as a valuable targeting moiety due to the 
high expression of the receptor on cancer cells (Zhao et al., 2008).  
 
Han et al., studied a way to target chitosan nanoparticles at the tumour vasculature using 
an Arg-Gly-Asp (RGD) peptide which binds to ανβ3-intagrin expressing cells. In this study 
Flow cytometry and fluorescence microscopy were used to assess the binding efficiency of 
the Arg, Gly, Asp-Chitosan-Nanoparticles (RGD-CH-NP). The RGD-CH-NP’s were 
conjugated to an Alexa555 fluorophore and siRNA and were roughly 200nm in size. Han 
et al., used siRNA against periostin osteoblast specific factor (POSTN) was used to assess 
the knockdown efficiency of the siRNA conjugated RGD-CH-NP’s. The RGD-CH-NP’s 
were also tested in-vivo. Tissue sections from relevant locations were studied under x200 
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magnification to confirm ανβ3-intagrin mediated binding (Han et al., 2010). A2780ip2 
(ανβ3 negative) and SKOV3ip1 (ανβ3-intagrin positive) breast cancer cell lines were used 
for the binding efficiency studies in-vitro. Comparison of binding efficiency of the CH-NP 
and RGD-CH-NP in each cell line showed the advantages of targeting ανβ3 with increased 
cellular uptake demonstrated by increased fluorescence in the given sections. Five 
concentrations were made of the RGD-CH-NP and tested in each cell line. Unsurprisingly, 
the five concentrations of NP had little effect on the A2780ip2 cells. In contrast, SKOV3ip1 
cells showed a marked, concentration dependent, increase in binding. When comparing the 
binding efficiency of CH-NP and RGD-CH-NP using Alexa555 labelled nanoparticles, 
A2780ip2 cells show little increase in binding whereas SKOV3ip1 cells exhibit a threefold 
increase in binding efficiency with the addition of RGD (Han et al., 2010). This shows that 
the expression of ανβ3 is a viable target for RGD-CH-NP as it dramatically increases 
binding efficiency and offers a tumour vasculature specific target. Transmission electron 
microscopy (TEM) was also used to observe binding of RGD-CH-NP in tumour cells. TEM 
images confirmed the higher binding efficiency of SKOVip1 cells. Confocal microscopy 
was used to observe intracellular delivery of CH-NP and RGD-CH-NP. Alexa555 staining 
showed higher internalisation of siRNA/RGD-CH-NP in SKOV3ip1 cells compared to 
siRNA/CH-NP, again showing the increased efficacy gained by targeting ανβ3-intagrins. 
In-vivo studies for RGD-CH-NP’s demonstrated similar increases in binding and targeting. 
A preliminary 48 h mouse study showed that the RGD-CH-NP’s showed up in > 80% of 
areas examined with a 3-fold higher localisation in tumour tissues compared to CH-NP. 
This data from (Han et al., 2010), shows that chitosan nanoparticles with siRNA can induce 
a knockdown in tumour endothelial cell related genes and that targeting the particles to the 
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endothelial cells themselves can increase the localisation of the particles to the tumour 
vasculature.  
 
Liposomes present another branch of active targeting. The similarity to the cell membrane 
allows liposomes to be tailored to incorporate the targeting ligands into their membrane. 
These membrane like properties allow for more natural release of the drugs upon reaching 
their target however liposomes come with their own drawbacks such as their fragility 
(Kelly et al., 2011, Singh and Lillard, 2009). 
siRNA: 
Fire and Mello discovered the revolutionary technology of small interference RNA 
molecules (siRNA) and their ability to induce sequence specific messenger RNA 
degradation (Fire et al., 1998). The mediators of this gene silencing are 21- and 22-
nucleotide small interfering RNA duplexes. RNA duplexes are generated by cleaving 
longer double stranded RNA molecules with ribonuclease III. Gene silencing through 
double stranded RNA molecules had been shown to work previously in insects, however, 
had not been shown to be possible in mammalian cell lines. It was shown that high 
concentrations of double stranded RNA molecules induced an interferon response which 
would be associated with an inflammatory response in an organism. Sayda et al., showed 
that double stranded base paired 21- and 22-nucleotide siRNAs could induce degradation 
of specific mRNA targets within Drosophila embryos and so paved the way for mammalian 
siRNA technologies (Elbashir et al., 2001). Sequence specific degradation of messenger 
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RNA allows for targeted silencing of endogenous gene expression in many mammalian 
cells and has gained a lot of attention for its potential in cancer therapies. 
 
Filleur et al., studied the potential of delivering VEGF siRNA to tumour endothelial cells 
to combat resistance to Thrombospondin-1 therapies. The strategy was to inhibit 
endothelial growth factor with siRNA thereby increasing the efficacy of any anti-VEGF 
therapy. The team implanted luciferase expressing cJ4-derived cells into nude mice and 
injected luciferase siRNA either into the tail vain or directly into the tumour (Filleur et al., 
2003). For this study there was no attempt to target the naked siRNA. Interestingly, the 
direct tumour administration had no effect on luciferase activity whereas systemic 
administration showed a 50% knockdown of luciferase.  
 
Schneider et al., uses bispecific VEGF-R2 antibodies to target anti CD31 (PECAM) siRNA 
to endothelial cells. MCF-7 xenograft cells which did not express CD31 were implanted in 
mice and did not express CD31 ensuring any knockdown was purely endothelial related 
(Schneider et al., 2012).  
Double stranded RNA sequences pertaining to the target gene are transduced into the 
cells. Upon entering the cell, the RNA gets incorporated into a variety of proteins 
forming the RISC complex. The double stranded RNA is then cleaved into two separate 
strands and the less stable strand is retained within the complex. The complex now 
“scans” for complementary sequences, binds them and induces mRNA cleavage. mRNA 
coming from the nucleus is now bound and cut as it is recognised as foreign by the cell 
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resulting in a lack of translation from the target mRNA to its relevant protein, thus 
silencing the gene (Figure 1.7).  
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Figure 1.7 
Figure 1.7 | siRNA and The RISC Complex 
siRNA (blue) enters the cell inducing the formation of the RISC complex (grey). AGO2 (green) binds to the 
complex, trapping the double stranded RNA. The siRNA is trapped inside the complex and the double strands 
are separated. One strand is cleaved. The complex then diffuses around the cell interior, binding any 
complementary strands (red) which are then separated again, and the complimentary strand cleaved. The 
binding and cleaving of complimentary strands result in removal of any complimentary mRNA which 
effectively silences the relevant gene.  
RISC 
RISC Assembly 
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Nanoparticles and their use as siRNA carriers 
 
Binding siRNA to a vector can improve delivery efficiency, targeting efficiency and offer 
protection for the siRNA from nucleases and other damaging conditions. When designing 
a vector to transport siRNA molecules to the tumour vasculature in-vivo the first, and 
potentially most important, decision must be the nature of that vector. Use of nanoparticles 
in cancer research has increased over the last 10 years. The potential for conjugation of 
large numbers of drugs or imaging probes offers novel opportunities for improving efficacy 
and resolution of treatments and research methods.  
 
Though the material used as the basis for the nanoparticle structure is important, the next 
step must be to establish the most effective way to bind the siRNA. siRNA can be attached 
to nanoparticles through several methods. Table 1 column 2 lists the various methods for 
siRNA conjugation discussed here. Some methods such as electrostatic binding present 
with easy release of siRNA but do not retain siRNA under physiological conditions as 
effectively. 
 
Though not targeting vascular endothelial cells, Katas and Alpar studied three methods for 
binding siRNA to chitosan nanoparticles; simple complexation and the two forms of ionic 
gelation, adsorption and entrapment (Katas et al., 2013). Varying forms of chitosan was 
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used in nanoparticle synthesis to assess the biological activity. Sodium tripolyphosphate 
(TPP) was added to the nanoparticle conjugate to increase the positive charge and aid in 
siRNA adsorption and entrapment. Chitosan glutamate showed the highest silencing of the 
pGL3 luciferase gene transfected into CHO K1 cells resulting in a 51% gene knockdown 
with simple siRNA complexation, 82% with TPP-entrapment and 63% with TPP-
adsorption at 24 h after incubation. In CHO K1, cells the chitosan glutamate showed higher 
knockdown percentages than Lipofectamine. Interestingly, when used in HEK293T cells, 
the chitosan glutamate nanoparticles were 22%, 14% and 64% less efficient than the 
Lipofectamine for TPP-adsorbed, TPP-entrapped and chitosan-siRNA complex 
respectively (Katas et al., 2013). This discrepancy in knockdown efficiency shows the 
importance of choosing the siRNA binding method best suited for the chosen nanoparticle 
and for the chosen cell type. It is for this reason that targeting tumour vasculature appears 
to be a rational choice. Tumour vessel endothelium vary genetically and phenotypically far 
less than the tumour cells themselves. Designing a nanoparticle vector to transport siRNA 
to the tumour vasculature would require far less alteration between tumour types and 
patient variations.   
 
MTT cell viability tests showed over 90% average cell survival for the chitosan-siRNA 
complex and naked siRNA. MTT viability assays test the reducing power of the 
mitochondria in the cell. If a chemical kills a cell, it will no longer be able to reduce the 
components of the MTT assay showing the cells to be non-viable. TPP-chitosan 
nanoparticles used for entrapment and adsorption had 18-40% loss in cell survival. Some 
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TPP-chitosan treated cells did recover 48 h after incubation; however, this does indicate 
transient stress when exposed to these TPP-chitosan nanoparticles. 
 
Knockdown efficiency of the chitosan particles was represented by percentage knockdown 
and relative response ratio. Silencing percentages and ratios were calculated through a 
decrease in fluorescence due to gene silencing.  The luminescent pRL-TK gene was used 
to account for cell death or off target effects. The method for attaining a comparison of 
luminescence were not mentioned and no images are provided. Gel electrophoresis and 
Western Blotting would have been a more accurate way to measure gene knockdown as it 
does not rely on selecting image slices if confocal imaging was used.  
 
Varied cell response presents a large problem with assessing the effectiveness of 
nanoparticle siRNA delivery in-vitro. Some immortalised cells are extremely efficient in 
uptake and delivery of nanoparticles whereas some primary cell types take up foreign 
structures far less readily. Studies that knockdown exogenous genes transfected into 
immortalised cells must be looked at with caution. Immortalised cells that have been shown 
to be easily transfectable with exogenous genes are not representative of the cellular 
trafficking and filtering of healthy endothelial cells. 
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Aim of this thesis: 
 
The overarching aim of this thesis is the development of a method for the delivery of 
therapeutics to perturbate the expression of CLEC14A in endothelial cells in-vivo. This 
will be attempted through two methods. First the development of a nanoparticle that can 
bind and retain CLEC14A siRNA to protect it from the reducing conditions and enzymatic 
breakdown within an organism’s vasculature. The particle will be tested for siRNA 
binding, siRNA release, Cellular uptake of the nanoparticle, method for cellular uptake and 
knockdown of CLEC14A using only siRNA bound nanoparticles. Methods for improving 
the knockdown of the particles will be examined.  
 
A CLEC14A fusion vaccine will be developed with the aim of breaking immune tolerance 
to CLEC14A so that an immune response can be mounted against CLEC14A expressing 
cells in tumour blood vessels. The nanoparticles created in the previous siRNA studies will 
be tested for binding and retaining proteins to better deliver the protein to antigen 
presenting cells.  
 
Finally, in-vivo and gene array studies will be performed to look at the biodistribution of 
the nanoparticles in a mouse model as well as the impact of the nanoparticles on gene 
expression within endothelial cells.  
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Chapter II. 
Materials and Methods 
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Materials: 
 
 
Table 2.1. Buffers and Solutions commonly used in experiments with concentrations of 
each chemical component.  
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Table 2.2. Primary Antibodies: 
 Western Blot (WB), ELISA, Nanoparticle Conjugation.  
  
Table 2.3. Secondary antibodies with manufacturer and catalogue details, species raised 
in and application in the lab e.g. Western Blot (WesBlot), Nanoparticle Conjugation (NP 
Conjugation) 
Table 2.4. Recombinant proteins showing epitope tags, the system used for expression, 
for what application they were used and the buffer they were kept in. These were 
synthesised in the Bicknell Lab.   
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Table 2.5 Oligonucleotide primers used for sequencing. The sequence is displayed 5’-
3’. Created by Genescript.  
 
Table 2.6. Plasmids used for protein production and restriction enzymes used to extract 
relevant fragments. FrC plasmids were created by the Kai Tolner group (University 
Birmingham) and the VLRB plasmids were synthesised by Genescript. 
 
Table 2.7. Cell Types The varying cell types used for experimentation. HEK293 for cell 
uptake and protein production. HUVEC for knockdown studies. LLC for mouse tumour 
implantation. HeLa for cell imaging.  
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Table 2.8. siRNA: The two duplexes of siRNA used to knockdown siRNA. It was found 
that Duplex 2 (D2) was more effective than D1 and so it was D2 that was used for the 
nanoparticle studies. Duplexes were synthesised by Source Bioscience.   
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Methods: 
 
Polymerase Chain Reaction 
Polymerase chain reaction (PCR) was performed on RNA extracted from cell lysis. RNA 
from the cell lysis was extracted via the RNeasy RNA extraction Kit (Qiagen) using the 
kits recommended protocol. The purified RNA was converted to complimentary DNA 
(cDNA) via the High-Capacity RNA-to-cDNA Kit™ (Thermo Scientific) using the 
provided protocol with the kit. PCR amplifications used forward and reverse oligonucleotide 
primers that were newly designed for the CLEC-FrC construct (Table Below).  
 
The Phusion high fidelity DNA polymerase kit New England Biolabs (NEB) was used for 
the PCR protocol. Specially designed forward and reverse primers were designed for the 
CLEC-FrC construct (Genscript).  
 
 
Template cDNA from HEK293 lysate  1 μL (500 ng)  
5xPhusion HF buffer  5 μL 
10mM dNTPs  0.5 μL 
10μM Forward primer  1.25 μL 
10μM Reverse primer  1.25 μL 
DMSO  0.75 μL 
Nuclease free dH2O  9.75 μL 
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PCR was carried out as follows, with annealing temperatures and protocol taken from 
New England Biolabs and the NEB Phusion annealing temperature calculation program.  
 
  
Restriction Enzyme Digest: 
All restriction enzymes were ordered from NEB and were used with the manufacturer’s 
suggested protocol. Enzyme digests were incubated at 37°C for 1 hour.  
 
Digested plasmids were separated by agarose gel electrophoresis. 1% agarose gels were 
made with 1 gram agarose (Bioline) in 100 ml of TAE buffer (table 1). The solution was 
microwaved for 2-3 minutes until the agarose was completely dissolved and the resultant 
liquid was boiling. The agarose solution was left to cool at room temperature. 10 µL of 
SYBR safe DNA gel stain (Invitrogen) was added after a 2-3 minutes of cooling. 6x DNA 
loading dye (Themo scientific) was added to the sample before loading onto the agarose 
gel. A 1kb DNA ladder (Themo scientific) was added to the first well to assess size of the 
DNA fragments.  
The New England Biolab protocol was followed for all restriction enzyme digests. 
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DNA/RNA Agarose Gel Electrophoresis: 
Molecular Biology grade agarose (Sigma) was used at varying concentrations.  
 
Restriction enzyme Restriction enzyme digest, 1% (w/v)  
siRNA dissociation 4% (w/v) 
Streptavidin dissociation 5% (w/v) 
 
All DNA agarose gels were made in 1 x TAE buffer with 1% SYBR safe DNA gel stain 
(Invitrogen). siRNA samples that contained a fluorophore did not require SYBR safe 
labelling. DNA/siRNA samples were mixed with 6x DNA loading dye (Thermo scientific). 
All DNA gels were run with Generuler 1kb DNA ladder unless specified otherwise (Them 
scientific). 
 
Restriction enzyme digests were run at 100 V for 30 minutes visualized using the 
GeneSnap imaging system. siRNA gels were run at 110 V for 30 minutes and were 
visualized using the Odyssey® Fc Imaging System (Li-COR).  
DNA and RNA gel electrophoresis followed the protocol laid out by Addgene. 
Electrophoresis experiments involving nanoparticles were developed specifically for this 
thesis.   
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Bacterial Transformations: 
Bacterial transformations were performed in competent gold efficiency DH5α E. coli 
(Bioline). Bacteria were kept in 20 µL aliquots which were thawed on ice and plasmid was 
added. The mix was incubated for 20 minutes on ice and then heat-shocked in a 42°C water 
bath for 90 seconds. The transformation mix was removed from the water bath and 
incubated for 2 minutes on ice. 200 µL SOC media was added and the mix was transferred 
to a shaking incubator at 37°C for 1 hour. After the hour incubation the mix was spread 
onto a pre-warmed LB agar plate, containing relevant antibiotic, and grown over night for 
isolated colonies.  
Bacterial transformations were performed using the ThermoFisher suggested protocol.  
 
Plasmid DNA Isolation: 
A single colony of E. coli was selected from the transformation plates and introduced into 
4 mL of LB media with the appropriate antibiotic (Ampicillin 100 µg/mL). Colonies were 
grown overnight in a shaking incubator at 37°C. The overnight cultures were pelleted by 
centrifugation (13,000 rpm) and plasmids isolated with GeneJET plasmid miniprep 
(Thermo scientific). DNA concentration was measured using a NanoDrop 1000 
spectrophotometer (Thermo scientific).  
The Thermo scientific protocol was followed for Plasmid DNA isolation. 
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Sequencing: 
DNA was sequenced using the terminal nucleotide sequencing method and was performed 
by the functional genomics service (The University of Birmingham).  
 
Gene Array: 
The gene arrays were purchased for Source Biosciences. HUVEC cells were treated with 
siRNA containing chitosan nanoparticles and the RNA was extracted with RNeasy 
isolation kit (Qiagen 74104) (Full nanoparticle transfection protocol can be seen in: 
Nanoparticle Transfections section of materials and methods). RNA samples were sent to 
Source Biosciences to perform the gene array. Analysis of the data was aided by Dr 
Zsuzsanna Nagy (z.nagy@bham.ac.uk).  
 
Cell Culture: 
Cell culture experiments were performed in a laminar flow hood under sterile conditions. 
Immortalized cell lines (HEK293 and HeLa) were grown in Dulbecco’s modified Eagle’s 
serum (DMEM) (Sigman-Aldrich, Gillingham UK) with 10% foetal calf serum (FCS 
GIBCO Life technologies), 4mM L-glutamine (Life technologies), 100 µg/ml penicillin 
and 100 µg/ml streptomycin (Life technologies. Primary cells (HUVEC) were grown in 
Medium 199 10% FCS, 1% bovine brain extract (Maciag et al., 1979), 90 µg/ml heparin 
(Sigma Aldrich), 4 mM L-glutamine (Life technologies) 100 µg/ml penicillin and 100 
µg/ml streptomycin (Life technologies).  
This protocol was developed by the Bicknell Lab. 
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siRNA Transfections  
All small interfering RNA (siRNA) duplexes were ordered from Eurogentec and made up 
to a stock concentration of 100 µM in RNase free water to be stored in aliquots at -80°C. 
 The day before siRNA transfection, 175,000 cells were plated in antibiotic free media onto 
a gelatine coated 6 well plate. The next day, for each separate transfection, two mixes were 
made. The first contained 167.5 μL Optimem medium (Thermofisher 31985062) and 2.5 
µL of 20 µM siRNA (resulting in a final concentration of 50 nM when added to the cell 
culture. The second mixes 27 µL Optimem with 3 µL RNAiMAX Lipofectamine 
(Invitrogen #13778-150) (resulting in a final concentration of 0.3%). Both of these mixtures 
were left at room temperature for 10 minutes. After 10 minutes the lipofectamine mix was 
added to the siRNA mix and this new mixture was again left for 10 minutes at room 
temperature.  800 µL Optimem was added to each well of the 6 well plate and after the 10 
minute incubation, the 200 µL siRNA/lipofectamine mix was added to the cells as well. The 
cells were incubated at 37°C for 4 hours upon which the media is removed and replaced by 
media without antibiotics. The cells were left for the next day and on the 4th day were 
collected and lysed for analysis.  
This protocol was developed by the Bicknell Lab. 
 
Lentiviral Transduction: 
Lentiviral transduction was performed in HEK293T cells. Plasmid transfection was 
achieved through the use of linear molecular weight 25000 Da polyethyleneimine (PEI) 
(Sigma-Aldrich #408727) using a 1:4 ratio of DNA:PEI. For 10 cm plates, HEK293T cells 
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were transfected with a pWPI plasmid containing the gene of interest (4.39 µg), psPax2 
(3.29 µg) and pMD2G (1.32 µg). 5 HEK293T plates were transduced and left to generate 
lentiviral particles for 24 hours. The media from 5 plates was used to transduce 1 plate of 
fresh HEK293T cells and so media from the 5 was concentrated down using Corning Spin-
X UF concentrators with 5 kDa molecular weight cut off (Sigma-Aldrich #CLS431487). 
Lentiviral constructs contain an internal ribosome entry site (IRES) followed by the GFP 
gene which results in the translation of both the gene of interest and GFP. GFP expression 
allows for microscope or flow cytometry analysis to asses transduction efficiency.  
The specific lentivirus protocol used was developed by the Bicknell Lab.  
 
Nanoparticle Transfection: 
Nanoparticle transfection was achieved without PEI or lipofectamine. Simply: A 
nanoparticle stock was made up in 1 ml of the required cell medium. The stock contained 
4.75 ng siRNA. 10 µL, 20 µL, 30 µL or 40 µL were taken from the stock and mixed with 
the cell medium to be incubated with the HUVEC. These volumes provided the 1x 2x 3x 
and 4x concentrations used for the knockdowns. 1x concentration of the nanoparticles 
contains 50 nM siRNA and each increasing volume contains more nanoparticles and 
thereby more siRNA.  Nanoparticle stock was added to 900 µL media in a 6 well plate with 
175,000 cells with more cell medium added to make the total volume to 1 mL.  
This method was modified for this thesis from the standard siRNA transfection (laid out 
in (siRNA transfections) but replaced the lipofectamine and siRNA steps with addition of 
siRNA containing nanoparticles. 
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HUVEC Isolation: 
Human umbilical cords were collected from Birmingham Women’s Hospital with written 
consent from the mother. Upon return to the lab the cords were placed in a laminar flow 
hood, cleaned thoroughly with 70% ethanol (v/v) and checked for any damage. Olive 
cannulas were attached to the cord via two cable ties. Sterile PBS was flushed through the 
cannulas and cord to clear blood clots. The cannula at one end of the cord was closed and 
collagenase 1A (Sigma-Aldrich #C2674) was injected into the cord to fill it. The cord was 
incubated at 37°C for 20 minutes after which one of the cannulas was opened and the detached 
endothelial cells washed out with two rounds of 20 mL PBS into a 50 mL falcon tube. The 
cells were centrifuged at 1100 rpm for 5 minutes and the supernatant removed. The pellet was 
re-suspended in either M199 or DMEM 10 μg/mL gentamicin and 250 ng/mL amphotericin B 
(Thermo Scientific #R01510), then seeded onto gelatine coated cell culture plates. The medium 
was changed the next day and again 24 hours later. The cells were considered passage 1 when 
they were confluent enough to split from 1 10 cm dish to 3.  
The specific HUVEC isolation from umbilical cords protocol used was developed by the 
Bicknell Lab. Licence 70/8704 held by Roy Bicknell 
 
Cell Lysis 
Cells were washed twice with PBS and removed from the cell culture dish via cell scraping 
or exposure to trypsin (for a 10 cm plate 2 ml of trypsin was added and incubated for two 
minutes at room temperature). For HEK293T cells 500 µL of lysis (RIPA) buffer was 
added to a 10 cm plate and cells were scraped from top to bottom as the plate was rotated 
around its axis. After collection, the cells were centrifuged at 1100 rpm for 5 minutes to 
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remove trypsin enzyme. Once centrifuged lysis buffer was added to the cells. After cell 
collection through cell scraping or trypsin digest and addition of lysis buffer, cells were 
vortexed for 1 minute. Large cell fragments were removed from the lysis through 
centrifugation at 15,000 rpm at 4°C for 30 minutes. The supernatant was removed and 
added to a fresh micro centrifuge tube to be stored at -20.  
The Thermofisher cell lysis protocol was followed.  
  
 
SDS PAGE Western Blotting 
Proteins were separated using the chromatography method of sodium dodecyl sulphate 
polyacrylamide gel electrophoresis (SDS-PAGE). SDS-PAGE gels were set in disposable 
XCell SureLOCK mini gel Cassettes (Thermo Scientific). Once set the gels were loaded 
and run in XCell Surelock apparatus in an SDS running buffer at 80 mV through the 
stacking gel and 140 mV through the resolving gel. The resolving gel can be made in 
several different percentages usually ranging from 8-18% with the most common being 
10%. A 10% gel was made using 97.5 mM Tris pH 8.8, 0.025% SDS, 0.001% ammonium 
persulphate, 0.001% TEMED with 10% polyacrylamide.  
 
Stacking gel was made with 15.8 mM Tris pH 6.8, 0.013% SDS, 5% polyacrylamide, 
0.001% ammonium persulphate and 0.001% TEMED. Once proteins were run on the SDS 
gel they were transferred to PVDF membranes using transfer buffer inside the XCell 
Surelock apparatus for 2 hours at 30 mV. After transfer, PVDF membranes were blocked 
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in 2% (w/v) milk in PBST for 1 hour at room temperature. After blocking, PVDF 
membranes were washed once in PBS-T and then incubated with Primary antibodies 
(concentrations found in table 2.2). PVDF membranes were incubated with the primary 
antibodies for 1 hour at room temperature or 4°C over night. Post primary antibody 
incubation, membranes were washed 5 times at 5 minutes per time in PBS-T. PVDF 
membranes were then incubated with HRP conjugated secondary antibodies for 1 hour at 
room temperature (concentration can be seen in table 2.3). Again, to remove non-specific 
binding after incubation with secondary antibodies the membrane was washed 5 times at 5 
minutes per wash in PBS-T. HRP conjugated antibodies were detected using enhanced 
chemi-luminescence (ECL) via Amersham ECL western blotting detection reagent (GE 
Healthcare). The membrane was visualised either using Amersham Hyperfilm X-ray film 
(GE Healthcare) or Odyssey® Fc Imaging System (Li-COR).   
Western Blot protocol was adapted from the Thermofisher protocol by the Bicknell Lab.  
 
ELISAs 
Enzyme-linked immunosorbent assays (ELISAs) were used to assess the binding efficacy 
of the antibody linked nanoparticles.  
 
First, 100 µL of CLEC14A antigen (diluted 1 in 500 PBS) was added to each of the relevant 
wells in the 96 well Nunc MaxiSorp™ flat-bottom dish and incubated at 4ºC overnight. 
The next day, liquid was removed from the wells and 200 µL of blocking solution (10% 
milk w/v in PBS) was added. The plate was then incubated for a further 2 hours at room 
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temperature after which it was washed 5 times with 100 µL PBS-T. Next, 200 µL sonicated 
antibody labelled nanoparticles were added to each well including the controls. The 
nanoparticles were incubated on the plate for 1.5 hours at room temperature with constant 
agitation. After the incubation period, all wells were washed 5 times with 100 µL PBS-T. 
After the final wash the plates were imaged on the Odyssey® Fc Imaging System (Li-
COR).  
This ELISA method was developed for this thesis by adaptation of the standard ELISA 
method found in Engvall and Perlmann (Engvall and Perlmann, 1972). 
 
Production of CLEC14A-FrC 
The CLEC14A-FrC construct was cloned in the pWPI plasmid. The plasmid was acquired 
from the Kai Tollner group (University of Birmingham 4th floor IBR) and was amplified 
in gold efficiency DH5α E. coli. The concentration of amplified plasmid was calculated 
through spectrophotometry analysis with the NanoDrop 1000 spectrophotometer (Thermo 
scientific).  
 
The protein was produced in HEK293-T cells. The gene was transfected into HEK293-T 
cells via lentiviral transduction (Lentivirus protocol can be seen in Lentiviral 
Transduction). Transduced cells were transferred to 10 cm cell culture dishes and grown 
to confluency in DMEM. The cell medium was replaced with Opti-MEM and left to 
produce and secrete the recombinant protein.  
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Protein was harvested through several methods including collection of the cell medium 
(Opti-MEM) and lysis buffer and sonication of cells using the Thermofisher protein 
harvesting protocol. The cell lysis was analysed for presence of the target protein through 
western blotting. No purification steps were performed.   
 
Production and Purification of CLEC14A-VLRB 
The L-VLRB plasmid was transduced into SHuffle® T7 Express lysY Competent E. coli 
(NEB #C3030J) using the heat shock method. Bacteria were grown over night at 30°C in 
150 ml LB medium, ampicillin (100 µg/ml). To ensure bacteria were in the exponential 
growth phase, OD590 was measured and the culture was diluted down with LB broth to 
OD590 0.3. The culture was then left to grow until it reached OD590 0.5. At OD590  1mM 
IPTG (ProMega #V395D) was added to all but two samples to induce protein production. 
10 ml samples were removed at 0.5 hrs, 1 hr, 2 hr, 4 hr and 22 hrs and frozen. The samples 
were defrosted and centrifuged at 4000rpm for 20 mins. The pellets were washed three 
times in PBS and lysed using sonication. The resultant lysis was left on ice for 30 minutes. 
The lysis was centrifuged again for 15 minutes at 15,000 rpm and 4°C. The supernatant 
and the pellet were kept. The Bradford assay was used to measure protein concentration 
and ensure equal loading into the SDS-PAGE. The SDS-PAGE was washed in Coomassie 
Brilliant Blue Dye (Expedeon) to visualize the proteins. 
Protein purification was achieved through Ni-NTA Agarose Beads (Qiagen) which bind to 
the HIS tag on the fusion protein.  After sonication of the cells, urea was added to make a 
5 M concentration (Saupe et al., 2017). The urea containing solution was then mixed with 
20 µL Ni-NTA agarose beads and incubated over night at 4°C. Urea is used to prevent 
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multimerising of the protein which hinders binding to the Ni-NTA beads (Chowdhury et 
al., 2014). After incubation the beads were centrifuged and washed. The protein should 
remain bound to the beads, but the supernatant was kept for future analysis in case of a low 
protein yield. Protein was removed from the beads by boiling them at 100°C for 5 minutes 
after addition of 10 µL 6x SDS-PAGE reducing loading buffer. The loading buffer and 
high temperature disrupt the binding of the HIS tag to the Ni-NTA beads. The resultant 
slurry was run on an SDS-PAGE to visualize the proteins with an anti polyhistidine tag 
monoclonal antibody.  
 
The yield was calculated through the growth of a 1 L culture of transformed SHuffle 
bacteria overnight. The culture was split into 4 250 mL samples and each centrifuged to 
produce a pellet. The pellet was again washed 3 times and re-suspended in 20 ml PBS. 10 
ml from each 20 ml was extracted and sonicated after the addition of 5 M urea. The 
remaining 10 ml was sonicated without urea. 500 µL of each 10 mL sample was taken and 
centrifuged at 4000 rpm for 20 minutes. The supernatant was removed, and the pellet was 
re-suspended in 500 µL PBS. The remaining 9.5 mL was also centrifuged at the same speed 
for 20 minutes. The supernatant from the 9.5 mL samples was removed and 50 µL of Ni-
NTA agarose beads (Qiagen) was added. The bead mixture was incubated at 4ºC overnight. 
After incubation the bead mixture was centrifuged at 12,000 rpm for 1 minute. The 
supernatant was discarded, and the beads were washed 5 times with agarose beads washing 
buffer. The protein was eluted from the beads by adding 100 µL elution buffer to 40 µL of 
beads and incubating at room temperature for 30 minutes. The beads were removed from 
the mixture via centrifugation at 12,000 rpm for 1 minute. The supernatant was removed 
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and tested for the presence of protein using the NanoDrop 1000 spectrophotometer (Thermo 
scientific). Yield was calculated through the use of BSA standards. After confirmation of 
the presence of protein the elutants were separated using reducing and non-reducing SDS-
PAGE. L-VLRB is known to form multimers of varying numbers and so both reducing and 
non-reducing were used to maximize the possibility of seeing multimers and the individual 
monomer unit. BSA standards of 5 µg, 2 µg and 1 µg were also loaded onto the gel to 
provide a reference for calculating the yield. Proteins were visualised on the gel using 
Coomassie Brilliant Blue Dye (Expedeon). The gels were imaged using the Odyssey® Fc 
Imaging System (Li-COR). 
This protocol was adapted from (Saupe et al., 2017)  
 
Nanoparticle Synthesis: 
 
Silica Nanoparticles Synthesis: 
All chemicals for silica nanoparticle synthesis were purchased from Sigma-Aldrich. 
Mesoporous silica nanoparticle synthesis was achieved by dissolving 100 mg 
cetyltrimethylammonium bromide (95%) in 48 mL dH2O and 350 µL sodium hydroxide 
(2M). The solution was heated to 80°C. Once at 80°C, 0.5 mL tetraethylorthosilicate (98%) 
was added. 127 µL 3-(trihydroxysilyl)propylmethylphosphonate (42%) was added 15 min 
later and was stirred for 2 hours. The synthesised particles were centrifuged at 15,000 rpm 
for 30 min and washed with methanol twice. The surfactants that enabled a porous surface 
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were removed by re-suspended and refluxing the particles in 20 mL methanol and 1 mL 
hydrochloric acid (12.1M) for 24 hours. The final particles were collected and washed 
through centrifugation with ethanol.  
 
5 mg of the particles were re-suspended in a 2.5 mg polyethyleneimine – 1 mL absolute 
ethanol, solution under magnetic stirring for 30 min. Loading of siRNA onto the 
nanoparticles was achieved by incubating siRNA and nanoparticles together in serum free 
medium at a 1:25 mass ratio under agitation at 4°C. Particles were collected 24 hours after 
via centrifugation  
The synthesis of silica nanoparticles followed the protocol in (Hom et al., 2010). 
 
 
Chitosan Nanoparticles (ChNP):  
Chitosan nanoparticles were synthesized using low molecular weight deacetylated (90%) 
chitosan and tripolyphosphate (TPP). Nanoparticle size is directly affected by chitosan 
concentration and inversely affected by TPP concentration. For ChNP: 1.3 ml 0.1% TPP 
(w/v) deionized water, was added dropwise to 3 ml 0.1% chitosan (w/v) glacial acetic acid 
under 15,000 rpm magnetic stirring. The solution was stirred magnetically at 15,000 rpm 
for 30 minutes then left at room temperature for a further 30 minutes. Finally, the particles 
were collected by centrifuging at 15,000 g for 30 minutes at 4°C. The supernatant was 
removed, and particles were re-suspended in desired solution.  
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The synthesis of chitosan nanoparticles adapted the protocol in (Katas et al., 2013). It was 
found during experimentation for this project that increasing the rate of magnetic stirring 
resulted in more reliable nanoparticle size.  
 
Chitosan Glutamate Nanoparticles (ChGlutNP): 
Chitosan glutamate (PROTASAN™ UP G 213) particles were synthesized in a very similar 
process to the normal chitosan particles. Chitosan glutamate particles resulted in an 
increased size for the same concentration of chitosan compared to the normal chitosan. To 
decrease the size of the particles the concentration of chitosan and TPP was reduced to 
0.025% and 0.05% respectively as well as increasing the temperature of the solution to 
45°C. These particles will be referred to as NP-Glut-siRNA and NP-Glut-Blank (For 
particles without siRNA).  
PROTASAN™ UP G 213 is 75-90% deacetylated. Normal base chitosan is only ~50% 
deacetylated. The extra deacetylation is replaced by glutamate residues. The glutamate 
content is 30-50%. The molecular weight is 150,000-600,000 g/mol and contains ultra-low 
levels of endotoxins and proteins.  
Viscosity [mPa*s]:  20-200 
Appr. Mw [kDa]: 200-600 
Deacetylation [%]: 75-90 
Endotoxins [EU/g] : ≤ 100 
This protocol was devised purely for this thesis and was an adaptation of the protocol 
used to synthesise the ChNP’s.  
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Ionic Gelation 
Ionic gelation is the process of “trapping” molecules inside the chitosan complex. To 
achieve ionic gelation, the molecule in question must be negatively charged and be added 
dropwise in the same manner as the crosslinker TPP. Ionic interactions occur during the 
dropwise addition of the crosslinking agent. Ionic interactions between the positively 
charged amino groups on chitosan and the negative groups of the polyanion (crosslinker) 
induce polymerisation of the chitosan strands into the nanoparticle structure. 
The entrapment of siRNA inside of chitosan nanoparticles followed the protocol laid out 
in (Katas et al., 2013). 
 
Antibody Conjugation to Nanoparticle Surface: 
 
NP-Antibody-1: 
Chitosan-Antibody conjugates were formed using the EDC sulfo-NHS reaction.  15 mg 
sulfo-NHS and 30 mg EDAC were added to 5 mL 0.1% chitosan glutamate in PBS (w/v). 
To this mixture 30 µL CRT4 antibody was added (0.67 mg/mL). The solution was agitated 
at room temperature for one hour. Nanoparticles were synthesised in exactly the same 
method as with the ChNP particles but using the 5 mL PBS-chitosan-antibody reaction 
mixture for the source of the 3 mL chitosan. The particles were collected through 
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centrifugation at 15,000 rpm for 30 minutes and washed with PBS twice to remove any 
unbound antibody. These particles will be referred to as NP-Antibody-1. 
 
This the method for conjugation of antibodies to chitosan was taken from (Lee et al., 2012), 
however the synthesis of the particles after conjugation of the antibodies was developed 
during this thesis. 
 
NP-Antibody-2: 
The activated antibodies method involved synthesizing ChGlutNP first. Before synthesis 
of the nanoparticles, 30 µL antibody was mixed with 30 mg EDAC and 15 mg sulfo-NHS 
in 5 mL PBS. The EDC reaction activates the carboxyl groups on the antibodies and 
prepares them for coupling to the glutamate on the nanoparticle surface.  The NP-Glut-
siRNA were re-suspended in 800 µL PBS. With vigorous magnetic stirring, 375 µL 
activated antibody, EDAC, sulfo-NHS solution was added dropwise and left over night at 
room temperature. The next day the antibody conjugate nanoparticles were collected by 
centrifugation at 15,000 rpm for 30 minutes. These particles will be referred to as NP-
Antibody-2. 
For assessing the binding of the antibody to the nanoparticle, several methods were used. 
First, a fluorescently tagged (Alexafluor 488) antibody was activated and added to the NP-
Glut-siRNA. The resultant conjugate particles were centrifuged at 15,000 rpm for 30 
minutes and washed with PBS twice to remove any unbound antibodies. The conjugated 
particles as well as blank particles were added to separate wells on a 96 well plate. The 
 
77 
plate was imaged in the Odyssey® Fc Imaging System (Li-COR) to compare the 
fluorescence of blank vs antibody conjugated particles.  
Conjugated nanoparticles with fluorescent antibodies were also run on an agarose gel to 
show  that the binding of the antibody was chemical and not electrostatic. A 1% gel was 
used so that nanoparticles would be prevented from moving and remain stuck in the wells 
but should allow un-bound antibody to move through the gel.  
 
This method of antibody conjugation was adapted from (Zhu et al., 2015) who had used a 
similar technique for attaching antibodies to Hed-CS-NPs, however this method was 
developed and improved on during this thesis. 
 
Techniques for Nanoparticle Sizing 
Dynamic light scattering: 
Samples were diluted to 5 ng/µL in 1 mL of deionized water. The samples were transferred 
to a plastic cuvette with a path length of 1 cm and placed into the Dynamic Light Scattering 
(DLS) machine (Malvern Panalytical ZetaSizer). Samples were measured multiple times 
to obtain statistical significance.  
 
Transmission Electron Microscopy: 
Transmission Electron Microscopy was used to image nanoparticles at up to 250,000 times 
magnification (Jeol 1200EX). Blank particles were synthesised, washed and re-suspended 
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in deionised water. 2 µL of nanoparticles were pipetted onto a carbon fibre film coated 
copper grid and left at room temperature for 30 minutes to evaporate. A 3% w/v 
Phosphotungstic acid deionised water solution was made. 2 µL of 3% phosphotungstic acid 
stain was pipetted onto the copper grid with the evaporated nanoparticles. The grid was left 
at room temperature for 5 minutes and then the stain was removed. The grids were placed 
inside the Jeol 1200EX and imaged by me at varying concentrations.  
 
To test antibody binding, gold nanoparticle labelled antibodies were conjugated to the 
nanoparticles. The conjugates were evaporated onto the copper grids in the same way as 
previously, however, no stain was added to visualise the chitosan.  The gold nanoparticles 
absorb electrons due to the density of gold and so show up as black dots on the TEM images 
giving a clear indication of antibodies bound to the surface of the nanoparticles. The lack 
of a negative stain will result in the chitosan particles being invisible, but a ring of black 
dots should clearly be seen, indicating the antibodies bound to the surface of the particles.  
Using gold nanoparticle tagged antibodies for visualising antibodies conjugated to the 
surface of nanoparticles is completely novel and developed during this thesis.  
  
Live Cell Confocal Microscopy Imaging: 
 
Nanoparticle Uptake: 
Cell uptake studies were performed using the Nikon A1R Inverted Confocal/TIRF 
microscope. To assess cellular uptake of chitosan nanoparticles (NP-siRNA) 175,000 
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HEK/HeLa cells were plated onto Matek imaging dishes the night before imaging.  The 
next morning, chitosan nanoparticles (NP-siRNA) with Alexafluor 488 tagged siRNA were 
synthesized. Two hours before imaging the nanoparticles were added to the cells at varying 
concentrations and left to incubate at 37°C. 10 minutes before imaging, 10 µL diluted 
Hoechst® 33342 stain was added, and the cells were incubated for a further 10 minutes at 
37°C. (Hoechst® 33342 stock solution was diluted 1:2,000 in PBS). After the 10 minute 
incubation the cells were washed 3 times with PBS to remove any stain or nanoparticles 
not taken up by the cells. The cells were taken to the microscope and imaged at varying 
magnifications.  
 
To assess the method of cell uptake of the nanoparticles an additional staining step was 
added. BacMam early endosome stain was added to the cells the night before imaging and 
left to incubate for a total of 16 hours. Again, the nanoparticles were added two hours 
before imaging and Hoechst® 33342, 10 minutes before. The cells were washed 3 times 
with PBS and imaged using the Nikon A1R Inverted Confocal/TIRF microscope at varying 
magnifications.  
 
In-Vivo Work: 
 
All animal work was performed in C57Bl.6 Mice. Mice were housed at the Birmingham 
Biomedical Services Unit (Birmingham, UK). All animal experimentation was carried out 
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in accordance with Home Office License number PPL I3FDCE112 and PPL 70/8704 held 
by Roy Bicknell.  
 
Subcutaneous injection of LLC: 
Exponentially growing LLC were treated with trypsin to remove them from the culture 
plate and were counted for concentration. The cells were centrifuged and washed with 5 
mL sterile PBS. 1 million cells were resuspended in 200 µL sterile PBS and subcutaneously 
injected into the right flank of male C57BL/6 mice aged 15 days old.  
  
Tumours were measured daily by callipers. After 15 days or when tumour size limit of 
1200 mm3 was reached animals were culled, tumours and organs excised fixed in 
formaldehyde. The organs were set in paraffin wax and cut into 10 micron sections which 
were stained with H&E stain by the Tissue Bank (Queen Elisabeth Hospital). Sections were 
later imaged by me on the Nikon Eclipse E600. 
 
 
Nanoparticle Localisation Study: 
Fluorescently tagged siRNA loaded nanoparticles were synthesised the day of injection 
(see methods: Nanoparticle synthesis) (mice were 15 days old or tumour had reached 1 cm 
in size) and were re-suspended in 200 µL sterile PBS. The same mass of nanoparticles was 
injected as were found to be most effective in the cell culture knockdown experiments. The 
mouse work was a bio distribution study and so the siRNA concentration did not need to 
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be optimised. Nanoparticles were injected intravenously into the tail vein. The mice were 
culled either two hours later or 24 hours later and all organs and tumour removed and fixed 
in formalin. The formalin preserved organs and tumour were embedded in paraffin wax, 
cut into 10 µm sections and stained using the H&E stain by the Tissue Bank (Queen 
Elisabeth Hospital). Sections were later imaged by me on the Nikon Eclipse E600. 
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Chapter III. 
Nanoparticle Development 
Introduction: 
 
It has been shown that knockdown of CLEC14A in-vitro results in decreased wound 
healing in scratch assays and decreased filopodia formation in spheroid assays (Mura et al., 
2012, Rho et al., 2011, Noy et al., 2015). Homozygous CLEC14A knockout mice show no 
gross developmental defects and when implanted with Lewis Lung Carcinoma (LLC) 
tumour angiogenesis and growth were significantly reduced compared to wild type mice 
(Noy et al., 2015). Other studies have shown that subcutaneous sponge implants have 
decreased FGF2-induced angiogenesis compared to wildtype controls (Noy et al., 2015).  
This evidence for the importance of CLEC14A in angiogenesis in-vitro and in-vivo points 
towards the possibility for targeted gene therapy and silencing of CLEC14A in tumour 
endothelial cells.  
 
The use of nanoparticles in the delivery of therapeutics has become an area of intense 
research. Specifically, their ability to deliver and protect small molecules including 
nucleotides such as siRNA make them ideal vectors for gene modulating therapies in 
cancer. The aim of this chapter was to synthesize a nanoparticle of the correct size (under 
200 nm), that is able to bind CLEC14A siRNA (enough to deliver roughly 50 nM siRNA 
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in cell culture as this is the amount given in a lipofectamine knockdown), that can retain 
and protect the siRNA under simulated  conditions, can enter cells in cell culture and induce 
a knockdown of CLEC14A comparable to other nanoparticles in the literature.  
 
In-vitro studies silence a gene using small RNA molecules such as small interfering RNA 
(siRNA) transported into a cell via Lipofectamine RNAi-Max (Invitrogen #12778-150). 
Lipofectamine captures the siRNA in a lipid vesicle that then passes through the cell 
membrane. Lipid assisted cellular uptake works very efficiently (80-90% knockdown) in-
vitro but cannot be used in-vivo due to the delicate nature of lipid vesicles. Solid 
nanoparticles present excellent alternatives for siRNA delivery vectors in-vivo as they can 
withstand the harsher environments of an organism’s vascular system.   
 
To deliver siRNA to a tumour in-vivo a more stable vector to protect the siRNA. Therefore, 
the development of a stable and reliable nanoparticle vector presents as an important step 
in the knockdown of CLEC14A in tumour blood vessels.  
Mesoporous Silica Nanoparticles: 
 
After searching the literature for the ideal nanoparticle for delivery of siRNA to the tumour 
vasculature, mesoporous silica nanoparticles (MSNs) were decided on as the particle to 
move ahead with. Hom et al., detailed a method for synthesizing mesoporous silica 
nanoparticles that contained “pores” an ideal size for siRNA to fit inside (Hom et al., 2010). 
The nanoparticles were relatively simple to synthesize but did require a full day of 
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synthesis. The average particle size was 130 nm with an average pore size of 2.5 nm. These 
particles were perfect for the aims of this thesis as they were below 200 nm and, most 
importantly, contained pores that would protect the siRNA from the reducing conditions 
and enzymes in the blood system. Degradation of siRNA is a large problem with nucleotide 
based therapies (Wang et al., 2010a). Silica particles were synthesized according to the 
protocol in Hom et al., Loading of siRNA onto the nanoparticles was achieved by 
incubating siRNA and nanoparticles together in serum free medium at a 1:25 mass ratio 
under agitation at 4°C. Particles were collected 24 hours after incubation with siRNA via 
centrifugation. 
 
MSNs with and without siRNA attached were sized using dynamic light scattering (DLS) 
(Figure 3.1). As can be seen the particles were synthesized at the expected size of 130 nm 
and addition of the siRNA had no appreciable effect on particle size. It was expected that 
siRNA would have no effect on size due to them being present inside the pores of the 
particle. Next the amount of siRNA bound and retained was assessed. siRNA was mixed 
with the nanoparticles and measured on the nanodrop for absorption at 260. This will give 
the absorption for all of the siRNA added to the nanoparticles whether bound or not. The 
particles were then centrifuged at 15,000 rpm for 1 minute, the supernatant removed and 
measured for absorption at 260 (Figure 3.1 (A)). The two measurements (1: Nanoparticles 
and siRNA in suspension and 2: the supernatant after the nanoparticles were centrifuged 
for 15 minutes) showed that 90% of the siRNA bound to the nanoparticle and only 10% 
remained in the supernatant unbound. This showed a high level of binding and that excess 
siRNA was present, so binding was saturated.  
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Next, it has been suggested that physiological conditions can cause premature release of 
siRNA from the nanoparticles. Cellular uptake studies performed by other labs have shown 
that the nanoparticles can enter cells within 1-2 hours and so siRNA release studies were 
performed at time intervals between 0 and 1 hours (Geiser et al., 2005).  
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Figure 3.1 
Figure 3.1 | Mesoporous Silica Nanoparticle siRNA absorption and retention (UV 
Absorption). 
(A) Absorption study of MSNs to see siRNA binding and effect of serum on siRNA retention. Suspension: 
Nanoparticles with siRNA attached to surface in suspension. Supernatant: Nanoparticles centrifuged 
to pellet, and supernatant tested for presence of siRNA. Suspension (FCS): nanoparticles resuspended 
in 50% FCS and measured for absorption at 260 again. Supernatant: Nanoparticles left in 50% FCS 
for 1 hour are centrifuged for a last time and the supernatant measured for presence of siRNA.  
(B) Increase in absorption of MSNs at 2-minute time points after the addition of FCS. It appeared that 
the addition of FCS affected the absorption of the nanoparticles in the 260 nm range, increasing in 
effect over time (up to 8 minutes). 
A 
B 
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To make sure the MSNs were retaining the siRNA, the particles were re-suspended in 10% 
FCS and the absorption measured at 260 nm. The particles were then centrifuged for 1 
minute at 15,000 rpm and the supernatant measured for absorption at 260 nm.  Confusingly 
it appeared as if the absorption increased from the first measurements (nanoparticles and 
siRNA in suspension). This first measurement should represent the highest absorption at 
260 as it contains the largest amount of siRNA. The experiment was repeated several times 
at different time points after the addition of FCS and the change in absorption appeared to 
differ depending on the time point.  
 
To assess what was causing this disparity FCS was added to siRNA containing MSNs and 
the absorption was measured every 4 minutes. Figure 3.1 (B) shows the increase in 
absorption over time with a plateau at 12 minutes. This shows that addition of FCS caused 
an increase in absorption over the first 12 minutes after addition.  
 
As mentioned previously, protein coronas have a dramatic effect on nanoparticle surface 
chemistry. This time dependent change in absorption after addition of FCS suggests the 
formation of a protein coroner. Interestingly absorption was not affected in a similar way 
if siRNA was not added to the MSNs before FCS (data not shown). Something about the 
interaction between the siRNA, nanoparticles and proteins present in FCS resulted in an 
increase in absorption at 260 nm. It can also be seen that FCS in the supernatant did not 
affect the absorption at 260 showing it was a nanoparticle dependent effect. 
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To attempt to overcome issues of absorption a new method for testing siRNA retention in 
serum was devised. Previous studies have used gel electrophoresis to measure siRNA that 
has been removed from the surface of a nanoparticle after exposure to FCS to check for 
damage by endonucleases (Hom et al., 2010). This idea was taken and modified. 4% 
agarose gel is required to separate the short strands of siRNA. A 4% agarose gel will be 
too dense to allow migration of 130 nm MSNs. The MSNs will remain stuck in the wells 
of the gel and any siRNA that has been dissociated from the particles because of FCS will 
be pulled through the gel.  
 
The MSNs were incubated in 50% FCS for 1 hour at room temperature. Samples were 
taken every 10 minutes and run on a 4% agarose gel along with fluorescently tagged siRNA 
bound MSNs and a release control (heparin induces 100% release of siRNA from the 
particle). Figure (3.2) shows the electrophoresis gel. It can be seen that there was no 
increase in release of siRNA. A majority of the siRNA was already released at time 0.  
 
siRNA is only bound to the surface of the MSNs through adsorption. This weak 
electrostatic bond is easily overcome by the forces holding the siRNA to the surface.  
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Figure 3.2 
10 20 30 40 50 60 Naked 
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Figure 3.2 | Mesoporous Silica Nanoparticle siRNA absorption and retention (Gel 
Electrophoresis). 
(A) MSN’s with bound fluorescently tagged siRNA are incubated in FCS over an hour with 
samples removed and frozen at 10-minute intervals. The nanoparticles are defrosted and added to 
the wells of a 4% agarose gel along with DNA loading buffer and run for 20 min. Naked siRNA 
(siRNA not attached to a nanoparticle) and nanoparticles incubated with heparin are used as 
negative and positive controls respectively. As can be seen, all of the siRNA is pulled off the 
nanoparticles with very little fluorescence remaining in the wells. The nanoparticles remain 
trapped in the wells due to their size. Any siRNA further down the gel has dissociated from the 
particle. The only difference that can be seen in the FCS treated particles is an extra band higher 
up the gel, likely some of the serum proteins binding to the siRNA.  
(B) This is a diagram shows the expected results from an siRNA retention and release study. 
The various conditions are shown at the top (nanoparticles yellow circle, siRNA yellow lines). 
The result of each condition can be seen at the bottom of the gel. It is expected that NP in PBS 
will leak little siRNA and NP in FCS will leak more siRNA as incubation time increases. 
Incubation with heparin should result in 100% siRNA release.  
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All the attempts to assess the effects of serum on the siRNA-MSN binding were 
unsuccessful in producing a clear result. The interactions between FCS and the siRNA 
bound MSNs provide doubt that they would be a good candidate for delivery of siRNA via 
the blood system. To this end it was decided that a different nanoparticle composition, that 
could hold onto siRNA with a stronger bond and withstand agarose gel analysis, should be 
researched.  
Switch to Chitosan Nanoparticles: 
 
Another literature search was performed to find a new candidate for delivery of siRNA. 
Chitosan nanoparticles represent the best solution as the synthesis is rapid (a few hours) 
and siRNA is trapped inside the nanoparticle mesh preventing premature siRNA release 
(Katas et al., 2013). Chitosan is also nontoxic, LD50 above 16 g/kg in mice (Paul W., 
2000) and have already been widely used for siRNA knockdown studies (Lu et al., 2010, 
Masiero et al., 2013).  
 
ChNP Sizing: 
The same tests were performed on the ChNP as the MSNs. The particles were synthesized 
as described in them methods section. ChNPs were synthesized with and without siRNA 
attached. To confirm the sizing, DLS, and transmission electron microscopy were used 
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(Figure 3.3, Figure 3.4). Chitosan particles are made from biological material and so suffer 
from a higher polydispersity index (PDI) (Katas et al., 2013). High polydispersity is the 
presence of many particles at varying sizes where as low polydispersity is characterized by 
an all the particles existing in one or only a few different sizes. It can be seen from the DLS 
that the chitosan nanoparticles were synthesized at 127 nm with the siRNA containing 
nanoparticles being slightly smaller. This decrease in size is due to the crosslinking 
between the positively charged chitosan polymer and negatively charged siRNA. The TPP 
is already acting as a crosslinker but the addition of more negatively charged crosslinking 
agents holds the polymer strands closer together rather than increasing the size of the 
particle.  
 
Secondly, for sizing, transmission electron microscopy gives the most detailed look at the 
particles, showing size, shape and polydispersity all in one image. To analyse the particles 
a Matlab script was written that picked out the particles from the image and measured their 
size in nanometers (Figure 3.4) for MatLab code see appendix 1. The TEM confirmed the 
nanoparticle size at around 130-140 nm, that they were spherical and that there was a range 
of sizes, but most were of the expected size.  
 
The program analyses pixel values and plots a histogram to find a threshold value. A 
threshold pixel value is needed to define a “threshold” above which any pixel is made white 
and below which any pixel is made black. The plotting and analysis of the histogram allows 
for the ideal pixel value to be chosen to provide the clearest black and white image. The 
black and white image generated is not perfect and often has holes in the middle of particles 
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as well as rough edges due to differential staining. The program runs over the image several 
times filling in blank holes in the middle of particles and smoothing the edges to give a 
more photo realistic black and white mask. The program next measures any continuous 
objects in the image providing data such as the largest number of pixels in a row 
(effectively the largest diameter of an object measured in pixels) and the volume of each 
object etc. The program next compares the number of pixels in the 100 nm scale bar to the 
number of pixels that line up to make the longest diameter of the objects in the image. From 
this, it is known how many pixels make up 100 nm (from the scale bar) and the diameter 
(in nm) can be calculated of the nanoparticles in the image. The code for this program can 
be seen in the appendix. 
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Figure 3.3 
3.3 
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Figure 3.4  
Figure 3.4 | Chitosan Nanoparticle Transmission Electron Microscope Images. 
ChNP-siRNA were synthesised, washed and 2 µl added to a TEM copper grid. The nanoparticles 
were left to dry and were then stained with phosphotungstic acid. The images were taken with the 
JEOL 1200EX Transmission Electron Microscope. Phosphotungstic acid is a negative stain and 
is taken up into the chitosan polymer mesh, as a result the nanoparticles appear black. Particles 
appear spherical and around 200 nm in size. (A) and (B) show two examples of the ChNP.  
  
A B 
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Figure 3.5  
Figure 3.5 | MatLab Analysis of TEM Images 
A program was written in MatLab that created a mask around the nanoparticles to separate them 
from the background. The process then counted the number of pixels that made up the longest 
diameter of each mask. The number of pixels is then compared to the number of pixels needed to 
make up the 100 nm scale bar, giving an accurate size of the nanoparticles. Individual 
nanoparticles can be seen to range from 105 nm up to 155 nm. The aggregation of particles 
prevents an accurate reading of all. 
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Chitosan siRNA entrapment:  
 
Similarly, to the MSN studies, ChNPs were assessed for their ability to bind and retain 
siRNA.  
 
Gel electrophoresis was used with the same method as the MSNs. The chitosan 
nanoparticles were too large to be pulled through the agarose gel, therefore any release of 
siRNA from serum will be pulled through the gel and form a band at the appropriate point. 
Chitosan nanoparticles solve many of the issues that were had with the MSNs, however, 
the siRNA is only held in the chitosan complex due to its cross linking and the cross linking 
of the TPP and Chitosan. Should a molecule in the serum have greater crosslinking abilities 
than siRNA or TPP, the nanoparticle will depolymerize and release the siRNA.  
 
Chitosan nanoparticles loaded with fluorescently tagged siRNA (Alexafluor 448) were 
incubated in FCS for 30 minutes and 1 hour. After incubation the siRNA-ChNPs were 
loaded onto a 4% agarose gel along with unconjugated siRNA (not attached to a 
nanoparticle) and a positive release control (Heparin). Heparin causes release of siRNA by 
competing for binding with the positively charged chitosan. Competition between the 
siRNA and anionic proteins present in the cell cause the dissociation of the nanoparticle 
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and release of siRNA. The gel was run at 110 V for 30 minutes then imaged in the Li-COR 
Odyssey Imaging System (Figure 3.6).  
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Figure 3.6  
B A1 A2 
B1 
C 
Figure 3.6 | Chitosan Nanoparticle siRNA entrapment and Release. 
Agarose gel electrophoresis of chitosan nanoparticles and, fluorescently tagged, siRNA exposed 
to various conditions. (A1) shows a gel run with: Lane 1: fluorescent siRNA by itself (siRNA). 
Lane 2: ChNP-siRNA in PBS (NP+RNA). Lane 3: Nanoparticles exposed to 50% FCS for 30 
mins (NP+RNA FCS). Lane 4: ChNP-siRNA in 50% FCS for 1 hour (NP+RNA FCS). Lane 
5: ChNP-siRNA incubated with heparin for 1 hour (NP+RNA Heparin).  
 
(A2) shows exactly the same samples incubated overnight in the same conditions.  
 
(B) shows chitosan nanoparticles exposed to 50% FCS at 37°C with samples taken every 10 
minutes with each lane running a sample of ChNP-siRNA that has been exposed to 10 mins 
more than the previous lane.  
0 10 20 30 40 50 60 siRNA 
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The gels show that the in the 30 min and 1 hour incubations the fluorescence remains in 
the wells with no siRNA leaking from the ChNPs. The two samples in 50% FCS were then 
incubated at 37C overnight. The nanoparticles in PBS were left at room temperature. A 
12 hour incubation in 50% FCS sees almost no fluorescence left in the well and a greatly 
increased fluorescence further down the gel at the same level as the blank siRNA control.  
 
To further assess any release of siRNA during the first hour of FCS incubation 
siRNA-ChNPs were incubated in 50% FCS at 37C with samples removed and frozen 
every 10 minutes. Figure 3.6 (B) shows the western blot gel. The same amount of siRNA 
was added to each nanoparticle and each well. The naked siRNA lane appears brighter than 
the nanoparticle treated lanes due to siRNA being lost during nanoparticle synthesis, 
siRNA degradation by serum proteins and occlusion/quenching from the nanoparticles as 
well as loss during synthesis and collection.  
 
Figure 3.6 (B) shows that the ChNPs retain the siRNA for over 1 hour in 50% FCS 
(simulating in-vivo conditions) which shows they are capable of delivering siRNA through 
the vasculature of an organism. It is ionic gelation that binds the siRNA to the chitosan 
nanoparticle and competition between the siRNA and anionic plasma proteins can cause 
depolymerisation of the chitosan mesh and premature release of siRNA.  
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This method for assessing siRNA binding to chitosan nanoparticles was developed for 
this thesis.  
Confirmation of passive cellular uptake allows for progression to the next stage of 
nanoparticle development; attempting a knockdown.  
 
 
ChNP-siRNA Cell uptake: 
 
The electrophoresis studies showed that siRNA can be efficiently trapped in the ChNPs 
and can retain the siRNA for over an hour in FCS. The ChNPs have proven their ability to 
work as siRNA vectors but now their cellular uptake must be assessed.  
 
Cellular uptake of nanoparticles can occur through several different methods. Untargeted 
nanoparticles are capable of being taken up by a cell through passive endocytosis, 
phagocytosis or by simply “punching” through the plasma membrane (A. Zubarevaa, 
2016). Cellular uptake is not guaranteed for any particular nanoparticle. siRNA has been 
developed by the Bicknell group that successfully knocks down CLEC14A leaving only 2-
5% expression (95-98% knockdown). Failure to induce a similar knockdown efficiency 
could be due to the nanoparticles failing to enter the cell to deliver the siRNA. To properly 
assess these questions studies were used to image the ChNPs inside cells and to ascertain 
the method of cellular uptake.  
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3.5x104 HEK293T cells were plated onto MatTek dishes the morning of the day before 
imaging.  The cells were left overnight. The next morning 100 µL Alexafluor 488 tagged 
siRNA entrapped inside ChNPs were incubated with the cells for 2 hours. After 2 hours of 
incubation 10 µL Hoechst® 33342 stain was added to the cells and left for 5 minutes. After 
the 5 minutes the cells were washed three times with PBS to remove excess BacMam 
reagent, nanoparticles and Hoechst® 33342. The cells were then imaged in the Nikon A1R 
Inverted Confocal/TIRF microscope (Figures 3.7 and 3.8).  
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Figure 3.7 
Figure 3.7 | Cellular Uptake of Chitosan Nanoparticles (ChNP-siRNA) 
HEK293T cells were incubated with Alexafluor 488 tagged siRNA entrapped inside ChNP. (A) 
and (C) show brightfield images with the green fluorescent nanoparticles overlaid. (B) shows the 
blue Hoechst® 33342 nucleic acid stain and green fluorescent nanoparticles. The green 
fluorescence of the nanoparticles can be seen to group together in sections of the cells leading to 
the suggestion that they may be entering through endocytosis.  
 
103 
 
Nanoparticles labelled with the Alexafluor 488 siRNA can clearly be seen in green inside 
the HEK293T cells confirming the ChNPs were passively taken up by the cells (Figure 
3.7). The nanoparticles can be seen to group together in sections inside the cells. This 
grouping suggests that the nanoparticles were inside endosomes and so further testing was 
done to assess the method of entry for the nanoparticles. The images in figure 3.7 show 
similarity to other nanoparticle uptake studies such as in a cellular uptake study with 
CADY self-assembling peptide-based nanoparticles (Rydstrom et al., 2011). However, in 
this paper the fluorescent siRNA containing particles were shown to enter the cell 
independent of endocytosis. The team use a lysotracker to show that the particles 
fluorescence does not overlap with nanoparticle fluorescence.  
 
Other papers have confirmed the uptake of chitosan nanoparticles through endocytosis 
(Jiang et al., 2017, A. A. Zubarevaa, 2016). Jiang et al., incubated FITC-ChNPs for 2 
hours before washing and imaging the macrophage cells. The nanoparticles used in the 
FITC-ChNP studies were ~250 nanometers in size however. The size of nanoparticles 
used varies in almost every study, so it is still necessary to confirm the method of cellular 
uptake for the particles used in this thesis.  
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Figure 3.8  
Figure 3.8 | Endosomal Uptake of Chitosan Nanoparticles (ChNP-siRNA) 
Confocal images were taken to show cellular uptake of chitosan nanoparticles through 
endocytosis. The BacMam early endosome (RFP) stain was used to visualise endosomes. 
Nanoparticles were visualised through Alexafluor 488-siRNA entrapped inside the nanoparticles 
and Hoechst® 33342 nucleic acid stain visualised the nucleus.  Cells were incubated with 
Alexafluor 488 tagged siRNA containing nanoparticles (2x concentration) The green nanoparticle 
fluorescence can clearly be seen inside the red endosome stain showing that the particles are 
present inside the endosomes.  
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To discern whether the nanoparticles in this thesis entered through endocytosis BacMam 
RFP early endosome stain was used. This particular stain was chosen due to its use in a 
previous study by another student in the Bicknell lab which aimed to visualise CLEC14A 
internalisation from the cell surface, using the BacMam RFP stain to visualise the early 
endosome (Puja Lodhia 2016). Should the red BacMam fluorescence and the green 
ChNP-siRNA fluorescence overlap, it can be concluded that the particles were inside 
endosomes.  
 
The evening before imaging, 200 µL of BacMam 2.0 reagent was added to the cells and 
cell medium in the MatTek dish. The cells were left over night with the nanoparticles and 
Hoechst® 33342 added the next day. Images were taken with the Nikon A1R Inverted 
Confocal/TIRF microscope (Figure 3.8).  
 
Figure 3.8 shows the green of the siRNA fluorescence can clearly overlapping with the 
red endosome stain confirming these 120 nm ChNPs were present in the early endosome.  
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ChNP-siRNA HUVEC Knockdown: 
 
A 95-98% knockdown (2-5% remaining expression) of CLEC14A in HUVEC can be 
achieved with siRNA developed by the Bicknell lab. To achieve this Lipofectamine RNAi-
Max (Invitrogen #12778-150) is used to deliver the siRNA into the cells. To test the ChNPs 
ability to deliver siRNA in-vitro, HUVEC were incubated with siRNA containing ChNPs 
at varying concentrations comparable to the concentrations used in a lipofectamine 
knockdown (1x, 2x, 3x and 4x concentration of siRNA delivered via lipofectamine, 
normally 50 nM). The concentration of siRNA inside any given nanoparticle remains the 
same, the increase in concentration of siRNA is achieved through the addition of more 
nanoparticles. Two duplexes were used in figure 3.9 (C) to knockdown CLEC14A in 
HUVEC using lipofectamine. This gel was used as a “gold standard” to compare to 
nanoparticle knockdowns later. It also served as a method to choose which duplex to use 
in the future nanoparticle experiments. As can be seen in figure 3.9 (C), D2 caused a greater 
level of CLEC14A knockdown and so was chosen as the duplex for all further 
experimentation.  
 
The knockdown percentage achieved by the nanoparticles was compared to a lipofectamine 
siRNA knockdown (positive control) and a negative control lacking siRNA. Figure 3.9 
shows the western blots from the ChNP-siRNA knockdown and figure 3.10 shows a graph 
of percentage expression remaining for the various concentrations of siRNA delivered by 
the nanoparticles. Knockdowns were assessed through polyacrylamide gel electrophoresis. 
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The gels were imaged and analysed using the Odyssey® Fc Imaging System (Li-COR). 
Pixel values of the ChNP knockdown bands were compared to the positive and negative 
controls to calculate the knockdown percentage of CLEC14A.   
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Figure 3.9  
Figure 3.9 | CLEC14A Knockdown in HUVEC by NP-siRNA 
(A) and (B) show examples of western blots imaged and analysed with the Odyssey® Fc Imaging 
System (Li-COR). Lane 1: Negative Control (No nanoparticles or siRNA). Lane 2 Naked siRNA 
(siRNA transfected with lipofectamine). Lane 3: ChNP-siRNA at a concentration equal to 25 nM 
siRNA added to the cells. Lane 4: ChNP-siRNA at a concentration equal to 50 nM siRNA added 
to the cells. Lane 5: ChNP-siRNA at a concentration equal to 100 nM siRNA added to the cells. 
Lane 6: ChNP without any siRNA.  
(B) Shows another example of a western blot similar to (A).  
(C) Shows a western blot of just lipofectamine transfected siRNA, the ideal result. Two different 
duplexes against CLEC14A (D1) and (D2) were used. Though some of the bands look similar, 
pixel density analysis was performed to account for protein loading differences to give the true 
knockdown percentage.  
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Figure 3.10  
Figure 3.10 | CLEC14A Knockdown in HUVEC  
This graph shows the relative remaining protein expression after incubation of HUVEC 
under various conditions. NC: Untreated HUVEC. siRNA: HUVEC treated with 50 
nM siRNA via lipofectamine. 1x: HUVEC incubated with ChNP-siRNA so that the 
total siRNA added to the cells equals 50nM. 2x: HUVEC incubated with ChNP-siRNA 
so that the total siRNA added to the cells equals 100nM. 3x: ChNP-siRNA 
concentration so that the total siRNA added to the cells equals 150nM. 4x: ChNP-
siRNA concentration so that the total siRNA added to the cells equals 200nM. The 
amount of siRNA per nanoparticle remains consistent between incubations. 
Concentration of siRNA is increased by increasing the number of nanoparticles added 
to the cells. Blank: ChNP without any siRNA entrapped inside. The 2x concentration 
represented the highest knockdown. “50 nM” represents the concentration of siRNA 
incubated with HUVEC. “entrapped” represents siRNA inside the chitosan 
nanoparticle.  
Percentage knockdown decreases as concentrations go up due to nanoparticle 
aggregation. 
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As can be seen, the knockdown via lipofectamine achieved a 95% knockdown (5% 
remaining). As for the nanoparticles, knockdown effectiveness was best at 2x concentration 
(100 nm siRNA inside ChNPs). The 2x concentration achieved a 60% knockdown (40% 
remaining expression). From 2x onwards the knockdown percentage decreased. This 
decrease is likely due to the aggregation of nanoparticles preventing cellular uptake. 
Chitosan nanoparticles are known to aggregate because of charge neutralization (Quinones 
et al., 2018). 
 
As the concentration of ChNPs increases the chance for aggregation increases as well as 
the size of the aggregates. As previously mentioned, <200 nm is ideal for passive uptake 
of nanoparticles (Geiser et al., 2005). The surface of chitosan nanoparticles, made with the 
TPP crosslinker, exhibit a highly positive net surface charge (~40 mV) over a large range 
of pH’s. The isoelectric point for TPP-Chitosan nanoparticles was found to be pH 9.0 (Gan 
et al., 2005). The crosslinking ability of chitosan with any free –OH or –COOH as well as 
several other functional groups results in aggregation of the nanoparticles, especially at 
high concentrations. Aggregation dramatically increases the size of the particles, 
decreasing the cell uptake efficiency therefore decreasing the concentration of siRNA 
delivered.  
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Conclusion: 
 
This chapter has outlined the successful development of a solid nanoparticle for the 
delivery of CLEC14A siRNA in-vitro. The MSN particles initially seemed ideal for the 
delivery of siRNA however, the issues with the weak electrostatic binding of siRNA made 
binding and retention studies inconclusive. It was decided that a new nanoparticle 
formulation should be used, and chitosan was chosen as the base chemical from which to 
compose these new particles.  
 
ChNP’s were shown to successfully bind siRNA and were shown to retain it inside the 
chitosan mesh under simulated in-vivo conditions. Cell uptake studies showed the particles, 
with siRNA present, inside the cells and further study with an endosome stain showed the 
location of the particles within the endosome.  
 
Knockdown studies showed a 60% knockdown (40% expression remaining) achieved with 
100M siRNA entrapped inside the ChNP. Knockdown percentage decreased as the 
concentration of nanoparticles increased.  
 
It was hoped that after a successful knockdown with the ChNPs, experiments would move 
onto an in-vivo mouse model. With papers claiming 80-90% knockdown using various 
nanoparticles, 60% seems too low. The next chapter looks at attempts to increase the 
percentage knockdown before moving to an animal model.    
 
 
112 
Chapter IV 
Nanoparticle Targeting 
Introduction: 
 
A 60% knockdown of CLEC14A was achieved with the siRNA-ChNPs. This is lower than 
other siRNA-Nanoparticle studies. Varying concentrations of siRNA containing ChNPs 
were incubated with HUVEC. The concentration of siRNA delivered to the cells was 
increased by keeping the amount of siRNA inside the ChNPs the same but increasing the 
number of nanoparticles per cell. The lower concentrations of nanoparticles had a better 
knockdown (60% at 2x conc) than the higher concentration (15% at 4x conc). The 
concentrations are comparable to the amount of siRNA delivered compared to a normal 
lipofectamine transfection (50 nM). 2x concentration is therefore 100 nM siRNA entrapped 
inside the ChNP. At the higher concentrations it is likely that the increased numbers of 
nanoparticles caused aggregation which prevented cell entry due to particle size increasing 
drastically. The lower concentration incubations achieved significant knockdown but still 
not near the 95% of a lipofectamine knockdown.  
 
With a knockdown being achieved it can be assumed that the particles were entering the 
cells and releasing the siRNA in a way that it can bind to the RISC complex. Likely, 
inefficient release of siRNA is resulting in a lower knockdown than desired. This could be 
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combated by increasing the concentration of siRNA delivered however, as the previous 
chapter showed, increasing the concentration resulted in nanoparticle aggregation and a 
decrease in knockdown percentage.  
 
One way to increase the amount of siRNA that reaches the cell is to target the nanoparticles 
directly at a membrane protein. Crosslinking between antibodies and membrane proteins 
induces membrane internalization (Moody et al., 2015). Conjugation of an antibody to the 
surface of a nanoparticle results in the nanoparticle being internalized with the membrane 
protein, increasing the rate of internalization of the siRNA containing ChNPs (Gao et al., 
2013).  
 
This chapter will focus on targeting the nanoparticles directly to the cells to increase cell 
uptake and therefore increase the amount of siRNA delivered increasing knockdown 
percentage.  
 
Anti CLEC14A antibodies have previously been created for the study of CLEC14A in-vivo 
(Ki et al., 2013, Mura et al., 2012). Several antibodies targeting the extracellular domain 
of CLEC14A have been developed by the Bicknell lab. A study by a previous PhD student 
in the Bicknell lab looked at targeting CLEC14A with antibody drug conjugates (Khan, 
2016). To visualise expression of CLEC14A in vivo, humanised antibodies (conjugated 
with Alexafluor 555) were administered to LLC tumour baring mice. CD32 was stained as 
a marker for the blood vessels. The localisation of CLEC14A was found to be mainly 
within the tumour, removing the concern for off target effects of ADC’s.  
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Analysis of the ADC treatments showed that the hCRT4-ADC had anti-tumour effects in 
the LLC mouse model whereas the hCRT3-ADC did not. It was noted, however, that all 
ADC treatments reduced slowed tumour growth considerably faster than the control 
mouse. The discrepancy between hCRT3 and hCRT4 was surprising considering hCRT3 
was shown to be more cytotoxic than hCRT4 in assays (Puja Lodhia unpublished data). 
Binding affinities could be different between the two species of antibody and could have 
different effects in human patients’ vs mouse. The data from these studies lead to the choice 
to use hCRT4 for nanoparticle targeting. 
 
Conjugation of the hCRT4 to the outside of the ChNPs should allow the particles to bind 
directly to the surface of HUVEC which have a high concentration of CLEC14A (Greene 
et al., 2018). As previously mentioned, CELC14A has a high internalization rate (Puja 
Lodhia unpublished data). A nanoparticle conjugated to an anti-CLEC14A antibody could take 
advantage of this high internalization rate and increase the cellular uptake rate.  
 
Antibody-modified chitosan nanoparticles have been developed for delivering siRNA 
across the blood-brain barrier (Gu et al., 2017). They show up to a 68.9 ± 38.7 percent 
increase in cellular uptake through antibody conjugation. The study did not include 
evidence for antigen binding studies, prior to cell uptake. Scrambled (Non-targeted 
antibody Ab0) antibodies were used but only in combination with either of their targeted 
antibodies (Ab1 and Ab2) never by themselves.  
 
 
115 
Lee et al., conjugates CD7-specific single-chain antibodies to chitosan nanoparticles (Lee 
et al., 2012). The study also shows an increase in cellular uptake upon increased antibody 
conjugation, however, also fails to show specific receptor binding through antigen capture 
or ELISA.  
 
Zhu et al., conjugates anti-CD147 antibodies to α-Hed-CS nanoparticles (Zhu et al., 2015). 
The study does perform a cell-based ELISA to show nanoparticle-antibody cell surface 
binding but no data for the ELISA experiments or proof of antigen binding was provided. 
FTIR characterization of α-Hed-CS-CD147-NPs was performed to determine the presence 
of any chemical substitution, elimination, or entrapped concealing of certain chemical 
groups. A 57.07% ± 0.60% decrease in antibody activity was noted, however this does not 
prove that antigen binding was the reason for cellular uptake.  
 
Results and Discussion: 
 
Two methods were chosen for attaching antibodies to chitosan nanoparticles: (Lee et al., 2012) 
and (Zhu et al., 2015) referred to as NP-Antibody-1 and NP-Antibody-2 respectively. These 
methods were selected as it required the minimum amount of change to the nanoparticle used 
in the previous chapter.  
 
Antibodies cannot be conjugated to the deacetylated chitosan used to synthesize the original 
ChNPs. Lee et al., and Zhu et al., both use chitosan-glutamate as the base for the 
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construction of the nanoparticles. The glutamate provides carboxyl groups that can be 
activated to form a peptide bond with other proteins. Carbodiimide crosslinking chemistry 
(EDC) is used to bind antibodies to the chitosan glutamate (Nakajima and Ikada, 1995).  
 
Now that a new material is again being used to construct the nanoparticle, the initial sizing 
and siRNA retention and release studies must be repeated for this new formulation.  
 
Chitosan glutamate nanoparticles (ChGlutNP) were synthesised using the same method 
as the ChNP particles in chapter 3 with the same concentrations of chitosan(glutamate), 
TPP and siRNA. The only difference is that chitosan glutamate is added dropwise instead 
of pure chitosan.  
 
Sizing for the pre-antibody conjugated particle (ChGlutNP and ChGlutNP-siRNA) was 
achieved in the same manner as with the chitosan nanoparticles in the previous chapter. 
DLS was used to measure the particles with and without siRNA. Sizing and rough shape 
were also confirmed with TEM (Figure 4.1).  The particles were bigger after the addition 
of siRNA measuring at roughly 250 nm. TEM was again used to ascertain the size and 
structure of the nanoparticles, confirming a size of around 220 nm. This change is due to 
steric hindrance from the glutamate sidechains and the fact that the increased deacetylation 
(75-90%) removes the amine groups that TPP and the negatively charged siRNA crosslink 
with. Decreasing the amine groups and replacing them with glutamate effectively decreases 
the concentration of the crosslinker and so is potentially the reason for the increase in the 
particle size. 
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siRNA release studies were performed using the same method as with the standard NP-
siRNA particles; by synthesising fluorescently tagged-siRNA entrapped chitosan-
glutamate nanoparticles and incubating them in 50% FCS for a range of times at 37˚C. The 
incubated samples were loaded onto 4% agarose gel for separation by electrophoresis. The 
samples were loaded along with siRNA not entrapped inside a nanoparticle, nanoparticles 
not exposed to FCS and nanoparticles incubated in heparin as a positive control (Figure 
4.2). 38% of the siRNA was released after an hour in 50% FCS at 37 ˚C. 
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Figure 4.1  
Figure 4.1 | Chitosan Glutamate Nanoparticle Sizing 
Chitosan glutamate nanoparticles represent a slight change in composition and so were re-
measured via DLS (A) and TEM (B). The particles were measured with and without siRNA to 
assess if siRNA affected nanoparticle size. For TEM, a negative stain (Phosphotungstic acid 3% 
w/v) was used. The Chitosan Glutamate particles were larger than the standard ChNPs. This is 
likely due to steric hinderance caused by the glutamate side chain. DLS sizing n=4 
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Figure 4.2  
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Figure 4.2 | Chitosan Glutamate siRNA Entrapment and Release 
Alexafluor 488-siRNA entrapped Chitosan glutamate nanoparticles were incubated in 50% FCS 
for either 1 hour or half an hour at 37˚C. The release of siRNA was compared to nanoparticles in 
PBS at room temperature and Heparin for an hour at 37˚C shown in the graph above. 
Nanoparticles in PBS represent the entrapment efficiency. Particles suspended in PBS should lose 
no siRNA, so any siRNA found at the bottom of the gel failed to attach to the nanoparticle. 
Nanoparticles in heparin represent a positive control where the maximum amount of siRNA is 
released. Heparin competes with the siRNA for binding to the chitosan causing release of siRNA 
from the nanoparticle. As can be seen in picture of the gel above. The amount of fluorescence in 
each well increases with prolonged exposure to serum. The final lane shows a similar amount of 
fluorescence to the first lane showing that heparin induced a significant amunt of the siRNA to be 
released though some can still be seen in the well.  
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The ChGlutNP particles are larger than the ChNP particles, 223 nm to 137 nm respectively.  
Though the particles were larger than desired, antibodies were still to be added to the 
surface and so efforts to decrease the size were made later. siRNA binding and retention 
was confirmed so experiments moved onto the conjugation of antibodies to the surface of 
the particles. As mentioned, two methods were adopted for the conjugation of antibodies, 
designated NP-Antibody-1 and NP-Antibody-2. The methods used to attach the antibodies 
are detailed bellow.   
 
NP-Antibody-1: 
 
There are 2 steps in the formation of NP-Antibody-1 particles (Figure 4.3): 
 
1: EDC reaction is used to conjugate antibodies to lose strands of chitosan in solution.  
2: The chitosan strands that now have antibodies conjugated to them are used to synthesise 
the nanoparticle using the same method laid out in chapter 3. Chitosan-antibody conjugates 
are stirred at 15,000 rpm using a magnet bar and the crosslinker and siRNA are added 
dropwise over the course of 1 minute.  
 
The first method for antibody conjugation to chitosan nanoparticles used the EDC sulfo-
NHS reaction.  15 mg sulfo-NHS and 30 mg EDAC were added to 5 mL 0.1% chitosan 
glutamate in PBS (w/v). To this mixture 30 µL CRT4 was added (0.67 mg/mL). The 
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solution was agitated at room temperature for one hour to create a PBS-chitosan-antibody 
conjugate mixture.  
 
The method was adapted from (Lee et al., 2012) by taking their method of antibody 
conjugation to chitosan but using the chitosan nanoparticle synthesis method detailed in 
chapter 3 which was also adapted for this thesis. Nanoparticles were synthesised using the 
method from the previous chapter however, the 3 mL Chitosan used previously was 
replaced with the PBS-chitosan-antibody conjugate mixture created through the EDAC 
reaction.  
 
The particles were collected through centrifugation at 15,000 rpm for 30 minutes and 
washed with PBS twice to remove any unbound antibody. These particles will be referred 
to as NP-Antibody-1. 
 
 
NP-Antibody-2: 
 
There are 3 steps in the formation of NP-Antibody-2 particles (Figure 4.4): 
 
1: EDC reaction is used to activate antibodies in sterile PBS solution.  
2: A ChGlutNP particles are synthesised   
3: The EDC reaction containing the activated antibodies and EDC reagents are added 
dropwise to the pre-synthesised ChGlutNP particles under 15,000 rpm magnetic stirring.  
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The second method of antibody conjugation involved conjugation of antibodies to the 
outside of an already synthesized chitosan glutamate nanoparticle. Synthesizing siRNA-
ChGlutNP without conjugating antibodies to the chitosan first, ensured that antibodies 
were only present on the outside of the particle.  
 
Before synthesis of the nanoparticles, 30 µL antibody was mixed with 30 mg EDAC and 
15 mg sulfo-NHS in 5 mL PBS. The EDC reaction activates the carboxyl groups on the 
antibodies and prepares them for coupling to the glutamate on the nanoparticle surface.  
The siRNA-ChGlutNP were re-suspended in 800 µL PBS. With magnetic stirring at 3000 
rpm, 375 µL activated antibody, EDAC, sulfo-NHS solution was added dropwise and left-
over night at room temperature. The next day the antibody conjugate nanoparticles were 
collected by centrifugation at 15,000 rpm for 30 minutes. These particles will be referred 
to as NP-Antibody-2. This method was adapted from (Zhu et al., 2015) by changing the 
synthesis of the initial (non-conjugated) particle to fit the synthesis already outlined in 
chapter 3, with concentrations, timings and temperatures altered later on (detailed below).  
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Figure 4.3  
Figure 4.3 | NP-Antibody-1 Antibody Conjugation Confirmation 
(1) is a representation of the NP-Antibody-1 antibody conjugation with antibodies (Orange), 
fluorescent tag (Green), conjugated to the chitosan glutamate polymer strand (Black line). These 
strands are taken and used in the synthesis of the particle. 
(2) is an SDS-PAGE. Lane 1: Unconjugated Alexafluor-antibody. Lane 2: Alexafluor-antibody 
conjugated to the chitosan polymer and synthesised into a nanoparticle. Alexafluor-antibody 
can freely move through the gel (A) and (C). Antibodies conjugated to chitosan and then 
synthesized into a nanoparticle are trapped in the well (B).  
(3) a gel electrophoresis (5%) of fluorescently tagged antibody in Lane 1 and antibody 
conjugated chitosan before nanoparticle synthesis. Again, Alexafluor-antibody is free to move 
through the gel (D). Chitosan conjugated antibodies appear higher and laddered due do varying 
numbers of chitosan strands attached (E).  
1 
2 
3 
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Figure 4.4  
Figure 4.4 | NP-Antibody-2 Antibody Conjugation Confirmation 
(1) is a representation of the NP-Antibody-2 antibody conjugation with antibodies (Orange), 
fluorescent tag (Green), conjugated to the chitosan glutamate nanoparticle (Black circle). 
ChGlutNP were synthesised first and EDC activated antibodies added to the particles dropwise. 
(2) A representation of what gold labelled antibody-conjugated nanoparticles were expected to 
look like under TEM imaging.  
(3) An image of the conjugation of the fluorescent antibody to the nanoparticle after 3 washing 
steps and compared to unconjugated particle.  
(4) TEM image of gold labelled antibodies conjugated nanoparticles. No stain was used.   
4 
1 
2 
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Figure 4.5  
Figure 4.5 | NP-Antibody-2 Transmission Electron Microscope Images. 
ChGlutNP-Antibodies were synthesised, washed and 2 µl added to a TEM copper grid. The 
nanoparticles were left to dry and were then stained with phosphotungstic acid. The images were 
taken with the JEOL 1200EX Transmission Electron Microscope. Phosphotungstic acid is a 
negative stain and is taken up into the chitosan polymer mesh and other carbon-based molecules. 
The nanoparticles appear black with a fainter coroner around them likely from the antibodies on 
the surface. Particles appear spherical and around 200 nm in size. 
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TEM: 
A second method for imaging the antibodies conjugated to the surface was the utilization 
of TEM and the phosphotungstic acid negative stain. Phosphotungstic acid selectively 
binds to basic amino acid residues lysine and arginine thereby providing visualization of 
proteins via TEM (Sheridan and Barrnett, 1969).  
 
As mentioned previously, phosphotungstic acid is used as a negative stain for the chitosan 
nanoparticles. If antibodies were present on the surface of the particle then a TEM image 
should look similar to the images captured in the previous chapter but with a lighter halo 
around the particle signifying the antibodies. Figure 4.5 clearly shows the expected halo 
not before seen in particles without the antibody conjugation. 
 
Another TEM method was used to assess antibody conjugation using 12 nm gold 
nanoparticle conjugated antibodies. For this, TEM imaging a negative stain was not used 
so the chitosan nanoparticle cannot be seen at all. Figure 4.4 shows what successfully 
conjugated particles should look like. As the chitosan particles contain no negative stain, 
they will be invisible, however, the 12 nm gold particles show up without a stain. 
Therefore, the expected image will be a clear circle with a black ring of gold nanoparticles 
around it. Figure 4.5 show the TEM images of the gold-antibody conjugated ChGlutNP. 
Though the chitosan nanoparticles themselves were not stained, clear black rings can be 
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seen. The black rings show the gold labelled antibodies surrounding the chitosan 
nanoparticles and so confirm antibody conjugation. If the antibodies were not conjugated 
to the outside of the particles they would have been removed through washing and simply 
aggregated into black shapes on the TEM grid. No study so far has confirmed antibody 
conjugation to chitosan nanoparticles through TEM imaging and this method was 
developed expressly for this thesis.  
 
Nanoparticle-antibody sizing: 
 
The addition of antibodies to the nanoparticles was likely to affect the size of the particles 
and it was important to keep the particles as small as possible to avoid hindering cellular 
uptake. DLS was used to measure nanoparticle-antibody sizing as it was higher throughput 
for the large number experiments needed. Figure 4.6 shows all nanoparticle sizes resultant 
from the varying conditions of synthesis. 
 
NP-Antibody-1 immediately presented an increased size. The NP-Antibody-1 synthesis 
involved conjugating the antibody to the chitosan strands before nanoparticle synthesis and 
was adapted from (Lee et al., 2011).  NP-Antibody-1 particles showed initial promise with 
confirmation of antibody binding to the chitosan strands through gel electrophoresis. 
Unfortunately, due to the uncontrolled orientation of the antibodies the nanoparticle size 
and range increased greatly (>400 nm). The NP-Antibody-1 synthesis method could also 
result in all antibodies facing inwards or simply orientated in a way that prevented ligand 
binding. Lee et al., does in fact show their particles to be up to 345 nm in size (Lee at al., 
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2011).  400 nm is too large for the purposes of this thesis due to the need for rapid cellular 
uptake.  
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Figure 4.6 
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Figure 4.6 | Nanoparticle-Antibody Conjugation Sizing 
The graph shows nanoparticle size with varying concentrations and conditions used to achieve the 
desired nanoparticle size. The graph represents a development from left to right as synthesis 
conditions were optimised. Varying concentrations of chitosan, TPP and siRNA were used as well 
as variations in temperature and order of addition of reagents. The first 7 bars represent NP-
Antibody-1 synthesis with the last 7 NP-Antibody-2. It was realised that a higher synthesis 
temperature would produce smaller particles but must not exceed 60 degrees as this would result 
in antibody denaturation. n=3 for every condition) 
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NP-Antibody-2 particle synthesis should give more control over the size of the particle and 
the orientation/location of the antibodies. NP-Antibody-2 were adapted from Zhu et al., 
and involved synthesizing ChGlutNP without antibodies, then adding EDC activated 
antibody along with the activation reagents (EDS and sulfo-NHS), dropwise to the NP-
ChGlutNP whilst being stirred magnetically at 3000 rpm (Figure 4.4) (Zhu et al., 2015). 
NP-Antibody-2 still resulted in particles >400 nm, however, the synthesis of the pre-
conjugation particles could easily be altered and so change the final particle size.  
 
Gan et al., demonstrated that increasing the temperature of the synthesis mixture results in 
a decrease in particle size (Gan et al., 2005). The change in particle size through increased 
temperature is due to lower viscosity of the chitosan glutamate solution. It was also 
necessary to decrease the concentration of chitosan glutamate and TPP. As stated 
previously, chitosan nanoparticles form by the aggregation of smaller particles as the 
crosslinker is added dropwise. The first drop of the crosslinker forms very small particles 
with the next drop binding those small particles together. The drop after that then binds the 
second particles together, again increasing the size of the nanoparticles present through 
aggregation. 
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Bellow the process of reaching an antibody conjugated nanoparticle is described. First the 
different conditions for NP-Antibody-1 then the conditions used for NP-Antibody-2. A 
graph showing the sizes resultant from each condition can be seen in Figure 4.6. 
 
NP-Antibody-1 Conditions: 
 
C = Chitosan Glutamate (no antibody conjugated) 
CA = Chitosan Glutamate-Antibody Conjugate 
T = Tripolyphosphate 
 
CA mix 0.1% C 0.1%T: 
The first condition used was simply to conjugate the antibody to the chitosan strands and 
form a nanoparticle from the resultant conjugate in precisely the same method as in the 
previous chapter. 0.1% chitosan-antibody conjugate was used with 0.1% TPP added 
dropwise under 3000 rpm magnetic stirring. A size of 423 nm was created from these 
conditions.  
 
0.1% C 0.1%T 200 µl CA mix added at the end: 
The drastic increase in size was likely due to the steric hindrance of the antibodies 
conjugated to the chitosan strands. To decrease this effect ChGlutNP particles were 
synthesized using unconjugated chitosan glutamate. TPP was added dropwise, however, 
200 µL TPP and 200 µL antibody conjugated chitosan glutamate were added dropwise 
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simultaneously after finishing the initial dropwise addition of TPP to the unconjugated 
chitosan glutamate. As previously mentioned, chitosan nanoparticles form through 
aggregation. Upon the first drop of TPP very small nanoparticles form. Each subsequent 
drop of TPP aggregates these smaller nanoparticles together. The rapid 3000 rpm stirring 
is to prevent too much aggregation. It was thought that the addition of the chitosan 
glutamate-antibody conjugate and TPP after synthesis of the ChGlutNP base could result 
in a coating of the existing nanoparticles in a surface layer of chitosan glutamate-antibody 
conjugate. These conditions resulted in particles 418 nm in size.  
 
0.1% C 0.05%T: 
The adding of the conjugated chitosan at the end rather than at the start of synthesis 
appeared to have little effect on the size of the particle. The next condition went back to 
using the chitosan glutamate-antibody conjugate from the start, however the concentration 
of TPP was halved. As expected, the size of the particle almost doubled resulting in a 
nanoparticle that was 744 nm. This doubling in size is due to there being less TPP to 
crosslink with the chitosan strands resulting in them being held less tightly together and 
producing a particle much larger in size.  
 
0.05% C 0.05%T: 
To further test the effect of the ratio between chitosan and TPP, the concentration of 
chitosan-glutamate-antibody conjugate was also halved. The halving of both chitosan 
glutamate-antibody conjugate and TPP resulted in a particle of 354 nm. This is smaller than 
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the original particle (likely due to there being less chitosan to form particles from), however 
still nowhere near the 200 nm needed.  
 
0.05% C 0.05%T - 200 µl CA mix added at the end: 
To ensure the conditions were tested fairly, the conditions used in the second attempt were 
tried again with the same concentrations as the previous method. These conditions involved 
the synthesis of a chitosan-glutamate particle (no antibody conjugated) using 0.05% 
chitosan and 0.05% TPP with 200 µL of the chitosan glutamate-antibody conjugate added 
along with 200 µL, dropwise at the end. These conditions produce a particle that was, again, 
smaller at 293 nm but still about 100 nm too large.  
 
0.05% C 0.05%T 50 µl - CA mix added at the end: 
In an attempt to reduce the effect, the antibodies had on size, the amount of chitosan 
glutamate-antibody conjugate that was added at the end was reduced from 200µL to 50 µL. 
This reduced the particle size to 290 nm, effectively no different from the previous results.  
 
0.05% C 0.1%T: 
The final method tried was to increase the ratio of TPP to chitosan glutamate-antibody 
conjugate. By increasing the amount of TPP, the chitosan strands should be held more 
tightly together and so decrease the particles size. These conditions resulted in a particle 
253 nm in size which is far closer to the desired 200 nm. Increasing the concentration of 
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TPP further could have resulted in an even smaller particle but it was thought that this 
would negatively affect the siRNA release and so a different method was required.  
 
NP-Antibody-2 Conditions: 
 
0.025% C 0.5%T: 
Learning from the previous conditions the concentrations of chitosan glutamate and TPP 
were kept low: 0.025% and 0.5% respectively. Method 2 differs from the first in that 
antibodies were never conjugated to the chitosan strands. Instead, antibodies were 
conjugated to the outside of a pre-synthesised ChGlutNP. Antibodies were activated 
separately from the nanoparticles and added dropwise along with the EDC activating 
agents once the ChGlutNP were synthesised. The concentration of chitosan was reduced to 
0.025% with a TPP concentration double as to ensure smaller particles before antibody 
conjugation. The particles produced through this method were 259 nm.  
 
0.025% C 0.5%T  (60°C): 
The size of nanoparticles is directly affected by chitosan:TPP weight ratio and must be kept 
between 3:1 and 6:1, however, increasing temperature has also been shown to decrease 
particle size (HueiChen, 2008b). To this end, the temperature of the initial synthesis 
(ChGlutNP without antibodies) was increased to 60 degrees. This could not be performed 
using method 1 particles as 60 degrees would denature the antibodies. The particles were 
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left to cool then stirred at 3000 rpm whilst activated antibodies and EDC reagents were 
added dropwise. These conditions created particles that were 64 nm.   
 
0.05% C 0.5%T  (60°C): 
64 nm had overstepped the target size, so the concentration of chitosan glutamate was 
increased, lowering the ratio of TPP to chitosan. The temperature was kept at 60 degrees. 
The synthesis under these conditions resulted in a particle 175 nm in size. 
 
0.025% C 0.5%T  (50°C): 
176 nm is almost perfect, however, siRNA must be present during the nanoparticle 
synthesis, to allow it to crosslink with the chitosan-glutamate. 60 degrees will cause 
separation of the siRNA double strands which will likely crosslink with the chitosan 
separately resulting in ineffective siRNA. To overcome this the temperature was lowered 
to 50 degrees. PCR annealing is performed at 50 degrees. These conditions resulted in 
particles 191 nm in size.  
 
0.025% C 0.5%T  (40°C): 
40 degrees was attempted as this was a safer temperature to ensure siRNA was annealed, 
producing particles 166 nm in size.  
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0.025% C 0.5%T siRNA (21.5µl, 100 M)  (40°C): 
siRNA had not yet been added to the synthesis mixture. 21.5 µL of 100 M siRNA is the 
normal amount added during synthesis. With the addition of 21.5 µL and a synthesis 
temperature of 40 degrees the nanoparticles were 275 nm.  
0.025% C 0.5%T siRNA (10.25µl 100 M)  (40°C): 
The size of the particles were now above 200 nm again. As the cause of this increase in 
size was the addition of siRNA, the volume of siRNA added during synthesis was halved. 
10.25 µL 100 M siRNA was added at a synthesis temperature of 40 degrees produced 
154 nm particles.  
 
 
Conformation of Conjugation: 
 
Conjugation of the antibody to the ChGlutNPs was confirmed through several methods 
detailed below. 
 
Gel Electrophoresis: NP-Antibody-1: 
NP-Antibody-1 is the conjugation of antibodies to the chitosan polymer before the 
synthesis of the particle. A method was independently devised to use SDS-Page to confirm 
the conjugation of the antibody to the chitosan polymer (Figure 4.3). Similar to the siRNA 
binding and retention studies, a fluorescent antibody was used. Conjugation to the 
nanoparticle was confirmed through the retention of the nanoparticle in the well of the gels. 
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Any fluorescent antibody conjugated to the particle will remain stuck in the well. Any 
unconjugated antibody will be pulled through the gel.  
 
Figure 4.3 shows two lanes, “Antibody” and “Nanoparticle.” The “Antibody” lane has just 
fluorescently tagged antibody before conjugation to a nanoparticle. The “Nanoparticle 
Lane” has that same fluorescent antibody conjugated to a nanoparticle. At the bottom of 
both lanes (A and C) the band for the unconjugated antibody can be seen. The “Antibody” 
lane has very little fluorescence left in the well. Any fluorescence there is likely due to 
aggregated antibodies.  
 
The “Nanoparticle” lane has a large amount of fluorescence remaining in the well with 
some antibody remaining unconjugated and forming a band at the same place as in the 
“Antibody” lane. The large amount of fluorescence in the well of the “Nanoparticle” lane, 
confirms the conjugation of the antibody to the nanoparticle surface. It can also be 
concluded that this conjugation is indeed through a strong bond like a peptide bond as 
previous experiments with the chitosan nanoparticles showed that electrostatic interactions 
were not enough to keep a chemical bound to the particle during electrophoresis.  
 
The third gel image (Figure 4.3 (3)) was of the antibody-chitosan conjugate prior to 
nanoparticle formation. Next to the unconjugated antibody band it can be seen that the 
chitosan-antibody conjugates have migrated less than the unconjugated antibodies due to 
their increased molecular weight. The chitosan-antibody conjugate also appears to have 
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separated out into several lines suggesting antibodies with differing numbers of chitosan 
polymers attached.  
 
 
Fluorescence and TEM: NP-Antibody-2: 
The confirmation of antibody conjugation for NP-Antibody-1 suggested that NP-
Antibody-2 should also be a success as the methods were similar. NP-Antibody-2 involves 
conjugation of the antibodies to the surface of a pre-synthesized ChGlutNP rather than to 
the chitosan before particle synthesis. This method aims to guarantee antibodies are on the 
outside of the particle and increase the chance of them remaining in the correct orientation.  
 
Fluorescence: 
Again, fluorescently tagged antibodies were used to confirm antibody conjugation. 
ChGlutNP particles were synthesized and then fluorescent antibody conjugated to their 
surface. The particles were centrifuged and washed 3 times then imaged in the Odyssey® 
Fc Imaging System (Li-COR).  
 
Figure 4.4 (3) shows two wells containing unconjugated vs washed conjugated particles. 
A large amount of fluorescence can be seen in the conjugated well showing that the 
antibodies were indeed conjugated to the surface.  
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Antibody-Ligand Binding:  
 
Antibody conjugation had been confirmed. The particle size had successfully been reduced 
below 200 nm. Next, antibody ligand binding was tested.  
 
Confirmation of antibody conjugation proves that the antibodies were bound strongly to 
the surface of the nanoparticles, however, it did not confirm the orientation or binding 
capabilities of the antibody. There is little control over the orientation of the antibody upon 
conjugation and so it is unknown if the FC binding sites were still accessible. Additionally, 
EDAC activation and conjugation to the particles may have affected the antibodies in other, 
unknown ways.  
 
To confirm antibody ligand binding several methods were used:  
 
Ligand Capture: 
Ligand capture was assessed through a newly invented method involving biotin 
streptavidin interactions. Biotinylation of CLEC14A allows for the binding of fluorescent 
streptavidin to biotinylated CLEC14A. A method was devised that would synthesise 
antibody conjugated chitosan glutamate particles with antibodies that would bind 
CLEC14A. Figure 4.7 (B) shows confirmation of CLEC14A biotinylation through western 
blot. The presence of an extra band with an increased molecular weight the size of 
CLEC14A + biotin confirms the successful biotinylation of CLEC14A. Biotinylated 
CLEC14A was washed over the particles resulting in the binding of CLEC14A to the 
conjugated antibodies on the surface of the particle. The particles were then washed in PBS 
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3 times and collected through centrifugation. After removal of unbound CLEC14A with 
PBS the particles were washed with Alexafluor 488 tagged streptavidin. The particles were 
again washed 3 times with PBS, collected through centrifugation and imaged using the 
Odyssey® Fc Imaging System (Li-COR). 
 
A negative control of antibody conjugated particles that were not washed with biotinylated 
CLEC14A was used. There was no significant difference between the fluorescence of the 
negative control and CLEC14A-biotin bound particles. This lack of disparity is again likely 
due to the protein corona effect common among nanoparticles (Oh et al., 2018) (Barbero 
et al., 2017). To negate this problem the nanoparticles were blocked with 10% FCS before 
and during binding the CLEC14A-biotin as well as before and during streptavidin binding. 
Unfortunately, figure 4.7 shows that there was still no significant difference between 
CLEC14A bound and the negative control particles. The binding of proteins to the surface 
of the nanoparticles is a complex but powerful interaction that is hard to overcome 
(Kokkinopoulou et al., 2017). 
 
Adapted ELISA: 
A new method was required to assess antibody binding. A literature search showed that 
ELISA’s were a common method used for nanoparticle-antibody antigen binding tests. A 
method was adapted from the standard ELISA method to test the antibody bound 
nanoparticles. Maxisorb 96 well plates (Nunc™ 44-2404-21) were used to bind antigens 
wells to test antigen specific binding of the antibody conjugated nanoparticles.  
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Nanoparticles were synthesised with Alexafluor-488 tagged anti-mouse IgG antibodies on 
the surface. The wells were divided into either CLEC14A adsorbed or BSA absorbed. The 
BSA worked as a negative control that the anti-mouse IgG antibody should not bind to it.  
 
Mouse-CLEC14A and Human-CLEC14A were absorbed to the Maxisorb wells. Each well 
was washed PBS 5 times then with Anti-CLEC14A (Mouse IgG). The wells were washed 
5 times again then with Anti-Mouse IgG bound nanoparticles or unconjugated anti-mouse 
IgG. All wells were washed 5 times with PBS and imaged with the Odyssey® Fc Imaging 
System (Li-COR), Figure 4.8.   
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Figure 4.7  
0
50
100
150
200
250
300
350
400
450
No Antigen CLEC-Biotin
A
rb
it
ar
y 
U
n
it
s 
(F
lu
o
re
sc
e
n
ce
)
State of Antigen Capture
Measuring Antigen Capture: ChGlutNP-Antibody
Un-Biotinylated CLEC14A 
Biotinylated CLEC14A 
Figure 4.7 | Nanoparticle-Antibody Antigen Capture 
(A) shows the ability for antibody conjugated nanoparticles to bind streptavidin. Two conditions 
were used: Half of the antibody conjugates were washed with CLEC-Biotin and the other half 
were blocked in FCS. Both were washed and incubated with fluorescently tagged streptavidin. 
Biotin-streptavidin affinity should result in higher level of fluorescence in the case of successful 
capture of the CLEC-Biotin however, there was equal fluorescence whether the CLEC-Biotin was 
present or not. This shows that this test was not useful to show antibody-ligand binding. n=10.  
(B) The western blot gel below the graph shows the purified fractions of the biotinylated 
CLEC14A.  
A 
B 
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Figure 4.8 
Figure 4.8 | Nanoparticle-Antibody Antigen ELISA 
(A) shows the results of the ELISA for Alexafluor448-antibody conjugated nanoparticles to the 
antigen on an ELISA plate. Wells contained either human or mouse CLEC14A as the CRT4 
antibody is known to bind more preferentially to mouse than human CLEC14A. These two 
conditions were compared to binding of the unconjugated antibody to mouse CLEC14A as the 
positive control (Far Right). The antibody conjugated nanoparticles bound to the (B) shows 
aggregation of the antibody-nanoparticle conjugates at high concentrations. n=3 
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As can be seen, there is a clear difference in binding between Human and Mouse CLEC14A 
as CRT4 has preference for mouse-CLEC14A. Nanoparticle binding to Mouse-CLEC14A 
is comparable to unconjugated antibody and has lower binding to Human-CLEC14A. 
These ELISA tests show that the antibody on the surface of the nanoparticles is binding its 
antigen and indeed binding preferentially.  
 
Knockdown using Ch-Glut-Antibody-2: 
 
Confirmation of antigen binding allows for progression to knockdown. The knockdown 
procedure was performed in exactly the same manner as the previous chapter.  
 
HUVEC were incubated with siRNA containing ChGlutNP-(CLEC14A Antibody) at 
varying concentrations comparable to the concentrations used in a lipofectamine 
knockdown 1x, 2x, 3x and 4x concentration. (1x concentration is equal to 50 nM of siRNA 
delivered via lipofectamine, in “gold standard” in-vitro test). The concentration of siRNA 
inside any given nanoparticle remains the same, the increase in concentration of siRNA is 
achieved through the addition of more nanoparticles. The knockdown percentage achieved 
by the nanoparticles was compared to a lipofectamine siRNA knockdown (positive control) 
and a negative control lacking siRNA. Figure 4.9 shows the western blots from the 
knockdown of CLEC14A and figure 4.10 shows a graph of the percentage expression 
remaining for the various concentrations of nanoparticles used. Knockdowns were assessed 
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through polyacrylamide gel electrophoresis. The gels were imaged and analysed using the 
Odyssey® Fc Imaging System (Li-COR). Pixel values of the ChGlutNP-Antibody 
knockdown bands were compared to the positive and negative controls to calculate the 
knockdown percentage of CLEC14A.   
 
Figure 4.9 shows images of a selection of Western Blot gels from the knockdowns.  Figure 
4.10 shows the percentage expression remaining after knockdown using ChGlutNP-
Antibody’s calculated from the western blots (Figure 4.9 shows only 2 of the gels) using 
pixel density analysis in ImageJ. 
 
As can be seen, similarly to with the unconjugated ChNP’s the effectiveness of the 
knockdown decreases as concentration goes up. Interestingly, the knockdown percentage 
for each concentration is actually less than with the ChNP’s (Figure 4.11). The variation in 
knockdown percentage is also increased.  
 
Monoclonal antibodies are known to aggregate under a variety of conditions similarly to 
many proteins in biological systems (Maas et al., 2007, Wang et al., 2010b). It is likely that 
the addition of antibodies to the surface of the nanoparticles increased the aggregation 
problems seen in the previous ChNP chapter. Due to this increased aggregation, cellular 
uptake was reduced and so knockdown was reduced. Aggregation would also prevent 
antigen binding, further decreasing cell uptake.  
 
146 
Figure 4.9 
Figure 4.9 | CLEC14A Knockdown in HUVEC Antibody-Nanoparticles 
((A) and (B) show examples of western blots imaged and analysed with the Odyssey® Fc Imaging 
System (Li-COR). Lane 1: Negative Control (No nanoparticles or siRNA). Lane 2 Naked siRNA 
(siRNA transfected with lipofectamine). Lane 3: ChNP-siRNA at a concentration equal to 25 nM 
siRNA added to the cells. Lane 4: ChNP-siRNA at a concentration equal to 50 nM siRNA added 
to the cells. Lane 5: ChNP-siRNA at a concentration equal to 100 nM siRNA added to the cells. 
Lane 6: ChNP-siRNA at a concentration equal to 150 nM siRNA added to the cells.  
 
(B) Shows another example of a western blot similar to (A).  
 
(C) Shows a western blot of just lipofectamine transfected siRNA, the ideal result. Two different 
duplexes against CLEC14A (D1) and (D2) were used. Though some of the bands look similar, 
pixel density analysis was performed to account for protein loading differences to give the true 
knockdown percentage.  
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Figure 4.10 
Figure 4.10 | CLEC14A Knockdown in HUVEC Antibody-Nanoparticles 
Relative remaining protein expression after incubation with siRNA and ChGlutNP-Antibody-
siRNA.  
 
NC: HUVEC not exposed to siRNA, siRNA: HUVEC transfect with 50 nM siRNA using 
lipofectamine. 1x: HUVEC incubated with ChNP-siRNA so that the total siRNA added to the 
cells equals 50nM. 2x: HUVEC incubated with ChNP-siRNA so that the total siRNA added to 
the cells equals 100nM. 3x: ChNP-siRNA concentration so that the total siRNA added to the cells 
equals 150nM. 4x: ChNP-siRNA concentration so that the total siRNA added to the cells equals 
200nM. The amount of siRNA per nanoparticle remains consistent between incubations. 
Concentration of siRNA is increased by increasing the number of nanoparticles added to the cells 
(concentration of siRNA labelled above respective bar).  
The 1x concentration represented the highest knockdown. “50 nM” represents the concentration 
of siRNA incubated with HUVEC. “entrapped” represents siRNA inside the chitosan 
nanoparticle. Percentage knockdown decreases as concentrations go up due to nanoparticle 
aggregation. 
n=3, error bars = SD 
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Figure 4.11 
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Figure 4.11 | NP-siRNA VS Antibody Targeted Nanoparticles: 
This graph is for the visual comparison of the knockdown of CLEC14A using ChNP-siRNA 
nanoparticles (Light Grey) vs ChGlutNP-Antibody-siRNA (Dark Grey). NC: HUVEC not 
exposed to siRNA, siRNA: HUVEC transfect with 50 nM siRNA using lipofectamine. 1x: 
HUVEC incubated with ChNP-siRNA so that the total siRNA added to the cells equals 50nM. 2x: 
HUVEC incubated with ChNP-siRNA so that the total siRNA added to the cells equals 100nM. 
3x: ChNP-siRNA concentration so that the total siRNA added to the cells equals 150nM. 4x: 
ChNP-siRNA concentration so that the total siRNA added to the cells equals 200nM. The amount 
of siRNA per nanoparticle remains consistent between incubations. Concentration of siRNA is 
increased by increasing the number of nanoparticles added to the cells. n=3.  
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Conclusion: 
 
In conclusion, ChGlutNP were shown to be effective in binding and retaining CLEC14A 
siRNA (comparable to the ChNP). The addition of antibodies to the surface of the particles 
drastically increased the size of the particles and a series of trial and improvement 
experiments were conducted to attempt to bring the size of the particles back down to below 
200 nm.  
 
The size was corrected, however, the addition of antibodies to the chitosan nanoparticles 
did not increase knockdown efficiency and, in fact, decreased it. This decrease is likely due 
to protein-protein induced aggregation decreasing cell uptake. The ChNP achieved a 60% 
knockdown which was comparable to other nanoparticle knockdown studies. There are 
other methods for potentially increasing knockdown, but it was decided that from here on, 
further studies will revert to using the ChNP’s without antibody conjugation.  
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Chapter V 
CLEC14A Vaccine: 
Introduction: 
 
The work done in this chapter was done in collaboration with an undergraduate student. 
(Elliot Brown: elliotjbrown@doctors.org.uk) and is included with his permission.  
 
Previous chapters attempted to develop a vector for the delivery of siRNA. It was shown 
that a chitosan nanoparticle formed through crosslinking with TPP was a sufficient vector 
for the binding and release of siRNA. siRNA can be bound inside the chitosan particle 
through a process called ionic gelation. Due to the negative charge of siRNA it can act as 
a crosslinker, similarly to TPP. Ionic gelation is based on the method of electrostatic 
interaction between carboxyl groups on the chitosan polymer with negatively charged 
groups of polyanions. Any negatively charged polyanion can act as a crosslinker. As long 
as a protein can be maintained in a pH above is pI during synthesis of the chitosan 
nanoparticle then it will be entrapped inside the particle in a similar way to the siRNA.  
 
Over the past decade nano-sized vectors such as viruses, liposomes and nanoparticles have 
garnered greater attention as delivery vehicles for vaccines (Gregory A.E., 2013). 
Nanoparticles have the ability to stabilize proteins or even act as adjuvants to break 
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tolerance. These vectors are able to enter antigen-presenting cells and modulate the 
immune response (Uto et al., 2009).  
 
Vaccines against endothelial markers have been studied. Facciponte et al., (2014) studied 
a murine TEM1 DNA vaccine that produced a CD8+/CD4+ T-cell response resulting in 
slowed progression of tumours in-vivo (Facciponte et al., 2014). The vaccine consisted of 
a plasmid containing the cDNA for mouse TEM1 joined with the cDNA sequence for 
fragment C of tetanus toxoid (FrC). DNA-fusion vaccines have the advantage of not 
needing extensive protein production, however they have been shown to have weaker 
immune responses in humans. The anti-cancer effect of the vaccine was seen through 
induction of CD3-T cells, however, no anti-TEM1 antibodies were found in the serum 
.   
Zuagn et al., showed the efficacy of the Fc domain from human immunoglobulin in a fusion 
protein vaccine against ROBO4. The vaccine successfully reduced tumour growth by 
inhibiting angiogenesis in mice without affecting wound healing (Zhuang et al., 2015). The 
success of the tetanus toxoid fragment c (FrC) fusion in breaking tolerance and inducing a 
T cell response lead to the development of a CLEC14A-FrC fusion protein.  
 
Delivering this fusion protein directly to antigen presenting cells in the vicinity of the 
tumour, via a nanoparticle vector, could have a dramatic effect on vaccine viability (Uto et 
al., 2009).  
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(Saupe et al., 2017) developed a fusion protein based around the variable lymphocyte 
receptor B (VLRB) from jawless fish Sea Lamprey. (Saupe et al., 2017) compare the 
efficacy of VLRB as a carrier for a fusion protein compared to bacterial thioredoxin (TRX), 
a proven and efficient carrier protein. Antibody titre, binding properties and duration of 
response were compared. VLRB carrier vaccines demonstrated a 2 – 10 fold increase in 
antibodies against self-titres and even more impressively, a decrease in foreign protein 
antibodies when compared to TRX fusion vaccines (Saupe et al., 2017). 
 
This chapter will look at the viability of entrapping a protein-based vaccine inside a 
chitosan nanoparticle for more effective delivery to antigen presenting cells. Entrapping 
proteins inside chitosan nanoparticles has been done before but the method used in this 
thesis is novel (Sawaengsak et al., 2014). Several CLEC14A fusion proteins (including 
Tetanus Toxoid FrC and the Sea Lamprey VLRB) will have sequences generated and 
cloned into plasmids for lentiviral and bacterial transformation. The proteins will be 
produced in either HEK293T cells or a relatively new bacterial strain, SHuffle® T7 
Express lysY Competent E. coli. 
 
Upon successful infection of mammalian cells or transformation of bacterial cells, the 
proteins were harvested from the cell medium or cell lysate, purified and identified by 
western blot analysis.  
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Results and Discussion: 
 
Nanoparticle Entrapment of Recombinant Protein: 
 
Before producing any of the fusion protein vaccines, the possibility of entrapping the 
resultant recombinant protein inside a chitosan nanoparticle must be tested first. A method 
was developed to test the entrapment of a protein inside chitosan nanoparticles.  
 
Streptavidin has a pI of ~ 5. To give streptavidin an overall negative charge, producing a 
polyanion, the nanoparticle synthesis must be conducted in a pH above this. The current 
nanoparticle synthesis is done at pH 5.5. Increasing the pH from 5.5 to 6 maintains the 
slight acidic conditions required for chitosan nanoparticle synthesis and keeps the pH 
above the pI of streptavidin. Dropwise addition of Alexafluor-488 tagged streptavidin, 
along with TPP, during chitosan nanoparticle synthesis at pH 6 will produce a nanoparticle 
with streptavidin entrapped inside.  
 
The streptavidin nanoparticles were synthesised and loaded onto a 5% agarose gel at 110 
V, 400 A for 30 minutes. Lanes were run with: 1) non-entrapped fluorescently tagged 
streptavidin and 2) with fluorescently tagged streptavidin entrapped nanoparticles. The 
same two lanes were run with and without SDS loading buffer as the buffer resulted in a 
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large amount of background noise on the gel during imaging. It was also not known 
whether the loading buffer would affect the integrity of the nanoparticle and cause it to 
release the streptavidin (Figure 5.1). This method for checking the entrapment of a protein 
inside chitosan nanoparticles is novel and was developed for this thesis.  
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Figure 5.1 
Figure 5.1 | Chitosan Nanoparticle Protein Entrapment : 
(1) A gel electrophoresis showing entrapment of fluorescently tagged (Alexafluor 488) 
streptavidin inside chitosan nanoparticles. Nanoparticles were synthesised in pH 6 rather than 
pH 5.5 to ensure pH was greater than the Pi of streptavidin (~5). Streptavidin alone (strep) was 
run next to streptavidin entrapped inside chitosan nanoparticles (NP). The gel was run with 
(Left) and without (Right) SDS-loading buffer. The loading buffer created a large amount of 
background noise upon imaging and may induce protein release from the nanoparticles. 
Streptavidin can be seen to move through the gel in both images (A and B). Nanoparticles with 
streptavidin entrapped inside can still be visualised in the wells (C and D) showing that a protein 
can remain entrapped inside the chitosan nanoparticles. 
 
(2) The CLEC14A-VLRB Fusion Protein. VLRB (Green), CLEC14A (Orange). VLRB fusion 
proteins can form multimers of up to 12 units. Only a single domain of CLEC14A was used in 
the VLRB fusion protein.  
(3) CLEC14A-FrC Fusion protein. CLEC14A (Orange), FrC (Blue). The FrC Fusion does not 
form multimers. The entire extracellular domain of CLEC14A was used in the FrC fusion 
protein.  
1 
2 
3 
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As can be seen, in both lanes (with and without SDS loading buffer), the non-entrapped 
streptavidin travels through the gel, showing up as a fluorescent band. The lane containing 
the streptavidin entrapped inside the ChNP’s maintains the bulk of the fluorescence in the 
well. This show that streptavidin has the ability to migrate through the gel, however, due 
to it being entrapped inside the ChNP’s it is retarded in the wells due to the ChNP’s being 
too large to move through the 5% gel. This confirms the stable entrapment of a protein 
inside the chitosan nanoparticles.  
 
Production of CLEC14A-FrC: 
 
As previously mentioned, the FrC portion of tetanus toxoid used for vaccinating against 
tetanus represents as a potential biological adjuvant for breaking tolerance against self-
antigens. A plasmid containing the CLEC14A-FrC fusion gene was previously produced 
by Kai Tolner’s group (University of Birmingham, IBR). The plasmid had been made and 
sequenced, however the protein had never been produced. For Plasmid structure and 
sequence see Appendix 3 and 5. 
 
The plasmid was amplified from the original stock through transformation of competent 
gold efficiency DH5α E. coli. The plasmid was purified from the E.coli using a miniprep 
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kit and a concentration of 267.9 ng/µl was quantified through spectrophotometry (Figure 
5.2).  
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Figure 5.2 
1 
3 
6 
0.25 
Undigested Digested 
2.5 
kb 
Figure 5.2 | CLEC14A-FrC Plasmid Amplification and Restriction Enzyme Digest: 
(A) Eluted DNA from CLEC14A-FrC plasmid amplified bacteria measured through 
spectrophotometry using the Nanodrop 1000 spectrophotometer at 260 nm. A concentration of 
267.9 ng/µL DNA material can be seen.  
 
(B) A restriction enzyme digest of the eluted plasmid showing a fragment, 2.5 kb in size in the 
digested lane corresponding to the expected size of the CLEC14A-FrC inset into the pWPI 
plasmid.  
  
A 
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A restriction enzyme digest was performed on the purified plasmid to extract the 
CLEC14A-FrC insert. The digested plasmid and full plasmid were run on a 1% agarose 
electrophoresis gel (Figure 5.2). A fragment, 2.5 kb in size in the digested lane 
corresponding to the expected size of the CLEC14A-FrC inset into the pWPI plasmid.  
 
A Lentivirus transduction of the plasmid was undertaken in HEK293T cells. The pWPI 
plasmid contains an IRES site connected to the GFP gene resulting in the co-translation of 
GFP along with the protein of interest. The transformation of HEK293T cells were assessed 
through fluorescence microscopy. The presence of green fluorescence in the transformed 
cells shows a successful lentivirus infection with the pWPI plasmid containing the 
CLEC14A-FrC fusion protein (Figure 5.3).   
 
 
160 
Figure 5.3 
Figure 5.3 |CLEC14A-FrC Transduced HEK293T Images: 
(A) A fluorescence image showing the green fluorescence given off by cells transduced with 
the CLEC14A-FrC pWPI plasmid containing the GFP gene. Cells in (A) were compared with 
un-transduced cells (B) to show successful transduction. Due to the IRES site in pWPI, green 
fluorescence shows successful transduction and transcription of the gene of interest.  
(A) CLEC14A-FrC Transduced HEK293T (B) Un-transduced HEK293T Cells 
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Production of CLEC14A-FrC Fusion Protein: 
 
Confirmation of successful lentiviral infection allowed for progression to growth of cells 
and collection of the synthesised protein from the cell medium. The inserted gene contained 
a signal peptide and so should be excreted upon production.  
 
Western blots were used to assess the presence of the fusion protein in transduced 
HEK293T cells. The cell medium was collected after two days of cell growth in DMEM. 
A cell lysis was also collected to assess if the protein was failing to be excreted. Cells were 
grown on a 10 cm cell culture plate and were collected at 80% confluence. Cells were lysed 
either by RIPA buffer or sonication in PBS with protease inhibitors. Un-transduced cell 
medium and lysate was used as a negative control for the western blots. Purified 
CLEC14A-FC was used as a positive control for the antibodies, though the protein is a 
different molecular weight. The primary antibody bound to extracellular CLEC14A. Initial 
western blots can be seen in figure 5.4. 
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Figure 5.4 
Figure 5.4 | Western Blot CLEC14A-FrC HEK293T: 
A western blot showing a western blot from a 10% SDS-PAGE looking for the presence of the 
CLEC14A-FrC fusion protein. The cell lysis of transduced cells (TL) was compared to the cell lysis 
from un-transduced cells (CL) and mouse CLEC14A-FC (PC) as a positive control. Primary antibody: 
R&D anti-CLEC14A. Secondary Antibody: polyclonal anti-sheep HRP.  A band can be seen (green 
circle) in the transduced lysis lane that is of the correct size for the fusion protein, however a band of 
the same size can be seen in the control (un-transduced) cell lysis. Co-migration may be the reason for 
bands that appear the to be the same molecular weight but are in-fact different proteins. This was studied 
further (Figure 5.6).  
PC: Positive Control  
(Mouse CLEC14A-Fc) 
  
TL: Transduced Cell lysate 
  
CL: Control Cell Lysate 
  
TM: Transduced Cell Medium 
  
CM: Control Cell Medium 
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No protein was found at the right molecular weight in the cell medium, however a band of 
the correct molecular weight could be seen in the cell lysis. A similar band can also be seen 
in the control (un-transduced) cell lysis. The expected outcome from the gel would have 
been a band at around 110 kDa in the cell medium from the transduced cells. No protein 
was found in the medium, so the next location expected was the cell lysate. A band of the 
correct molecular weight does show up in the transduced cell lysate, however, an identical 
band also shows in the untraduced cell lysate. Non-specific binding can also be seen in the 
cell medium and further tests were performed to show that the bands found in the cell 
medium were non-specific binding of the secondary antibody, not the primary targeting 
CLEC14A.  
 
There was the possibility that two proteins, both binding the primary or secondary 
antibody, had similar molecular weights and so co-localized on a western blot in the 
transduced cell lysis (Bass et al., 2017). To remove this possibility, a gradient gel was 
made. The gradient gel ran from 10-18% was created with the two cell lysates run with a 
positive control (Figure 5.5). HEK293T cells were grown to 80% confluency on 20 cm 
plates to increase the amount of protein present in the cell lysate.  
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Figure 5.5 
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Figure 5.5 |Western Blot CLEC14A-FrC HEK293T Gradient Gel: 
A western blot showing the gradient gel (10-18%) for the production of the CLEC14A-FrC fusion 
protein. The cell lysis of transduced cells (TL) was compared to the cell lysis from un-transduced 
cells (CL) and mouse CLEC14A-FC (PC) as a positive control. Primary antibody: R&D anti-
CLEC14A. Secondary Antibody: polyclonal anti-sheep HRP.  Two bands can be seen in TL 
proving the co-migration of 1 protein separated by the gradient gel.  
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As can be seen, two bands were separated in the TL (Transduced cell lysate) lane. These 
two bands previously co-localised but can now be seen to, in fact, be two separate proteins.  
 
The yield for the fusion protein was calculated at 45 µg of protein per 20 cm plate of 
HEK293T cells. As can be seen, in comparison to the positive control (Figure 5.5), the 
protein concentration gathered from the transduced cells was low. The failure to excrete 
the protein may have been a result of the unfolded protein response as the addition of a 
bacterial protein will likely effect the folding of CLEC14A (Hetz, 2012). Eukaryotic 
translation initiator factor 2α (elF2α) halts translation of proteins after phosphorylation and 
can affect endoplasmic reticulum function on a broad scale. The unfolded protein response 
is a likely reason for failure of protein secretion as the FrC protein is a bacterial protein and 
so contains no glycosylation which would likely impact the correct folding of CLEC14A. 
To check that the protein had indeed been properly transduced, and the band seen on the 
gradient gel was still unspecific binding, RNA expression was assessed to check that the 
gene was correctly transduced. 
  
RNA was collected using the miniprep kit (Qiagen #27104). 520.2 ng/µl of RNA was 
collected from a 10 cm plate. A 1% agarose gel was run using cDNA of mRNA collected 
from transduced HEK293T cells. A band at roughly 1 kb shows the presence of a protein 
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the expected size (1.197 kb) for the mRNA from the CLEC14A-FrC fusion gene (Figure 
5.6).  
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Figure 5.6 
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Figure 5.6 |Gel electrophoresis of HEK293T mRNA: 
1% agarose gel of cDNA of mRNA collected from transduced HEK293T cells. A band at roughly 
1 kb shows the presence of the expected size (1.197 kb) for the mRNA from the CLEC14A-FrC 
fusion gene.  
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Two primers were designed to sequence the entire construct and check for mutations. No 
mutations were found, see appendix 3 for sequence details. 
 
Several tests were performed to check that the plasmid was transduced correctly, and that 
the gene was being transcribed into mRNA. The folding issues and lack of excretion would 
result in a very small yield of protein. It was decided that a different method of protein 
production should be used which would require designing a new fusion protein.  
 
VLRB-CLEC14A Fusion 
 
The production of the CLEC14A-FrC fusion resulted in an extremely low yield due to the 
protein failing to be excreted, likely due to protein miss-folding. Bacteria proteins do not 
undergo glycosylation compared to eukaryotic proteins and so would likely cause large 
folding issues in eukaryotic cells (Nothaft and Szymanski, 2013). A new fusion protein 
was needed to allow for better excretion and more rapid synthesis.  
 
Saupe et al., developed the VLRB fusion protein base, stemming from a Sea Lamprey fish 
protein (Saupe et al., 2017). They compared the efficacy of VLRB as a carrier for a fusion 
protein compared to bacterial thioredoxin (TRX), a proven and efficient carrier protein. 
Antibody titre, binding properties and duration of response were compared. VLRB carrier 
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vaccines demonstrated a 2 – 10 fold increase in antibodies against self-titres and even more 
impressively, a decrease in foreign protein antibodies when compared to TRX fusion 
vaccines. Interestingly, the VLRB multimer structure could generate and sustain immune 
responses against several targets simultaneously.  
 
Due to the exciting possibilities provided by VLRB fusion proteins, two CLEC14A fusion 
proteins was developed. Multimers form by disulphide bonds between VLRB domains and 
can form multimers of anything from 2 to ≥10 monomers. The range of these multimers 
(from monomers to 4-unit multimers) can be seen on a reducing SDS-PAGE. Only a 12 
unit multimer could be seen in non-reducing conditions showing the propensity to form 
high number multimers (Tesniere et al., 2008, van der Most et al., 2008, Ullrich et al., 
2008).  
 
The two VLRB fusion protein plasmids was designed based of work done by Anna Karren 
(Saupe et al., 2017). The sequence was sent to Genscript to be synthesized. 5 µg of plasmid 
were provided and amplified in gold efficiency DH5α E. coli. See the gene sequence, amino 
acid sequence and protein domains of the fusion proteins in appendix 4. The amplified 
plasmids were assessed for the presence of the VLRB fusion protein gene fragments 
through restriction enzyme digests. The samples were digested and run on a 1% agarose 
gel with a 10 kb ladder. Undigested plasmid was also added as a negative control (Figure 
5.7) 
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Figure 5.7 
Figure 5.7 |CLEC14A-VLRB Restriction Enzyme Digest : 
(A) A restriction enzyme digest of the L-VLRB plasmid after amplification in competent gold 
efficiency DH5α E. coli. A band can be seen at 0.6 kb (green circle) which is of the expected size 
for the L-VLRB fusion protein DNA fragment.  (B) Shows a restriction enzyme digest of the F-
VLRB collected from SHuffle® T7 Express lysY Competent E. coli. A band at 0.6 kb can be seen 
in the digested lane (green circle) signifying the presence of the F-VLRB fusion protein. 
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Protein 1 which made from the lectin domain of CLEC14A and VLRB (L-VLRB) and 
Protein 2 made from an immunogenic fragment from residues 97-108 of CLEC14A (F-
VLRB) shown to bind multimerin (Khan 2016). This immunogenic fragment for the F-
VLRB was chosen as it was thought the large domain from CLEC14A would result in 
difficulties for protein folding in bacteria similarly to the CLEC14A-FrC fusion.  
 
The plasmids were ordered and amplified in competent gold efficiency DH5α E. coli. The 
presence of the fragments was again tested using a restriction enzyme digest using the NdeI 
and XhoI restriction digest sites (Figure 5.7). Figure 5.7 (A) shows a band at 0.6 kb (green 
circle) which is of the expected size for the L-VLRB fusion protein DNA fragment.  Figure 
5.7 (B) Shows a restriction enzyme digest of the F-VLRB collected from SHuffle® T7 
Express lysY Competent E. coli (NEB #C3030J). A band at 200 base pairs can be seen in 
the digested lane (green circle) signifying the presence of the F-VLRB fusion protein. 
 
Confirmation of the presence of both gene fragments, the plasmids were introduced into 
SHuffle® T7 Express lysY Competent E. coli (NEB #C3030J) through the heat shock 
method (Froger and Hall, 2007).  
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Issues in Transformation of the F-VLRB into SHuffle® T7 Express lysY Competent E. 
coli (NEB #C3030J) that were later resolved lead to progression with protein production 
in L-VLRB alone.  
 
To assess protein expression of L-VLRB, a Bradford assay with BSA standards was used. 
Un-induced bacteria were used as a negative control and the pellet from the lysate was 
loaded as to check in the protein was left stuck to cell fragments. It was expected that a 
band around the 21 kDA size would be seen in the cell lysis, slowly increasing in 
concentration as the cells from which the lysis was taken produced more protein (Figure 
5.8).  
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Figure 5.8 
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Figure 5.8 |L-VLRB Protein Production: 
An SDS-PAGE stained with Coomassie Brilliant Blue Dye showing the production of L-VLRB 
in SHuffle® T7 Express lysY Competent E. coli. The bacteria were induced with isopropyl β-D-
thiogalactopyranoside and collected at various time points. No increase in protein production can 
be seen at the target size (21 kDa) however, a band can be seen at the correct size in the pellet. 
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There appeared to be an increasing production of protein as time progresses, however, a 
band of the correct size can also be seen in the pellet lane. The target protein was likely 
sticking to cell fragments and so some remained in the pellet. In an attempt to ensure the 
target protein can be found in the cell lysis the bacteria were sonicated in PBS with 5 M 
urea to prevent the protein binding to cell fragments. This protocol was adapted from Saupe 
et al., (2017). The bacterial cell lysis, either through sonication or RIPA buffer (Lysis 
negative control), was purified through the use of Ni-NTA agarose beads with affinity for 
the His-tag. Beads were directly loaded onto an SDS-PAGE gel after boiling at 100 degrees 
to release the proteins. Supernatant from the purification steps was also loaded in case the 
protein failed to bind to the Ni-NTA beads. Again, lysate from the un-induced bacteria was 
purified and used as a negative control. Due to the His-tag on the target protein, an anti-
polyhistidine tag monoclonal primary antibody was used to bind to the protein on the 
western blot after transfer to a membrane. Two bands can be seen in the His-beads 
(sonication) lane (Figure 5.9). The band at the top of the gel is the protein left on the beads 
that was not removed by boiling. Cells were lysed through sonication. RIPA buffer was 
used as a negative control as well as to remain consistent with the CLEC14A-FrC cell lysis 
protocol.  
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Figure 5.9 
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Figure 5.9 |L-VLRB Protein Purification : 
An SDS-PAGE loaded with Ni-NTA beads from various protein production conditions. Ni-NTA 
beads were washed with the induced proteins from two methods of cell lysis (RIPA Buffer) and 
(Sonication). These were compared to un-induced cell lysis and the supernatant gathered after 
bead the bead washing steps. No bands were present except in the sonicated-induced cell lysis.   
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Spectrophotometry was used to initially assess the yield of protein eluted from His-tagged 
beads. From 250 ml of culture lysed in the presence of 5 M urea, 100 μL of protein with a 
concentration of 1.95 mg/ml was eluted from His-tagged beads. 
 
Protein yield was assessed through western blot analysis. Purified protein from specified 
volumes of bacteria was loaded onto SDS-PAGE and run with known concentrations of 
BSA (Figure 5.10). (Initial absorption studies estimated the protein gathered from the His-
tag beads to be roughly 1.95 mg/mL). To replicate Saupe et al., the bacteria were sonicated 
in the presence of 5 M urea which was reported to result in the highest protein yield. The 
protein was run with and without urea to see the effect of urea on protein concentration. 
Urea is a powerful denaturing agent and has been shown to unfold proteins (Saupe et al., 
2017). A strong denaturing agent is useful as it prevents the aggregation of proteins into 
inclusion bodies, lowing the effectiveness of purification beads.  
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Figure 5.10 
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Figure 5.10 |L-VLRB Protein Yield: 
A reducing SDS-PAGE stained with Coomassie Brilliant Blue Dye. The gel was loaded with BSA 
standards so as to assess protein yield, L-VLRB with and without urea at two different dilutions. 
The protein containing lanes were compared to un-induced cell lysis and the pellet.  
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Figure 5.10 shows the reducing gel with 5 μg, 2 μg and 1 μg BSA samples and protein eluted 
from the His-tagged beads in the presence (+U) or absence (-U) of urea and at two dilutions 
(50% and 10%). Purified protein was visualised through an anti-CLEC14A-antibody with 
an HRP tagged secondary antibody. A band at 21 kDa can be seen in all 4 conditions though 
it is far clearer in lanes with urea present (+U) though the same band is present in all 
purified protein lanes. No protein can be seen in the pellet, confirming the beads removed 
all of the target protein after sonication.  
 
Interestingly a band at 55 kDa can be seen in the (-U) lanes. VLRB proteins are well known 
for multimerising and the lack of urea to properly dissolve the protein allowed for 
multimerization (Saupe et al., 2017). 55 kDa is not a multiple of the CLEC14A-VLRB 
monomer protein size and so is likely an aggregation with other cytoplasmic proteins. 
Conservative calculations from the BSA standards put the purified protein yield at 0.178 
mg of L-VLRB per litre of bacterial culture.  
 
 
The purified L-VLRB protein was also run on a non-reduced gel (Figure 5.11) to check for 
effects on protein multimerization. The band for the monomer at 55 kDa in the (+U) and (-
U) can still be seen however extra bands at 250 kDa can also be seen in both lanes. 250 
kDa is 12 times the size of the monomer and is not seen under reducing conditions 
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suggesting that non-reducing conditions allow for the protein to multimerise to its 
maximum of 12. 
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Figure 5.11  
Figure 5.11 |L-VLRB Protein Multimers: 
Reducing and non-reducing SDS-PAGE stained with Coomassie Brilliant Blue Dye. The gel was 
loaded with bacterial cell lysis containing L-VLRB fusion protein with and without 5 M urea. The 
reducing gel (left two) shows a monomer and multimers of 2 and 4 units. The non-reducing gel 
(right two lanes) shows a band for monomers and multimers of 12 units. This range of multimers 
is expected from studies performed by Saupe el al., 2017). The presence of urea prevents 
multimerization. Reducing and non-reducing gels were used to further assess multimerization of 
the fusion protein.  
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In agreement with Saupe et al., Multimers of the CLEC14A-VLRB protein can be seen in 
a close up of the reduced and non-reduced gels (Figure 5.11). A monomer, 2 unit and 4-
unit multimer can be seen in the reducing gel whereas only monomer and 12-unit multimers 
can be seen in the non-reducing gel. Saupe et al., suggests that it is the formation of these 
large multimers that allows for a consistent antibody titre after vaccination and so their 
presence is a clear indication of the successful production of this protein.   
 
VLRB has been shown to readily form multimers and so without the addition of urea 
(Figure 5.11) shows a band at 55 kDa that is recognised by the CLEC14A antibody. In 
agreement with Saupe et al., Multimers of the CLEC14A-VLRB protein can be seen in 
figure 5.13. A monomer, 2 unit and 4-unit multimer can be seen in the reducing gel whereas 
only monomer and 12-unit multimers can be seen in the non-reducing gel. Saupe et al., 
suggests that it is the formation of these large multimers that allows for a consistent 
antibody titre after vaccination.  
 
For the yield experiments a protein yield of 178 µg per litre of bacterial culture was 
calculated. 178 µg was lower than expected and it was hypothesised that the formation and 
presence of proteins with di-sulphide bonds inside the bacteria puts them under stress. 
Further experiments would be needed to optimise bacterial growth through pH, growth 
medium and temperature to maintain high protein yields.  
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Conclusion: 
 
These experiments show the potential for entrapment of a protein within the chitosan mesh 
of a chitosan-TPP nanoparticle as well as the production of a CLEC14A fusion protein 
with the potential for high immunogenicity. They also showed the difficulties of producing 
a fusion protein containing a prokaryotic protein which resulted in misfolding and failure 
to secrete the protein.  
 
The synthesis of two fusion proteins of CLEC14A and VLRB were attempted. One fusion 
was with the entire lectin domain and the other a small immunogenic fragment from 
CLEC14A. The large lectin domain protein proved problematic to produce in shuffle 
bacteria and the transformation never took hold, however, the immunogenic fragment 
fusion was produced and purified using Ni-NTA beads.  
 
Future work would look at the immunogenicity of the F-VLRB protein in a mouse model 
through the measure of antibody titres. Nanoparticle delivery, potentially targeted at 
dendritic cells, vs injection without nanoparticles would be compared to see if nanoparticle 
delivery improved antibody titre.  
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Chapter VI 
Gene Array Data: 
Introduction: 
The overall aim of this project was the development of a vector for delivering siRNA to 
the endothelial cells in tumour blood vessels. The original ChNPs generated a 60% 
knockdown of CLEC14A. The particles were not as effective as other examples in the 
literature and that aiding cellular uptake with antibodies may improve the knockdown 
efficiency. Antibody conjugation was attempted to try and increase cellular uptake and 
thereby the concentration of siRNA delivered to each cell. The conjugation of antibodies 
to the surface, in fact, decreased the knockdown effectiveness rather than increasing it. This 
was thought to be due to increased aggregation caused by the antibodies. Due to this 
decrease in knockdown efficiency, it was decided that experiments would progress with 
the ChNPs without antibody conjugation.  
 
ChNP’s had been shown to successfully bind siRNA and retain it in serum conditions. They 
had been shown to enter cells and to induce protein knockdown of CLEC14A which was 
studied through western blot (Chapter 3).  
 
In-vitro, siRNA delivery through chitosan nanoparticle delivery has been shown to knock 
down CLEC14A on a protein level. It was thought that microarray analysis of HUVEC 
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treated with siRNA containing ChNP’s could further elucidate the action of chitosan 
nanoparticles (aimed at knocking down CLEC14A) on endothelial cells.   
 
Microarrays are miniature, extremely sensitive and specific devises that are used to detect 
changes in gene expression on a genome wide scale. Analysis can study mutations or gene 
expression profiles of affected genes. It is difficult to compare this study to others from the 
literature regarding nanoparticle-based siRNA therapies as there are very few nanoparticle-
siRNA studies analysed using microarrays.  
 
Previous work done by the Bicknell group looked at the expression of genes related to 
blood flow in developing zebrafish embryos (Mura et al., 2012). This study highlighted 
many genes, including CLEC14A, as being affected by blood flow. Using the Ingenuity® 
Pathway Analysis (IPA) software package, gene expression in the blood flow experiments 
can be compared with the gene expression in the NP-siRNA knockdown studies.  
 
This chapter aims to look at the effects of siRNA-ChNP’s on the gene expression of 
CLEC14A and other endothelial specific genes compared to other microarray data on 
endothelial related genes.   
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Results and Discussion: 
HUVEC were incubated with siRNA containing ChNP-siRNA at the 2x concentration (100 
nM siRNA delivered) as this was found to be the most effective concentration in chapter 
2. A control group was also incubated for the same time but treated with cell medium 
containing no ChNP or siRNA.  
The cells were harvested, and RNA extracted using the RNeasy mini kit (QIAGEN 74104) 
 
Analysis of Data: 
Microarray layout data was collated using the feature extraction programme. The 6x60K 
Whole Human Genome microarrays were processed to analyse the effect of the ChNP-
siRNA on endothelial cell genes in HUVEC. A link to the full data set can be found in 
Appendix 5. 
 
Statistical analysis of gene expression was performed for all endothelial cell related genes 
using the “Statistical Analysis of Microarray” software (SAM). An unpaired, two sample 
T-Test was performed for each gene in the group of interest compared to the control cells. 
Genes that present with an estimated false discovery rate (FDR) above 5% and 10% were 
put into separate groups. SAM was performed with 1000 permutations with duplicates 
removed from the output.  
 
Functional analysis of genes of interest that were differentially regulated were carried out 
in IPA Ingenuity. Cluster and Tree View programs were used to create visualisations for 
analysis from the microarray results (Eisen et al., 1998).  
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The flow studies were performed by the Bicknell group and analysed using microarrays. 
The array data showed that CLEC14A, among other endothelial specific genes, was down-
regulated by an increase in blood flow and up-regulated by low blood flow. The study 
exposed HUVEC to differing levels of laminar flow shear stress (1.5 Pa vs 0 Pa for 24 
hours).  
 
CLEC14A was identified to be of particular interest as its expression was 10-fold higher 
in the static cells compared to the shear stress, laminar flow, HUVEC. Real time PCR 
confirmed the down-regulation of CLEC14A in response to shear stress (Mura et al., 2012).  
The data from this study was compared to the gene expression profile produced by the 
ChNP-siRNA knockdown of CLEC14A. Nearly half (297 out of 641) endothelial related 
genes had similar altered expressions in both the blood flow and NP-siRNA gene array 
studies.  (Figure 6.1).    
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Figure 6.1 
(A) NP-siRNA Dataset 
(B) Blood Flow (More than 10-fold) Dataset 
(C) Blood Flow (More than 5 FDR) Dataset 
Figure 6.1 | Blood Flow vs NP-siRNA gene array datasets: 
(A) A representation of genes that were similarly regulated in the Zebra Fish blood flow 
experiments vs the NP-siRNA knockdown experiments. (A) NP-siRNA dataset, (B) Blood Flow 
(More than 10-fold) dataset, (C) Blood Flow (More than 5-fold) dataset. Nearly half (297 out of 
641) genes from the NP-siRNA data set had similar alterations to expression in the blood flow 
data set. This correlation suggests a high similarity between the effects of an increase in blood 
flow and a decrease in expression of CLEC14A. 
(B) a table showing the fluorescence level of the CLEC14A wells from the microarray data 
showing a 0.0996-fold change in fluorescence between the control cells and ChNP-siRNA 
treated cells.   
  
CLEC14A Average: 0.996-Fold Change 
A 
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Interestingly, analysis of the ChNP-siRNA knockdown shows that CLEC14A mRNA 
expression does not change. CLEC14A knockdown was confirmed through western blot 
analysis but a lack of mRNA knockdown suggests that loss of protein expression must be 
happening through a different rout.  
 
Though the NP-siRNA gene arrays show no knockdown of CLEC14A mRNA there were 
marked changes in expression of other genes related to blood flow. The comparison of the 
two experiments (Mura Lamina Flow and NP-siRNA gene arrays) lead to an interesting 
conclusion. CLEC14A mRNA is not knocked down (Figure 6.1 B), however, the changes 
in the expression of other endothelial genes were consistent with changes due to an increase 
in laminar flow. Using the data from both the NP-siRNA gene array and blood flow gene 
array gives an interesting view of CLEC14A.  
 
Changes in gene expression after exposure to ChNP-siRNA were similar to the expression 
changes induced by an increase in laminar flow. CLEC14A expression is known to 
decrease due to an increase in laminar flow. These changes suggest that CLEC14A 
signalling was indeed inhibited though the gene was not knocked down at the mRNA level. 
Additionally, this suggests CLEC14A is a is a flow gene regulator rather than being 
regulated itself by another gene. Alterations in CLEC14A protein have the same effect as 
alterations to blood flow. This also suggest that the up and down regulation of CLEC14A 
protein expression could be directly controlled by the physical stimulus of laminar flow.  
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This correlation suggests that therapies that can alter CLEC14A protein expression can 
have drastic effects on physiology. At the start of this thesis it was stated that angiogenesis 
was a vital area of research as it is a major factor in the homeostasis of the tumour 
microenvironment. Comparing these two sets of data suggests that CLEC14A could 
potentially be a regulating gene rather than a regulated gene meaning that large, micro-
environmental, changes can be made by altering the expression of CLEC14A.  
 
The nanoparticle knockdown experiments did not knockdown CLEC14A mRNA but 
multiple CLEC14A regulated genes were changed. Studies have shown that CLEC14A 
expression decreases in zebra fish embryos as the heart develops (Mura et al., 2012). As 
the vascular system of a zebra fish develops the blood flow increases and down-regulates 
CLEC14A (Pociute et al., 2019). Combining the data from the zebra fish studies, the 
laminar flow studies and the data from the gene arrays I suggest that CLEC14A down-
regulation stimulates endothelial cell maturation.  
 
As previously stated, CLEC14A was not knocked down at the mRNA level but I have 
suggested that it was knocked down at the protein level. As a result, genes that are regulated 
by CLEC14A are also altered in their expression.  IPA analysis of the array data compared 
to the laminar flow data suggested that the ChNP-siRNA affected several signalling 
pathways. 
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Figure 6.2 shows several pathways that were affected in HUVEC through the incubation 
of ChNP-siRNA particles. As can be seen the VEGF pathway is directly affected resulting 
in a decrease in angiogenesis and lyphanogenesis.  
 
Figure 6.3 shows that the NP-siRNA particles cause an inhibitory effect on the mTOR 
pathway. The mTORC1 pathway is known to regulate many oncogenes and tumour 
suppressors such as the Ras/Raf/MEK/ERK pathway, the phosphoinositide 3-kinase 
(PI3K)/AKT (PKB) pathway and the protein synthesis machinery, eukaryotic initiation 
factor eIF4E.  mTORC1 function is estimated to be hyperactivated in up to 70% of all 
human tumours. Reduced VEGF production and decreased angiogenesis have been 
suggested to contribute to the anti-tumour effects of mTOR inhibitors (Falcon et al., 2011). 
Rapamycin is a well-known mTOR inhibitor and which has key roles in cell growth, 
proliferation. mTORC1 and mTORC2 are kinases that form a complex to induce signalling.  
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Figure 6.2 
Figure 6.2 | NP-siRNA effect on endothelial related genes 1: 
Here can be seen a representation of the effects of NP-siRNA on the VEGF cell signalling pathway. This 
diagram was generated using the IPA software package. (Orange = up-regulation) (Blue = down-regulation). 
As can be seen, NP-siRNA induce the upregulation of cell migration and cell proliferation whilst down-
regulating angiogenesis, Lymphanogenesis and cell survival. This image was generated from IPO analysis 
of endothelial gene regulation by the ChNPs (microarray data). 
 
192 
Figure 6.3 
Figure 6.3 | NP-siRNA effect on endothelial related genes 2: 
Here can be seen a representation of the effects of NP-siRNA on the VEGF cell signalling pathway. This 
diagram was generated using the IPA software package. (Orange = up-regulation) (Blue = down-regulation). It 
can be seen that NP-siRNA cause a down-regulation of mTORC1 and mTORC2 resulting in an upregulation of 
autophagy and translation. This image was generated from IPO analysis of endothelial gene regulation by the 
ChNPs (microarray data). 
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mTORC1 promotes several anabolic pathways such as protein synthesis, ribosome 
production, nucleotide synthesis and lipogenesis which all contribute to cell growth 
proliferation and tissue growth (Kennedy and Lamming, 2016). Suppression of key 
catabolic process and induction of autophagy by inhibiting its activation or suppressing 
production of lysosomes by mTORC1 makes its inhibitors attractive for anti-cancer or anti-
aging therapies (Kim and Guan, 2015).  
 
Eukaryotic initiation factor (eIF4E) is a key component in the positive regulation of protein 
synthesis machinery. eIF4E mediates recruitment of ribosomes to mRNA for translation 
(Brunn et al., 1997). eIF4E-binding proteins (4E-BPs) are small phosphoproteins that 
inhibit eIF4E. mTORC1 induces release of the 4E-BPs, thereby removing their inhibition 
of eIF4E. Other links of mTORC1 to the activation of protein synesis can be found here 
(Huo et al., 2011, Iadevaia et al., 2012). 
 
Given the multitude of oncogenic pathways, oncogenes and tumour suppressors linked to 
mTOR signalling it is unsurprising that it is hyperactivated in most human tumours. This 
hyperactivation and prolific involvement in cell growth, proliferation and autophagy means 
that any perturbation of its signalling is of great interest.   
 
Even though CLEC14A did not appear to be knocked down at an mRNA level it appears 
that the nanoparticles have the desired effect by down-regulating angiogenesis. The Zebra 
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Fish experiments show that, as the embryo develops and blood flow increases, CLEC14A 
expression is decreased. This down-regulation of CLEC14A coincides with the maturation 
of endothelial cells and decrease in angiogenesis. The NP-siRNA gene array data suggests 
that down-regulation of CLEC14A on a protein level has the same physiological effects as 
an increase in blood flow. Therefore, decreasing the expression of CLEC14A in tumour 
blood vessels would result in maturation of endothelial cells and a decrease in 
angiogenesis.  
 
One focus of future work would be to study the reason for CLEC14A being knocked down 
at a protein level and not at the mRNA level. Sometimes cleavage of the target mRNA 
molecule does not occur. In some instances, endonucleolytic cleavage of the siRNA 
phosphodiester backbone may be suppressed by mismatches of siRNA and the target 
mRNA near the RISC cleaving site. Other times, the, patient specific, Argonaute proteins 
of the RISC lack endonuclease activity even when the target mRNA and siRNA are 
perfectly paired (Tomari and Zamore, 2005).  If this occurs then gene expression will be 
silenced by miRNA induced mechanism rather than through RISC cleavage (Carthew and 
Sontheimer, 2009). The gene array data here was gathered from one umbilical cord and so 
future work would look at repeating the analysis with multiple cords. It is also possible that 
the nanoparticles themselves caused the alteration in the method of knockdown. Chitosan 
nanoparticles are well known to generate a protein corona from endogenous proteins inside 
cells or from the serum (Lundqvist et al., 2011). Should the RISC complex get entrapped 
inside the protein corona, this could affect its siRNA cleavage efficiency, again, resulting 
in a miRNA induced knockdown. 
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Other future work would include QPCR analysis of western blot knockdowns. Western 
blots were used to confirm a ~60% knockdown of CLEC14A at a protein level by NP-
siRNA. Future work would investigate combining western blot analysis with QPCR to 
ascertain the true nature of the CLEC14A knockdown.  
 
 
 
Conclusion: 
 
The discovery that the ChNP’s did not induce knockdown at an mRNA level was at first 
confusing. However, after studying the gene data and comparing it to already published 
data an image immerged that gave a deeper understanding of the role of CLEC14A in 
angiogenesis.  
 
Genes and proteins can be either regulated or regulators, i.e. either their expression is 
controlled by another gene/protein or an outside stimulus affect them resulting in their 
regulation of the expression of other genes/proteins. Thee gene array data shows the 
knockdown of CLEC14A on a protein level resulted in changes in the expression of 
endothelial genes similar to if the cells experienced an increase in laminar blood flow.  
 
 
196 
It was already known that CLEC14A expression was affected by low sheer stress, but it 
has not been shown the drastic effects its loss of expression has on the expression of other 
endothelial related genes. This regulatory nature of CLEC14A shows its value as a 
prominent tumour endothelial marker. 
 
As well as its regulatory role, the ChNP-siRNA’s effects on the mTORC1 pathway suggest 
potentially useful anti-cancer properties through the targeting of CLEC14A on endothelial 
cells.  
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Chapter VII 
In-Vivo: 
 
Introduction: 
 
The aim of this project was the development of a vector for delivering siRNA to the 
endothelial cells in tumour blood vessels. The original ChNPs generated a 60% knockdown 
of CLEC14A. It was thought that the particles were not as effective as they could be, and 
antibody conjugation was attempted to try and increase cellular uptake and thereby the 
concentration of siRNA delivered to each cell. The conjugated of antibodies to the surface, 
in fact, decreased the knockdown effectiveness rather than increasing it. This was thought 
to be due to increased aggregation caused by the antibodies. Due to this decrease in 
efficacy, it was decided that experiments would progress with the ChNPs without antibody 
conjugation.  
 
The attempts at conjugating targeting moieties to the chitosan nanoparticles decreased their 
effectiveness in knocking down CLEC14A. It was decided to progress with the un-targeted 
ChNP’s as many papers have shown their passive uptake by tumours (Lu et al., 2010 Geiser 
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et al., 2005). Rather than targeting tumour cells, the ChNP’s developed in this thesis aim 
to be taken up by endothelial cells.  
 
Relying on passive uptake of nanoparticles risks distribution of the siRNA to organs other 
than the tumour blood vessel endothelium. Lu et al., studies the biodistribution of siRNA 
containing chitosan nanoparticles aimed at knocking down Enhancer of zeste homolog 2 is 
a histone-lysine N-methyltransferase enzyme (EZH2), another endothelial marker (Lu et 
al., 2010). The study shows the distribution of fluorescently labelled nanoparticles between 
organs showing qualitatively that the particles were not taken up predominantly by 
macrophages as was feared but that distribution was spread between the lungs, kidney, 
spleen, liver and tumour. It appeared that the greatest deposit of siRNA was in the kidneys. 
The liver and tumour next with a similar concentration of siRNA fluorescence. The study 
shows the distribution of the nanoparticles/siRNA, however, they fail to show that the 
siRNA has, in fact, reached the endothelial cells. Admittedly the western blot of the tumour 
tissue shows that there appears to be an effect, but it would have been more complete with 
evidence of siRNA present in the target cells. Howard et al., targets siRNA containing 
chitosan nanoparticles to the bronchioles of mice and shows pictures of the fluorescently 
tagged particles inside the target cells (Howard et al., 2006).   
 
A 60% knockdown was achieved by the nanoparticles produced in this thesis but to provide 
a complete study of these particles a biodistribution study was conducted. The aim was to 
see siRNA fluorescence in the endothelium of tumour blood vessels.  
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An in-vivo knockdown of CLEC14A and perturbation of its signalling could have a drastic 
effect on angiogenesis in tumours. A study by a previous PhD student in the Bicknell lab 
looked at targeting CLEC14A with antibody drug conjugates and protein fragments (Khan, 
2016). To visualise expression of CLEC14iA in vivo, humanised antibodies (conjugated 
with Alexafluor 555) were administered to LLC tumour baring mice. CD32 was stained as 
a marker for the blood vessels. The localisation of CLEC14A was found to be mainly 
within the tumour, removing the concern for off target effects of ADC’s.  
 
Additionally, the study looked at using a binding fragment from MMRN2 to prevent the 
pro-angiogenic signalling of CLEC14A and CD93. LLC cells were transduced with the 
gene for the production of the MMRN2 fragment rather than use recombinant proteins. The 
transduced cells were injected subcutaneously into the flank of 7, C57BL6 mice. Tumour 
growth was monitored daily with callipers. Tumours made from the MMRN2 expressing 
LLC cells showed a clear decrease in growth rate compared to the wild type. Growth 
difference became significantly different on days 11 and 14. From days 12 onwards the 
difference in tumour growth appeared to reduce and tumour growth caught up with the 
wild type. After 14 days the mice were culled, and tumour weighed. No significant 
difference was found when comparing fragment expressing cells vs wild type.  
 
This data reinforced the potential anti-angiogenic effect of disrupting CLEC14A 
signalling. This PhD, rather than blocking signalling, aims to reduce expression of the 
protein entirely which may have a longer lasting effect.  
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This chapter will look at the biodistribution of ChNP with entrapped fluorescent siRNA 
inside a mouse model. Two experiment were performed, each with 3 mice. The 
experiments looked at the distribution of ChNPs. The two experiments were identical apart 
from the use of different fluorophores to tag the ChNP-siRNA.  
 
Results and Discussion: 
 
Alexafluor 488 stained nanoparticles: 
 
1 million Lewis Lung Carcinoma cells (LLC) were implanted in the left flank of 6 week 
BALBC mice and left to grow for 15 days or until 1 cm in size. At 15 days the mice were 
injected with Alexafluor 488 tagged siRNA containing chitosan nanoparticles through the 
tail vain.  3 mice were used for the Alexafluor tagged nanoparticles: Control (Injected with 
solution containing no nanoparticles), Nanoparticles (culled 2 hours after injection), 
Nanoparticles (culled 24 hours after injection). The organs and tumour were extracted and 
fixed in paraformaldehyde. The organs and tumour were imbedded in paraffin wax and cut 
into sections 10 micrometres in thickness. The sections were fixed to microscope slides, 
stained with H&E and imaged on the Leica DM6000 Fluorescence microscope.  
. 
10 micrometre sections from the tumour and each organ were imaged and can be seen in 
Figure 7.1. The sections are of organs including, heart, kidney, liver and lungs, as well as 
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from the tumour itself.  One mouse was culled 2 hours after injection with nanoparticles 
and the other 24 hours after injection.  
 
Figure 7.1 (Culled 2 hours after nanoparticle injection) clearly shows the difference in the 
presence of green fluorescence in different organs. Strong green fluorescence can be seen 
in surrounding the blood vessel in the tumour and some can also be seen in the kidneys. 
Localisation of chitosan nanoparticles to the kidneys is consistent with other published data 
(PengZhou, et al., 2014). Figure 6.2 (Culled 24 hours after nanoparticle injection) shows a 
similar disparity of green fluorescence in the tumour vs other organs. Interestingly, 
fluorescence could not be found in the kidneys, but a small amount was found in the lungs. 
This may have been due to a large aggregation of particles becoming wedged in a vessel 
or lymph.  
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Figure 7.1 
Figure 7.1 |Alexafluor 488 Mouse Sections 2 hours: 
Fluorescent images of sections made from the organs and LLC tumours in mouse culled 2 hours 
after injection with Alexafluor 488 tagged siRNA-nanoparticles without antibody targeting. 
ChNP-siRNA particles were tagged with Alexafluor 488. High levels of green fluorescence can 
be seen in the tumour sections suggesting a high concentration of nanoparticles. Fluorescence 
appears to aggregate around blood vessels. Some green fluorescence can be seen in the lining of 
the heart (Arrow A). Clear green fluorescence can be seen surrounding blood vessels in the kidney 
(Arrows B and C) Greater magnification images can be seen in figure 6.3 and 6.4. 
Heart 
Kidney 
Liver 
Lung 
Tumour 
B 
C 
A 
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Figure 7.2 
Heart 
Kidney 
Liver 
Lung 
Tumour 
Figure 7.2 | Alexafluor 488 Mouse Sections 24 hours: 
Fluorescent images of LLC tumour sections from mouse culled 24 hours after injection with 
Alexafluor 488 tagged siRNA-nanoparticles without antibody targeting. High levels of green 
fluorescence can still be seen in the tumour sections (Arrows A and B). Some green fluorescence 
can be seen in in the lung though this was one of only 3 examples found (Arrow C). Higher 
magnification images can be seen in figure 6.3 and 6.4. 
C 
A 
B 
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Figure 7.3 
Figure 7.3 | Alexafluor 488 Tumour Sections (Increased Magnification): 
Fluorescent images of LLC tumour sections from mouse culled 24 hours after injection with 
Alexafluor 488 tagged siRNA-nanoparticles without antibody targeting. High levels of green 
fluorescence can still be seen surrounding the blood vessel. Bright field images of the H&E stain 
show no presence of red blood cells which are known to exhibit green auto-fluorescence. The 
ChNP are tagged with a green Alexafluor (488). The presence of large amounts of green 
fluorescence in the cells surrounding a blood vessel indicate that the nanoparticles are present in 
high concentrations within the tumour vessel endothelium.    
20 x 
40 x 
100 x 
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Figure 7.4 
Figure 7.4 | Alexafluor 488 Organ Sections (Magnified): 
Fluorescent images of organs sections from mouse after treatment with Alexafluor 488 tagged 
siRNA-nanoparticles. (A) shows spots of green fluorescence in the liver. (B) shows a spot of 
strong green fluorescence in the lung. (C) shows a more yellow stain around the lining of the heart 
ventricle showing an increased green fluorescence.  
A B 
C 
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Figure 7.3 shows images of the tumour sections at greater magnification next to bright field 
images of the H&E stain. The H&E stain is useful to observe as it was noticed that red 
blood cells gave off a large amount of green auto-fluorescence. No red blood cells can be 
seen in the tissue. It must also be noted that the green fluorescence seems to predominate 
in cells adjacent to the blood vessel walls suggesting that the siRNA does, in fact, end up 
in its target cells i.e. tumour blood vessel endothelium. Sections taken from the mouse 
culled after two hours (Figure 7.1) show significantly more strong green fluorescence in 
other organs compared to the 24 hour incubation (Figure 7.2). At greater magnification the 
images of the relevant organs can be seen in figure 7.3. The kidney is unsurprisingly a 
location of strong green fluorescence due to the established preference of chitosan 
nanoparticles for the kidney tissue (PengZhou, et al., 2014).  Lu et al., found the greatest 
concentration of fluorescent siRNA deposited in the kidneys with the liver showing the 
next greatest (Lu et al., 2010). This study therefore agrees with the distribution of chitosan 
nanoparticles; however, far greater fluorescence was found in the tumour than the kidney.  
 
ATTO 395 stained nanoparticles: 
 
The large amount of green auto-fluorescence in mammalian cells, especially red blood 
cells, made distinguishing true nanoparticle signals in the endothelium challenging. To 
ensure that any fluorescence see was coming from the siRNA entrapped inside the 
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nanoparticles, a second experiment was conducted with ATTO 395 fluorophore (Blue) -
tagged to siRNA instead of Alexafluor488. There was negligible blue auto-fluorescence in 
the previous images so any strong blue fluorescent signal would only be from siRNA 
entrapped nanoparticles.  
 
1 million LLC were implanted in the left flank of 6 week BALBC mice and left to grow 
for 15 days or until 1 cm in size. At 15 days the mice were injected with ATTO 395 tagged 
siRNA containing chitosan nanoparticles.  Mice were left for 24 hours before being culled. 
The organs and tumour were extracted and fixed in paraformaldehyde. The organs and 
tumour were imbedded in paraffin wax and cut into sections 10 micrometres in thickness. 
The sections were fixed to microscope slides, stained with H&E and imaged on the Leica 
DM6000 Fluorescence microscope.  
 
Figure 7.5 shows the prevalence of blue fluorescence surrounding blood vessels in the 
tumour. There was a complete lack of blue stained blood vessels in tumour sections from 
the control mouse (not injected with nanoparticles).  
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Figure 7.5 
Figure 7.5 | ATTO 395 tagged nanoparticles, 24-hour Tumour Sections: 
Fluorescent images of sections made from the LLC tumours in mouse culled 24 hours after 
injection with ATTO 395 tagged siRNA-nanoparticles without antibody targeting. High levels of 
blue fluorescence can be seen in the tumour sections. Fluorescence appears to aggregate around 
blood vessels suggesting that the blue fluorophore tagged nanoparticles are present in the tumour 
vessel endothelium cells.  
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Figure 7.6 
Heart 
Lungs 
Liver 
Kidney 
Figure 7.6 | ATTO 395 24-hour Organ Sections: 
Fluorescent images of organs sections from mouse after treatment with ATTO 395 tagged siRNA-
nanoparticles. There is a large amount of blue fluorescence in lung, however, due to the dispersed 
nature of this fluorescence it was concluded that this was autofluorescence from the lung cells 
(Arrows B and C).  
Blue fluorescence can be seen surrounding some blood vessels in liver (Arrow A).  
C 
B 
B 
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Figure 7.6 shows sections from organs from mice treated with ATTO 395 staining 
nanoparticles. There is a distinct lack of blue fluorescence found in most organs with a few 
vessels in the liver and some staining in the lungs. These images are from sections of a 
mouse culled 24 hours after injection and the distribution of fluorescence is constant with 
the 24 hour Alexafluor 488 tagged nanoparticle mouse.  
 
The presence of clear green fluorescence in endothelial cells from the Alexafluor 488 
tagged particles and blue surrounding the blood vessels from the ATTO 395 stained 
nanoparticles shows that the nanoparticles are distributing mainly to the tumour 
vasculature. The presence of fluorescence in the kidney and liver agree with other literature 
on chitosan nanoparticle distribution (Lu et al., 2010, Howard et al., 2006). 
 
Conclusion: 
 
Both fluorescently tagged nanoparticles confirm the presence of (and preference of) 
chitosan nanoparticles in the tumour. Magnified images show the presence of nanoparticles 
in the endothelial cells surrounding blood vessels. This in-vivo study shows that the 
nanoparticles end up predominantly in the tumour blood vessels as well as the fluorescent 
tagged siRNA being present in the endothelial cells. This study contradicted some of the 
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literature which states that nanoparticles predominantly end up in the kidneys but still 
agrees that the main area of distribution is the tumour (Lu et al., 2010, Howard et al., 2006).  
More in-vivo work would look at isolating tumour blood vessel endothelium to perform 
western blot analysis on to assess the in-vivo knockdown ability of the ChNP.  
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Chapter VIII 
General Discussion: 
Introduction: 
 
CLEC14A is a tumour endothelial marker that has been studied for its involvement in 
angiogenesis and its potential in anti-cancer therapeutics. Multiple studies within the 
Bicknell group, coming before and running parallel with this PhD project, have studied the 
mechanics, interactions, function and methods for perturbation of its expression. Such 
projects include the targeting of chimeric antigen receptors (CAR) T-Cell targeting (Dr 
Steve Lee University Birmingham unpublished data), vaccine approaches, antibody drug 
conjugates and elucidating the interactions between CLEC14A and multimerin 2 
(MMRN2) (Khan, 2016). The use of data previously and currently being gathered has led 
to the development of a therapy aimed at targeting CLEC14A to reduce its expression 
inside tumour blood vessels thereby preventing growth of new blood vessels.  
 
A key study that reinforced the role of CLEC14A in angiogenesis looked at a homozygous 
knockout in mice (Noy et al., 2015). The mice were viable and showed no defects during 
development. Lewis lung carcinomas (LLC) were introduced and it was shown that tumour 
growth and angiogenesis were reduced compared to wild type mice. Subcutaneous sponge 
implants also showed FGF2-induced angiogenesis to be reduced.  
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Previous studies looked at targeting CLEC14A with antibody drug conjugates and protein 
fragments (Khan, 2016). MMRN2 protein fragments were shown to reduce the rate of 
tumour growth in LLC implanted tumours in a BALBC mouse models by binding to and 
inhibiting CLEC14A signalling. hCRT4-bevacizumab ADC’s were also shown to 
successfully target and destroy tumour blood vessels.  
 
This thesis has looked at the disruption of pro-angiogenic CLEC14A signalling through 
two methods. Firstly, the delivery of small interfering RNA molecules with the aim of 
knocking down CLEC14A in tumour blood vessels. Secondly, the production and delivery 
of a CLEC14A based fusion protein that could be used as an anti-cancer vaccine.  
 
It was realised that, to achieve the delivery of siRNA in-vivo, a protective vector was 
needed. Nanoparticles are becoming more important as modern drugs require precise 
dosage or protection due to the presence of proteins or nucleic acids (Vo et al., 2012, 
Tatiparti et al., 2017, Infante, 2018).  
 
Additionally, over the past decade nano-sized vectors such as viruses, liposomes and 
nanoparticles have garnered greater attention as delivery vehicles for vaccines (Gregory 
A.E., 2013). Nanoparticles have the ability to stabilize proteins or even act as adjuvants to 
break tolerance (Kishimoto and Maldonado, 2018). These vectors are able to enter antigen-
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presenting cells and modulate the immune response (Uto et al., 2009, Chesson and Zloza, 
2017).  
 
The efficiency of most existing drug delivery methods is directly related to their size. 
Smaller nanoparticle carriers present with higher bioavailability, can cross the blood brain 
barrier, enter the pulmonary system, be absorbed directly by cells or move through tight 
junctions of endothelial cells (Kohane, 2007, Xie et al., 2017).  
 
The first aim of this project was to develop a nanoparticle that was below 200 nm in size. 
It has been demonstrated that nanoparticles synthesized at greater than 200 nm are more 
likely to activate the lymphatic system and be removed from the vascular system sooner 
(Prokop and Davidson, 2008) A study also found that particles smaller than 200 nm were 
capable of passive cellular uptake (Geiser et al., 2005, Howard et al., 2006).  
 
Mesoporous silica nanoparticles were chosen as a suitable vector for the protection of 
siRNA in-vivo. It was found that the silica particles failed to “hold onto” the siRNA 
effectively whilst exposed to vasculature. Gel electrophoresis caused 10% dissociation of 
the siRNA from the particles. To this end chitosan nanoparticles were selected as a 
replacement. The chitosan particles succeeded in binding and retaining siRNA when 
exposed to 50% serum at 37°C for over an hour. It is widely understood that endonuclease 
enzymes in the serum digest siRNA and using a nanoparticle vector can mitigate these 
effects (Choung et al., 2006). Generally, studies will expose the nanoparticle-siRNA to 
serum then actively dissociate the siRNA with something like heparin and test the siRNA 
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for its integrity in a comet assay for example.  Exposure to serum is an important test for 
the ChNPs as it has been shown that animal serum contains factors that induce 
depolymerisation of chitosan-TPP nanoparticles. Any study of siRNA release must 
therefore be considered under near physiological conditions (Raja et al., 2015). The 
particles were synthesised at roughly 130 nm, TEM imaging allowed for visual analysis of 
size and also the development of a MatLab program that could automatically calculate the 
size of any particles imaged through TEM (see appendix 1). This analysis of TEM images 
via MatLab was developed from the ground up for this thesis and represents a useful tool 
for future nanoparticle size analysis.  
 
Studies with fluorescent tagged siRNA and confocal microscopy showed that the ChNPs 
were capable of passive cell uptake. Further study with an early endosome marker, (a 
marker previously used to study CLEC14A internalisation rates), showed that the green 
fluorescence of the ChNP-siRNA overlapped with the red of the BacMam RFP early 
endosome stain.  
 
ChNP’s achieved a 60% knockdown of CLEC14A. Varying forms of nanoparticles have 
been developed for the delivery of siRNA and the results gained for this thesis are 
consistent with some of the literature, if not better than. A study silencing the pGL3 
luciferase gene transfected into CHO K1 cells showed an 82% silencing with chitosan 
nanoparticles (Li et al., 2003). A similar study showed a 61% reduction in expression of 
EGFP in PANC-1 cells through the use of siRNA-PEI-MSNs (Hom et al., 2010). Han et 
al., showed a 51% reduction in POSTN expression, however this was  (Han et al., 2010). 
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Deshpande and Singh used a variety of nanoparticles, eventually achieving a 50% 
knockdown of the PLK1 gene (Singh, 2018). The knockdown effectiveness of nanoparticles 
appears to vary greatly from particle to particle. 60% knockdown seems to be average 
within the current literature, however some are far higher. To attempt to increase the 
knockdown percentage, efforts were made to improve the knockdown effectiveness of the 
ChNPs by targeting them directly at CLEC14A on the surface of endothelial cells.  
 
The addition of antibodies to the surface of the nanoparticles aimed to increase the 
knockdown effectiveness to above 60%. Lee at al., saw a ~30% increase in knockdown 
effectiveness after the addition of anti-CD7 antibodies to the surface of chitosan 
nanoparticles (Lee et al., 2012). Similarly, Zhu et al., used CD147-mediated internalization 
through the Caveolae-dependent pathway and lysosomal escape to improve cellular uptake 
of their chitosan based nanoparticles in liver cancer cells (Zhu et al., 2015).  
 
The addition of antibodies to the surface of the particles required a modification from 
chitosan to chitosan glutamate. The glutamate side chains provided a carboxyl group for 
the EDC reaction to act on and form a peptide bond with activated antibodies. Due to the 
success of the two studies mentioned above, both their methods for attaching antibodies to 
chitosan nanoparticles were used in this project to attempt to increase the effectiveness of 
the nanoparticle knockdown.  
 
The siRNA entrapment/release studies showed that ChGlutNP were able to entrap 84% of 
the siRNA added during synthesis. The particle size was unaltered by addition of siRNA. 
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NP-siRNA also retained the siRNA under near physiological conditions, releasing only 
32% of the siRNA after an hour in 50% FCS at 37°C. It is difficult to compare this to other 
chitosan nanoparticle studies as most do not study the effect of serum on release of siRNA, 
only the effect of endonuclease enzymes. Considering 32% of the siRNA was lost within 
an hour it is potentially an important area for future studies to look at.  
 
Nanoparticles are expected to be taken up by cells within an hour (Geiser et al., 2005) but 
the 32% release explains why the 2x concentration of nanoparticles results in a greater 
knockdown than the 1x for unconjugated particles. The best knockdown with non-antibody 
conjugated nanoparticles was around a 60% knockdown or 40% remaining expression 
figure 3.10.  
 
It was thought that improving cell uptake may increase the knockdown percentages 
achieved by the nanoparticles. Antibodies, targeted at CLEC14A, were conjugated to the 
surface of the particles to increase cell uptake of the siRNA containing particles.  
  
Two methods were used to attempt to conjugate antibodies. Method 1 resulted in particles 
that were too large >400 nm. This increase in size is consistent with that observed in the 
paper from which the method was adapted (Lee et al., 2012). The addition of anti-CD7 
antibodies in the Lee et al., study produced particles ranging from 305-345 nm. The study 
did show that nanoparticle size decreased with a lower percentage of antibody added to the 
particle. Attempts were made to reduce the size of the particle by modulating the 
percentage of antibody and other chemicals during synthesis as well as changing the timing 
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of the addition of reagents. All these methods were developed and adapted for this thesis 
and can be seen in chapter 4.  
 
A second method was developed and altered to eventually synthesise particles that were 
less than 200 nm (Zhu et al., 2015). This second method mirrored methods for attaching 
antibodies to other nanoparticles by attaching them to pre-synthesised particles (Bailes et 
al., 2012, Khashayar et al., 2017, Dreau et al., 2016). Again, a range of conditions were 
experimented with such as concentration of Chitosan, concentration of cross linker, 
concentration of siRNA, temperature and stage at which each of the constituent elements 
were added to the synthesis. Eventually the particles were brought down to below 200 nm.  
 
The conjugation of antibodies to the surface of the nanoparticles did not drastically increase 
the knockdown efficiency and in-fact, decreased the knockdown at higher concentrations 
(Figure 4.10).  
 
Antibody-modified chitosan nanoparticles have been developed for delivering siRNA 
across the blood-brain barrier (Gu et al., 2017). In this study, antibody conjugation resulted 
in a 68.9 ± 38.7 percent increase in cellular uptake and 1.57-fold increase in knockdown 
effectiveness through antibody conjugation. The study did not include evidence for antigen 
binding studies, prior to cell uptake which were demonstrated in this thesis (Figure 4.7 and 
4.8). Scrambled (Non-targeted antibody Ab0) antibodies were used but only in 
combination with either of their targeted antibodies (Ab1 and Ab2) never by themselves, 
however they suggest a significant increase in cellular uptake after conjugation of 
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antibodies to the particles. No extra steps were taken to reduce aggregation. It would be 
interesting to study potential ways to mitigate this aggregation in future work with the 
particles in this thesis.  
 
The decrease in knockdown effectiveness seen after antibody conjugation in this project 
was thought to be due to increased aggregation caused by antibody-antibody attraction. 
Monoclonal antibodies are known to aggregate under a variety of conditions similarly to 
many proteins in biological systems (Maas et al., 2007, Wang et al., 2010b). Figure 4.7 
shows the aggregation of antibody conjugated particles at higher concentrations.  
 
ELISA studies provided a comprehensive view of antibody-antigen interaction. The 
discrepancy in binding human vs mouse CLEC14A for the CRT4 antibody was repeated 
in the nanoparticle-antibody ELISA studies. Wells treated with fluorescently tagged 
antibody conjugated nanoparticles bound to the mouse variant of CLEC14A with greater 
specificity than to the human variant. This preference shows the CRT4 preference for 
human CLEC14A thus showing successful antigen binding by the antibody after being 
conjugated to the surface of the nanoparticle (figure 4.7). Unfortunately, the positive results 
from the ELISA experiments did not translate to the HUVEC knockdown experiments 
which did not improve the knockdown efficiency from the ChNP study. The knockdown 
percentages were, in fact, worse than without the antibodies. This is likely due to antibody 
induced aggregation (Li et al., 2016a) 
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It has been suggested the efficacy of vaccines could be improved through the use of 
nanoparticles in their delivery (Salem, 2015). Nanoparticles have been identified as 
potentially helpful in increasing the efficacy of vaccines (Pati et al., 2018). Several 
nanoparticle formulations have been tested in the literature including Chitosan 
nanoparticles, liposomes, gold nanoparticles, Poly(D,L-lactic-co-glycolic acid) 
nanospheres, Polypeptide Nanoparticles, Iron oxide Nanoparticles and virus like particles 
(O'Neal et al., 1997, Pusic et al., 2013, Raghuvanshi et al., 2002, Chen et al., 2010, 
Abraham, 1992, Feng et al., 2013).  
 
Nanoparticle vectors for vaccines can improve antigen stability, targeted delivery and 
enhance the immunogenicity of the vaccine itself (Brouwer et al., 2019). A large number 
of soluble antigens are not endocytosed effectively by antigen presenting cells and being 
incorporated into an insoluble vector can resolve this (Vetro et al., 2017).  
 
Polymeric nanoparticles such as chitosan nanoparticles have attracted much attention for 
their ability to deliver drugs and biological molecules as well as being biodegradable and 
generally non-toxic (Peng et al., 2008). Additionally, the release of molecules loaded into 
the particles can be controlled by compositional changes to the copolymer. 
 
Chitosan nanoparticles were selected for this project due to their biodegradability into non-
toxic products in vivo and the particles innate ability to open up tight junctions between 
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epithelial cells (Sonaje et al., 2012). Tokumitsu et al., 1999 used chitosan nanoparticles to 
enhance the uptake of insulin through a nasal spray.  
 
Vaccines are generally protein based and so the first experiments for this section of the 
thesis were to test the ability for chitosan nanoparticles to entrap proteins inside their 
polymer mesh. Figure 5.1 shows a gel electrophoresis of fluorescently tagged streptavidin 
entrapped inside the nanoparticle. As can be seen, the fluorescent streptavidin remains in 
the well suggesting it remains trapped inside the large nanoparticles. The in-vivo studies 
seen in chapter six show the, untargeted, nanoparticles predominantly distributing to the 
tumour. The review “Vaccine delivery using nanoparticles” by Gregory et al., (2013) 
suggests that, for an effective vaccine, particles should be targeted at dendritic cells. This 
presents potential further experimentation though the targeting experiments with 
CLEC14A failed to increase knockdown efficiency, maybe a different cellular target would 
result in a better outcome.  
  
A novel fusion protein was also developed to vaccinate against tumour derived 
angiogenesis. The development of this protein took on two stages.  The initial construct 
consisted of a fragment of the tetanus protein form the FRC domain – fused to full length 
CLEC14A. The protein was successfully transfected into HEK293 cells using lentiviral 
infection. The protein was synthesised and seen clearly on a western blot. A gradient gel 
was used to visualise the fusion protein as it co-ran with a protein which also exhibited 
non-specific antibody binding. Yield quantity analysis showed that the protein was being 
synthesised at very low concentrations. It was thought that this low production was likely 
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due to folding issues and therefore the protein remaining stuck in the endoplasmic 
reticulum. CLEC14A has an excretion signal meaning the protein should have been 
excreted and allowed to gather in the cell medium. No protein was found in the cell medium 
and the only method to harvest the fusion protein was through cell lysis. Due to the 
infeasibility of high yield production of the tetanus fusion protein, new candidate proteins 
were selected. 
 
The second fusion protein tested fused fragments of CLEC14A to a protein from the Sea 
Lamprey fish. The VLRB fragment from Sea Lamprey was shown by Saupe et al., to form 
massive multimers that were also highly immunogenic (Figure 5.1). Two fragments from 
CLEC14A were synthesised, the Lectin domain (L-VLRB) and an immunogenic fragment 
(F-VLRB). The template for the cloned fusion proteins was taken from Saupe et al., The 
two fragments were transduced into SHuffle® T7 Express lysY Competent E. coli. and 
grown on ampicillin containing agar plates to check for successful transduction. Multiple 
attempts failed to transduce the lectin-domain fusion protein. It was thought that this was 
most likely due to a failure of folding due to the lack of glycosylation in bacteria.  
 
The immunogenic fragment was successfully transduced, and SHuffle bacteria were 
cultured and grown to produce the protein at higher yields. The F-VLRB was collected and 
purified using Ni-NTA Agarose beads which bound to the his tag on the fusion protein. 
Western blot analysis (figure 5.9) identified the fragment with an anti-CLEC14A antibody. 
A band can be seen at the top of the gel which identifies the protein still stuck to the beads 
after most was removed.  
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In agreement with Saupe et al., Multimers of the CLEC14A-VLRB protein can be seen in 
(Figure 5.12). A monomer, 2 unit and 4 unit multimer can be seen in the reducing gel 
whereas only monomer and 12 unit multimers can be seen in the non-reducing gel. Saupe 
et al., suggests that it is the formation of these large multimers that allows for a consistent 
antibody titre after vaccination and so their presence is a clear indication of the successful 
production of this protein.  
 
Future work will look at incorporation of the successfully purified fragment into chitosan 
nanoparticles as well as checking immunogenicity of the fragment by itself in mice.  
It is difficult to compare this study to others from the literature regarding nanoparticle-
based siRNA therapies as there are very few nanoparticle-siRNA studies analysed using 
microarrays.  
 
The gene array analysis provided more compelling reasons for further study of CLEC14A 
knockdown via ChNP-siRNA. As previously discussed, it was shown that the ChNP-
siRNA did not cause an mRNA knockdown of CLEC14A, however, gene regulatory 
effects consistent with a decrease in blood flow were seen. The western blots from chapter 
3 showed that CLEC14A protein expression was diminished by the NP-siRNA. There is 
precedent for siRNA molecules to cause protein knockdown without affecting mRNA 
expression.  
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There are several potential ways that siRNA could cause a protein knockdown without 
affecting the mRNA levels. Sometimes cleavage of the target mRNA molecule does not 
occur. In some instances, endonucleolytic cleavage of the siRNA phosphodiester backbone 
may be suppressed by mismatches of siRNA and the target mRNA near the RISC cleaving 
site. Other times, the, patient specific, Argonaute proteins of the RISC lack endonuclease 
activity even when the target mRNA and siRNA are perfectly paired (Tomari and Zamore, 
2005).  If this occurs then gene expression will be silenced by miRNA induced mechanism 
rather than through RISC cleavage (Carthew and Sontheimer, 2009). The gene array data 
here was gathered from one umbilical cord and so future work would look at repeating the 
analysis with multiple cords. It is also possible that the nanoparticles themselves caused 
the alteration in the method of knockdown. Chitosan nanoparticles are well known to 
generate a protein corona from endogenous proteins inside cells or from the serum 
(Lundqvist et al., 2011). Should the RISC complex get entrapped inside the protein corona, 
this could affect its siRNA cleavage efficiency, again, resulting in a miRNA induced 
knockdown. Additionally, CLEC14A mRNA may get trapped inside the protein corona 
without being cleaved which would produce the same effect as an siRNA induced 
knockdown, however, when it came to collection of the mRNA the various reagents used 
to purify the mRNA would elute it from the particle surface.  
 
Microarray analysis of the delivery of siRNA to tumours using lipid nanoparticles 
containing PEG-lipid targeting moiety revealed 7 genes and 21 genes were upregulated in 
the liver and spleen respectively, after i.v injection of the siRNA-lipid nanoparticles 
(Hatakeyama et al., 2011). Toll-like receptors 3 and 7 are known to mediate the immune 
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response to siRNA due to the production of inflammatory cytokines and type I IFN (Judge 
et al., 2005, Hornung et al., 2005, Kawai and Akira, 2010). The up-regulation of interferon 
associated genes in patients treated with the siRNA-nanoparticles is consistent with an 
siRNA mediated innate immune response suggesting that siRNA was indeed taken up into 
these organs and not digested in the serum beforehand. This does not answer the question 
of the siRNA knockdown but does show that an immune response can be elicited by siRNA 
bound to a nanoparticle.   
 
Analysis of the microarray data from the ChNP-siRNA using IPA software suggests that 
ChNP-siRNA particles affect the VEGF and mTOR pathways (Figure 6.2 and 6.3). The 
mTORC1 pathway is of interest to any anti-cancer therapy as it is known to regulate many 
oncogenes and tumour suppressors, including, Ras/Raf/MEK/ERK, phosphoinositide 3-
kinase (PI3K)/AKT (PKB), the protein synthesis machinery and eukaryotic initiation factor 
eIF4E. The large prevalence of mTORC1 hyperactivation in human tumours makes it an 
interesting target for an anti-cancer therapy.  
 
NP-siRNA particles also appear to affect the VEGF pathway. This analysis in combination 
with the bio-distribution studies strengthens the case that the NP-siRNA particles have the 
desired anti-angiogenic effects. The VEGF pathway as well as mTOR signalling is being 
perturbed and the distribution studies show that the particles locate predominantly to the 
tumour blood vessels.  
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Of great interest was the realisation that CLEC14A is a regulatory gene rather than a 
regulated gene. By comparing the microarray data from this thesis and the data gathered in 
Mura et al., 2012, it can be seen that a reduction of CLEC14A on a protein level, not an 
mRNA level, causes alterations to endothelial gene expression in the same way that 
increasing laminar blood flow would. This finding suggests that pertubation of CLEC14A 
can have wide reaching effects similar to physilogical stimulus and changes in blood flow.  
 
Biodistribution studies were performed with ChNP as it was shown that the addition of 
antibodies did not increase the knockdown effectiveness of the ChNPs. Experiments with 
CLEC14A knockout mice as well as monoclonal antibody-based therapies targeting 
CLEC14A in LLC tumour implanted in mice provided a good basis for study into the in-
vivo potential of the ChNP-siRNA (Khan 2016). 
 
1 million Lewis Lung Carcinoma cells (LLC) were implanted in the left flank of 6 week 
BALBC mice and left to grow for 15 days or until 1 cm in size. At 15 days the mice were 
injected with Alexafluor 488 tagged siRNA containing chitosan nanoparticles through the 
tail vain. 
 
First the tumours and organs were harvested, fixed in paraffin wax, cut into 10 micron 
sections and stained with the H&E stain. Two fluorophores were used to image the ChNPs 
in the mouse sections: Alexafluor 488 and ATTO 395. 
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It was seen that the NP-siRNA particles were predominantly distributed to the tumour, 
though a small amount went to the liver and kidneys. The kidney is unsurprisingly a 
location of strong green fluorescence due to the established preference of chitosan 
nanoparticles for the kidney tissue (PengZhou, et al., 2014).  Lu et al., found the greatest 
concentration of fluorescent siRNA deposited in the kidneys with the liver showing the 
next greatest (Lu et al., 2010). This study therefore agrees with the distribution of chitosan 
nanoparticles; however, far greater fluorescence was found in the tumour than the kidney. 
 
The ATTO 395 fluorophore can be seen in the circumference of the blood vessel lumens 
within the tumour figure 6.5. The combination of this tumour blood vessel localisation and 
the confirmation of the 60% knockdown in cell culture, suggests a positive future for the 
particles. A vital future experiment would be the isolation of mouse tumour endothelial 
cells, from an in-vivo model, for western blot analysis. Han et al., showed a 51% reduction 
in POSTN expression,  (Han et al., 2010). Analysis was performed through western blot 
and future studies into the in-vivo effects of the ChNP-siRNA would likely follow the 
protocol set out in this study.  
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Conclusion: 
This thesis documents the development and characterisation of a vector for the delivery of 
CLEC14A siRNA or a potential CLEC14A based fusion protein for anti-cancer 
vaccination. To improve on some of the published examples that use a nanoparticle vectors, 
this thesis assessed every required ability of the vector. MSN particles were initially 
synthesised and studied but presented issues with siRNA binding and retention. Chitosan 
nanoparticles were chosen as a replacement for the MSNs. Studies were done to look at 
nanoparticle sizing, siRNA/protein entrapment, siRNA release, in-vitro knockdown, 
antibody conjugation, antibody targeted in-vitro knockdown and distribution studies. The 
in-vitro studies confirmed the ability for chitosan nanoparticles to enter HUVECs and 
knockdown CLEC14A to around 40% relative expression remaining. The studies 
confirmed the predominant distribution of nanoparticles to endothelial cells inside the 
tumour blood vessels. The protein studies showed that the nanoparticles could entrap 
protein inside them. The vaccine synthesis experiments successfully produced a CLEC14A 
fragment-VLRB fusion protein that is read for immunisation experiments.  
 
Combining all the previous data with the gene array data paints an interesting picture for 
the NP-siRNA particles. The particles retain the siRNA entrapped inside and are able to 
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enter mammalian cells through endocytosis. The nanoparticles appear to distribute 
predominantly to the tumour blood vessels when tested with a mouse model. The in-vitro 
cell uptake studies, in combination with the distribution, suggest that the particles do reach 
their target. Western blot analysis suggests they have the desired effect of knocking down 
CLEC14A in endothelial cells. The gene array data suggests that CLEC14A is not knocked 
down at an mRNA level, however, alterations to other endothelial related genes are 
consistent with a decrease in expression of CLEC14A as seen previously in a blood flow 
gene array analysis. Not only this, but through IPA analysis it appears as if the NP-siRNA 
particles also effect the VEGF and mTOR pathways providing interest for future projects 
exploring potential additional anti-cancer characteristics of the ChNP-(CLEC14A siRNA).  
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Appendix 1. 
Nanoparticle Sizing MatLab Code: 
 
clc 
close all 
ImageFile=imread('Nanoparticle2.jpg'); 
[IG]=ReadImage(ImageFile); 
I=IG;figure;imshow(I); 
  
T=FindThreshold(I); 
BW = im2bw(I, T); 
figure;imshow(BW); 
  
MF=MorphFilter(BW); 
figure;imshow(MF); 
  
Diameter=DiameterMeasure(MF); 
 
 
 
function [IG] = ReadImage(ImageFile) 
I=imread('Nanoparticle2.jpg'); 
figure; imshow (I,[]); 
IG=I(:,:,1); 
ReadImage 
This section of code reads the image 
file and converts it to a matrix of 
pixel values (0-256).  
FindThreshold: 
Image is converted to black and 
white.  
MorphFilter: 
The image is filled out with the 
MorphFilter function and is now 
ready to be measured.  
DiameterMeasure: 
The longest diameter is measured and 
compared to the scale bar at the 
bottom of the image.  
ReadImage 
This section of code reads the image 
file, separates it into each 3 RGB 
layers and converts them to a matrix 
of pixel values (0-256).  
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end 
 
function [T] = FindThreshold(I) 
maxI=max(I(:)); 
binSize=0.002; 
nBins=256; %nBins=maxI/binSize 
h=(hist(double(I(:)),nBins))'; 
L=length(h); 
M=find(h==max(h)); 
  
for k=M+1:L 
    x=(M:k)'; 
    X=[x [ones(size(x))]]; 
    y=h(x); 
    P=X\y; %This is the same as P=(X'*X)^-1 *X'*y; 
    Y=X*P; 
    R1(k)=sum( (h(x)-Y).^2 ); 
     
    clear x 
    x=(k:L-1)'; 
    X=[x [ones(size(x))]]; 
    y=h(x); 
    P=X\y; %This is the same as P=(X'*X)^-1 *X'*y; 
    Y=X*P; 
    R2(k)=sum( (h(x)-Y).^2 ); 
     
    R(k)=R1(k)+R2(k); 
end 
FindThreshold: 
To convert the image into black 
and white a threshold pixel value 
is needed. The FindThreshold 
function takes the pixel value 
matrix previously generated and 
plots a histogram which is 
analysed toto identify the ideal 
pixel value for the cut off. 
Anything above this value is made 
white; anything below is black.  
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eps=R(M+1:L); 
index=M+1+find(eps==min(eps)); 
  
figure; hold on 
plot(h) 
plot(index,h(index),'or'); 
  
% For illustration compute and display the linear fits 
x=(M:index)'; 
X=[x [ones(size(x))]]; 
y=h(x); 
P=X\y; %This is the same as P=(X'*X)^-1 *X'*y; 
Y=X*P; 
plot(x,Y,'--c'); 
  
clear x 
x=(index:L-1)'; 
X=[x [ones(size(x))]]; 
y=h(x); 
P=(X'*X)^-1 *X'*y; 
Y=X*P; 
plot(x,Y,'--c'); 
  
% Threshold image 
T=index*binSize 
  
end 
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function [ MF ] = MorphFilter(BW) 
BWO = bwareaopen(BW, 5); 
figure;imshow(BWO); 
%Fills in holes in binary images 
BWI=imcomplement(BWO); 
figure;imshow(BWI) 
  
X = imfill(BWI,26,'holes'); 
figure;imshow(X); 
  
%Forms filter disk for erosion and dilation 
SE = strel('disk', 5:5); 
%Dilation 
Di = imdilate(X,SE); 
  
X=double(Di); 
MF=bwlabel (X); 
  
end 
 
 
function [WMF] = DiameterMeasure(MF) 
  
rp = regionprops(MF,'All');  
  
MorphFilter: 
Once the image is 
converted to black and 
white there are often 
holes left in solid 
structures due to an 
imperfect threshold 
value (it is almost 
impossible to get a 
perfect value as solid 
structures are never 
binary in colour).   
The MorphFilter 
function passes over the 
black and white image 
filling in any holes that 
are smaller than 26 
pixels. Next a disk that 
is 5x5 pixels is passed 
over the matrix to 
smooth any edges and 
fill in any extra gaps left 
in solid structures.   
 
xxix 
  
ObjDI=zeros(size(rp,1),1); 
CenterX=zeros(size(rp,1),1); 
CenterY=zeros(size(rp,1),1); 
for i=1:size(rp,1) 
    ObjDI(i)=rp(i).MajorAxisLength; 
    CenterX (i)= rp(i).Centroid(1); 
    CenterY (i)= rp(i).Centroid(2); 
end 
  
Final=[ObjDI CenterX CenterY]; 
WMF=imcomplement(MF); 
imshow(WMF); 
hold on 
for i=1:size(Final,1) 
    text(Final(i,2),Final(i,3),num2str(Final(i,1)),'Color', 
'red'),... 
    'HorizontalAlignment'; 'center'; 
    'VerticalAlignment';  'middle'; 
     
end 
title('Diameter of Particles'); 
 
 
DiameterMeasure: 
This function creates a database of 
information about the image and 
defines the shapes within the image 
to be analysed. “Centroids” or 
spheres, as well as the scale bar, are 
identified and measured for the 
number of pixels on their longest 
axis.  
The data is superimposed on the 
image over the relevant “centroids” 
and the error bar so that the data can 
be compared, and size calculated.  
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Appendix 2. 
CLEC14A-FrC Plasmid Construct: 
CLEC14A-FrC Plasmid Construct: 
A diagrammatic representation of the structure of the pWPI plasmid used to synthesise 
the CLEC14A-FrC fusion protein. As can be seen, the fusion protein is inserted between 
the PacI and Pmel restriction sites. A GFP IRES site is placed after the fusion protein to 
give visual confirmation of gene transfection. 
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Appendix 3. 
CLEC14A-FrC Plasmid Sequence: 
 
CLEC14A-FrC Sequencing 
Results: 
Presented here are the results 
from the CLEC14A-FrC 
sequencing. The fusion 
protein failed to be excreted 
in any significant 
concentration, so the plasmid 
was sequenced to check for 
any mutations preventing 
synthesis or secretion.  
 
It was later decided that 
glycosylation issues resulted 
in incorrect folding and a 
therefor a failure to be 
excreted.   
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Appendix 4. 
VLRB Fusion Plasmid Sequences: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
His-CLEC14A-Fragment: 
Presented here are the 
domains, nucleotide 
sequence and translated 
amino acid sequence for the 
F-VLRB fusion protein that 
was produced in SHuffle® 
T7 Express lysY Competent 
E. coli.  
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His-CLEC14A-Lectin: 
Presented here are the 
domains, nucleotide 
sequence and translated 
amino acid sequence for the 
L-VLRB fusion protein that 
was produced in SHuffle® 
T7 Express lysY Competent 
E. coli.  
 
The size of this protein 
caused issues in protein 
synthesis. As a result, only 
the fragment fusion was 
carried forward for 
purification.  
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Appendix 5. 
ChNP CLEC14A Knockdown in HUVEC 
Microarray Data: 
The complete Microarray data from the ChNP CLEC14A knockdown in HUVEC can be 
found in the University Birmingham E-Data storage:  
 
Pearce, Jack (2019) Jack Pearce Chitosan Nanoparticle (CLEC14A siRNA) Knockdown 
in HUVEC: Microarray analysis. 
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